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ABSTRACT 
 
Background: Osteoarthritis (OA), one of the commonest joint diseases of unknown aetiology is a major 
source of pain and disability in the ageing population.  Current therapeutic agents for OA focus on 
symptomatic relief.  Patients often present to clinics with long established disease when the boundaries 
between ageing and pathology are indistinct.  A greater understanding of early OA is thus required and may 
help achieve the goal of disease modification.  OA is associated with chondropathy, synovitis, subchondral 
bone remodelling and osteophyte formation.  Angiogenesis, the growth of new blood vessels from pre-
existing ones may contribute to each of these features.  Inflammation is increasingly recognised as an 
important feature of OA.  Synovitis is detectable within the osteoarthritic joint both radiologically and 
histologically, evidenced by symptoms such as stiffness or pain, signs such as effusion and use of anti-
inflammatory drugs for treatment of OA.  Pain is the predominant symptom of OA, but little is known 
about the mechanism by which this pain arises.   
Objectives: This thesis describes studies examining the contributions of angiogenesis to 
inflammation, structural damage and pain in OA.   
Hypothesis: Inflammation and angiogenesis are co-dependent processes that can exacerbate and 
mediate structural damage and pain in OA. 
Methods: In-vivo, in animal models and ex-vivo in human meniscal tissue, using 
immunohistochemistry, joint histology and pain behaviour testing, the effects of enhancing synovitis on 
angiogenesis, structural damage and pain in OA, and whether inhibiting either synovitis or angiogenesis 
could reduce this structural damage and pain were investigated.   
Results: It is shown for the first time that blood vessel growth at the onset of resolving synovitis leads to its 
subsequent persistence.  Exacerbating synovitis in the rat meniscal transection (MNX) model of OA 
enhanced synovial angiogenesis, total joint damage and pain behaviour.  Following treatment with the anti-
angiogenic compound, PPI-2458 [(1R)-1-carbamoyl-2-methyl]-carbamic acid-(3R, 3S, 5S, 6R)-5-methoxy-
4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl) oxiranyl]-1-oxaspiro (2*5) oct-6-yl ester], synovial 
angiogenesis, vascularisation of channels penetrating into the articular cartilage (osteochondral 
angiogenesis), synovitis, joint damage (mainly attenuation of osteophyte growth) and pain behaviour were 
all reduced.  Anti-inflammatory drugs (dexamethasone and indomethacin) reduced synovitis, synovial 
angiogenesis and pain behaviour in the rat MNX model of OA.  Treatment with dexamethasone reduced 
joint damage score by decreasing cartilage damage.  Indomethacin however did not affect joint structure.  
Human meniscal tissue from knees with high chondropathy displayed increased degeneration of collagen 
bundles, increased vascular densities both in the synovium and at the fibrocartilage junction with a greater 
density of perivascular sensory nerve profiles in the outer region.  Increased penetration of the synovial 
tissue towards the tip of the meniscus was noted in menisci from high chondropathy group compared to 
those from the low chondropathy group.  
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Conclusion: Data from animal studies indicates that conversion of acute inflammation to chronic 
inflammation may be due to the stimulation of angiogenesis.  Furthermore, these data provide evidence that 
synovitis contributes to joint pathology and pain behaviour in the rat MNX model of OA and this may be 
partly due to the angiogenesis in the synovium and at the osteochondral junction.  Data from human studies 
highlights that tibiofemoral chondropathy is associated with altered matrix structure, increased vascular 
penetration and increased sensory nerve densities in the medial meniscus.  Angiogenesis and associated 
sensory nerves in the meniscus may therefore contribute to pain in knee OA. 
Summary: These findings support the hypothesis that inflammation and angiogenesis are indeed co-
dependent processes, exacerbating and mediating structural damage and pain in OA.  Angiogenesis 
inhibition has the potential to reduce synovitis, joint damage and pain in OA. 
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1 INTRODUCTION 
 
1.1 The Synovial Joint 
A joint is an essential part of the human body, allowing for movement and providing mechanical support.  
It can be defined as an area of the body where bones link together.  Diarthrodial joints, also known as 
synovial joints are the most common and the most moveable joints in the human body composed of several 
different tissues including the synovium, cartilage, bone, and menisci that all interact in a specified way to 
function relatively well over many years.  The health of the joint deteriorates when these tissues are 
affected.   
 
The knee joint is an example of a synovial (diarthrodial) joint, where the distal end of the femur, consisting 
of the medial and lateral femoral condyles, meets the proximal part of the tibia.  These two bones form a 
KLQJH MRLQW ZLWK WKH SDWHOOD ERQH RU ³NQHH FDS´ DW WKH IURQW  Joint capsule, menisci and the four main 
ligaments help to stabilize the joint, the medial and lateral collateral ligaments at either side of the knee 
hold the two adjoining bones in close proximity and serve to protect the joint against inward and outword 
forcing, the central anterior and posterior cruciate ligaments extend down from the lateral and medial 
condyles of the femur to the anterior and posterior intercondylar areas of the tibia respectively (Figure 1.1).   
 
The knee joint contains two menisci, a medial and a lateral, located between the femoral condyles and the 
tibial plateaux.  The anterior and posterior horns of the menisci are attached to the tibial plateaux by 
insertional ligaments.  Menisci are cresenteric shaped wedges of fibrocartilage.  Human meniscal tissue 
consists of fibrochondrocytes suspended in an extra cellular matrix (ECM) of collagen, glycoproteins, 
proteoglycans and elastin (McDevitt et al., 1990; Gray 1999).  Cells of the menisci are known as 
fibrochondrocytes owing to their chondrocytic appearance, yet ability to synthesise a fibrocartilage matrix 
(McDevitt et al., 1990).  The body of the meniscus consists of principally type I collagen fibres running in 
a circumferential orientation.  Less numerous fibres running in a radial orientation are thought to function 
to bind the circumferential fibres together (Messner et al., 1998).  The collagen content of the meniscus 
consists of greater than 90% type I collagen with smaller proportions of types II, III, IV and V collagen 
(McDevitt et al., 1990).  The menisci are known to have important roles in increased joint congruity, 
dispersal of weight, reduction of friction, shock absorption and proprioception (Seedhom et al., 1974; 
Assimakopoulos et al., 1992; Messner et al., 1998).   
 
Chondroitin sulphate is the principal glycosaminoglycan (GAG) of meniscal proteoglycans with smaller 
proportions of dermatan sulphate, keratin sulphate and hyaluronic acid proteoglycans (Herwig et al., 1984; 
Nakano et al., 1997).  The distributions of proteoglycans in the meniscus show regional variations 
reflecting the differences in loading across the tissue (Collier et al., 1995; Nakano et al., 1997; Messner et 
al., 1998). 
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The blood supply to the menisci mainly originates from the medial and lateral genicular arteries which give 
rise to a perimeniscal vascular plexus.  The perimeniscal plexus is predominantly circumferential in 
organization and sends radial branches into the meniscus supplying only the outer portion of the meniscus, 
whilst the inner region is avascular.  The extent of vascularisation is greater in the anterior and posterior 
horns compared to the meniscal body (Arnoczky et al., 1982; Danzig et al., 1983; Day et al., 1985).  
Myelinated and unmyelinated nerves are mostly found in the peripheral and middle thirds of the body of 
the meniscus, some of which are free nerves and others are associated with blood vessels.  The inner third 
of the meniscal body is devoid of innervation.  As with the vascularisation, nerve supply is greater in the 
anterior and posterior horns than in the body of the meniscus (Wilson et al., 1969; Day et al., 1985; Zimny 
et al., 1988; Mine et al., 2000).   
 
 
 
Figure 1.1: Frontal view of the right knee with quadriceps tendon cut and the patella reflected 
distally. 
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Synovial joints such as the knee are characterized by a fibrous capsule that surrounds the ends of the two 
bones, within which is the synovium.  The synovium consists of two layers of cells; the outer intimal layer 
is largely fibroblast-like synoviocytes and the subintimal below this surface layer is largely macrophages.  
The synovial lining is approximately 2 to 3 cell thick and highly vascularised.  However, during 
inflammation, local fibroblast proliferation as well as macrophage infiltration and recruitment to the 
synovium cause the lining to become up to 8 or more cell thick.  This hypercellularity of the sub-intimal 
layer often contains perivascular lymphoid aggregates (Haywood et al., 2003).  The superficial (shallow) 
layers of the synovium are highly vascular in order to satisfy the metabolic demands of both the 
synoviocytes (synovial cells) and avascular articular cartilage, whilst the deeper layers of the synovium are 
far less vascular.  The synovial fluid secreted by the synovial lining into the joint space lubricates the joint 
and provides nutrients and transports cellular repair components to the chondrocytes in the cartilage and 
buffers the force between the two bones (Lorenz et al., 2006). 
 
Normal joint surfaces are covered by a thin layer of hyaline articular cartilage, with subarticular calcified 
cartilage resting on subchondral bone, forming the gliding surface of the diarthrodial joints (Muir 1995).  It 
provides a low-friction surface for the opposing bones with increased compressive force and is able to 
withstand a lifetime of load bearing and motion.  Cartilage is made up of ECM, with around 1-5% of its 
volume comprising of chondrocytes but it is devoid of nerves and blood vessels.  Chondrocytes ensure that 
the cartilage matrix is kept rich in collagen and proteoglycans (Bruckner et al., 1994) and are essential in 
maintaining a balance between synthesis and degradation of ECM components.  The quality of ECM is 
critical for maintaining the functional properties of the cartilage (Poole et al., 1988).  The remaining ECM 
is between 65-80% water based with type II collagen fibrils forming a macro fibular network arranged to 
withstand tensile, shear and compressive stresses thereby distributing static and dynamic joint loading and 
decreasing friction (Burr 2004).  Collagen fibrils and the chondrocytes act to organize these 
macromolecules into a unique structure that depends on the depth of the cartilage (Imhof et al., 1997).  The 
general orientation of the collagen fibrils defines the four main cartilage layers (Figure 1.2).  Collagen 
orientation and water content differs in response to the pressure and shear force experienced by the 
cartilage (Imhof et al., 1997).  Proteoglycans of the cartilage exert osmotic pressure to draw water into the 
cartilage which counteracts mechanical forces during movements that force water out (Imhof et al., 1997).  
This mass transport of fluid ensures that the whole body of cartilage is nourished and acts as a shock 
absorber against joint articulation and movement.   
 
As the articular cartilage is avascular, its nourishment is supplied by the synovial fluid produced by 
synovial vasculature. Such vessels are fenestrated, allowing fluid and small molecules, including glucose to 
enter the synovial cavity and thus come into contact with the cartilage.  Between the third layer and the 
calcified cartilage is the tidemark; a thin line that interlocks the two layers of cartilage and can often be 
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seen microscopically.  In pathophysiological conditions such as OA, this is subjected to high stress leading 
to its duplication (Imhof et al., 1997).   
 
Calcified cartilage (layer 4) is a highly specialized mineralized region of the articular cartilage.  It is 
thought to provide attachment of the cartilage to the underlying bone, aid in transmitting and dissipating 
mechanical forces to the bone and prevent diffusion from the bone to radial layers of the cartilage (Oegema 
et al., 1997).  The subchondral bone spaces contain vascular channels. These are small 10-ȝPGLDPHWHU
channels, often containing 1-2 blood vessels within them.  These tend to grow up from the bone marrow 
towards the osteochondral junction and are enclosed in concentric layers of bone, forming a sheath.  They 
can be open-ended, where the leading edge is covered by only a thin layer of endothelial cells, or close-
ended, where the endothelial cells have been replaced by bone (Clark 1990).  The function of these 
channels is yet to be fully understood.  However, earlier studies have shown that such channels are in 
greater numbers under areas of greater weight bearing (Woods et al., 1970).  The purpose of these channels 
have been proposed as a mechanism of getting blood-borne nutritional support to the articular cartilage and 
as a major part in the re-modelling of the subchondral bone that contributes to disease pathology (Clark 
1990).  Vascular channels have been shown to breach the osteochondral junction in ageing and arthritic 
disease.  Here, penetration of the articular cartilage compromises the barrier of calcified cartilage between 
the bone and overlying cartilage.  Subsequent invasion of blood vessels via these channels may contribute 
to cartilage changes in OA, such as cartilage calcification or endochondral ossification, and with it, 
cartilage thinning (Fenwick et al., 1999; Walsh et al., 2007). 
 
Figure 1.2: Illustration of the four layers and collagen distribution of the hyaline cartilage.  (Adapted 
from Imhof et al., 1997). 
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1.2 Innervation of the knee joint 
Knee joints are supplied with both primary nerves; branches of peripheral nerves passing adjacent to the 
joint and accessory nerves; branches of intra-muscular nerves crossing the joint capsule (Mapp 1995).  The 
knee joint is richly innervated by sensory and sympathetic nerves.  Sensory nerves detect and transmit 
mechanical information from the joint to the central nervous system (McDougall 2006) detecting pain.  
Structures such as the musculature, joint capsule, synovium, tendons, ligaments, menisci, periosteum and 
subchondral bone of the joint also have a rich nerve supply, whereas the articular hyaline cartilage is 
aneural (Hunter et al., 2008).   
 
The nerves which serve the joint arise from several levels of the spinal cord and around 60% of such nerves 
are sensory nerves.  There are four classes of such afferents, classified according to their activation 
threshold by mechanical stimulation.  Large diameter (5 ȝP) myelinated nerve fibres encoding and 
transmitting proprioceptive signals that are either dynamic (movement sensations) or static (position sense) 
DUHPDLQO\ IURPJURXSV,DQG,, $ȕP\HOLQDWHGQHUYH ILEUHVZLWKDFRQGXFWLRQYHORFLW\RI-100 m/s.  
Small diameter (2- ȝP) P\HOLQDWHG QHUYH ILEUHV ZKLFK EHFRPH D IUHH QHUYH HQGLQJ DUH JURXS ,,, $į
fibres with a conduction velocity of < 20 m/s.  They have a low mechanical threshold and so respond to 
passive joint movement.  While the small diameter unmyelinated C fibres which carry nociceptive 
information belong to group IV having a conduction velocity of < 1 m/s, responding to extreme, noxious 
stimuli; indicating a noxious function.  3URSULRFHSWLYH$ȕILEUHVRI WKH MRLQW WHUPLQDWH LQ WKHFDSVXOH IDW
SDG OLJDPHQWV PHQLVFL DQG SHULRVWHXP  1RFLFHSWLYH $į DQG & ILEUHV LQQHUYDWH WKH FDSVXOH OLJDPHQWV
menisci, periosteum and mineralized bone especially areas of high mechanical load (Hunter et al., 2008).  It 
is these fibres which are responsible for pain transmission in the joint (Heppelmann 1997), their main 
function being to detect moxious stimuli and transmit this information to the central nervous system from 
the joint.   
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1.3 Osteoarthritis 
Arthritic disease is a significant health problem worldwide placing enormous burden on society (van Saase 
et al., 1989) due to its progressive and debilitating nature leading to chronic pain, disability, high morbidity 
and reduction in quality of life.  OA is the commonest form of arthritis affecting the whole diarthrodial 
(synovial) joint.  It is the biggest cause of joint pain in the elderly (Peat et al., 2001) and the main cause in 
the increase of joint replacement therapy (Dixon et al., 2004).   
 
In 1986, the Subcommittee on Osteoarthritis of the American College of Rheumatology Diagnostics and 
7KHUDSHXWLF &ULWHULD &RPPLWWHH GHILQHG 2$ DV ³$ KHWHURJHQHRXV JURXS RI FRQGLWLRQV WKDW OHDG WR MRLQW
symptoms and signs which are associated with defective integrity of articular cartilage, in addition to 
UHODWHG FKDQJHV LQ WKH XQGHUO\LQJERQH DW WKH MRLQW PDUJLQV´ (Altman et al., 1986).  In 1994, the World 
Health Organization Conference for Guidelines in Osteoarthritis Research, Diagnosis and Treatment 
XSGDWHGWKHGHILQLWLRQRI2$WR³2$LVDUHVXOWRIERWKPHFKDQLFDODQGELRORJLFDOHYHQWVWKDWXQFRXple the 
normal balance between degradation and synthesis by articular cartilage chondrocytes and ECM, and 
subchondral bone.  OA involves all tissues of the diarthrodal joint.  Ultimately, OA is manifested by 
morphologic, biochemical and biomechanical changes.  When clinically evident, OA is characterized by 
joint pain, tenderness, limitation of movement, crepitus, occasional effusion and variable degrees of 
LQIODPPDWLRQ´(Mollenhauer et al., 2002).      
 
OA can be seen as a condition that results from a heterogeneous group of overlapping chronic and painful 
conditions affecting the synovial joints.  No general definition of the disease is accepted as OA can be 
described in terms of the radiographic and histological changes seen in the joint as well as the symptoms, 
however structural changes and symptoms rarely correlate exactly.  As a result some patients complaining 
of joint pain will hardly have any structural radiographic changes but on the other hand some patients with 
complete joint destruction will experience no joint pain.  This makes the diagnosis of OA extremely 
challenging as it is based on a combination of these features. 
 
OA is thus defined not as a single disease entity but rather a collection of disorders with different 
underlying pathophysiological mechanisms that have a similar final common pathway (Aigner et al., 2002).  
Numerous researchers are now compelled to regard OA as a "process" rather than a disease because it is 
observed in all those conditions that display an imbalance between mechanical stresses applied to the 
articular cartilage and its ability to withstand that stress (Slemenda et al., 1998), this leads to the loss of 
articular cartilage within the synovial joints causing joint damage. 
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1.3.1 Aetiology 
The exact underlying cause of OA is unclear.  Epidemiological studies, analysis of patterns of familial 
clustering and twin studies have all suggested that there is a definite genetic component (Valdes et al., 
2006). There are also numerous interacting environmental and mechanical factors that contribute to the 
onset of OA.  Perhaps the most obvious of these is age, since the incident of arthritis increases almost 
exponentially with age (Petersson 1996).  Other factors including (but are not limited to), gender (being 
more common in women), joint instability and/or malalignment, malnutrition (Swoboda 2001), muscle 
weakness (Goldring et al., 2007), obesity (Felson 1990), occupation involving repetitive heavy joint use 
(Felson 1988) and trauma/joint injuries (Doherty et al., 1983) have all been implicated in the onset of OA.  
These risk factors may trigger biochemical and molecular pathways, leading to the progression of OA 
(Figure 1.3).   
 
 
 
 
Figure 1.3: Potential causative factors that may lead to initiation and progression of OA.  Systemic 
and extrinsic factors can result in altered biochemical and molecular pathways in the joint leading to 
structural damage. 
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1.3.2 Signs, Symptoms and Characteristics 
OA mainly affects the large weight bearing joints such as knees, hip and lower spine, as well as the joints 
of hands and feet (Cushnaghan et al., 1991). OA can be classified as being primary/idiopathic (affecting 
previously healthy individuals over the age of 40 years) or secondary (develops in response to injury of the 
joint) in nature. 
 
Since OA is not defined by a particular joint involvement pattern, clinical presentation is thus difficult to 
assess.  OA is mostly not diagnosed until it has progressed to the later stages where more pronounced 
alteration in the joint lead to pain and radiographically detectable changes.  Clinical symptoms of OA 
include (Hunter et al., 2008): 
 
x Joint pain; intensity of which increases upon excessive joint movement and weight bearing but is 
relieved by rest except in advance form of the condition where OA can cause rest and night pain leading to 
loss of sleep, further exacerbating pain.  This pain is often deep, aching and not well localized.  It is usually 
of insidious onset and when pain persists, pain-related psychological distress is also evident. 
x Stiffness; felt intermittently upon resuming activity after rest but with time it becomes permanent.  
x Reduced function and joint movement. 
x Joint instability, buckling or giving way. 
x Crepitus (creaking of the joints with movement).  
x Deformities, bony enlargement of the joint.  
x Altered gait.  
x Muscle atrophy or weakness.  
x Joint effusion, swelling and inflammation, tenderness usually located over the joint.   
 
Pain is the main symptom experienced as a result of the pathophysiology of OA and is shown to originate 
from several sources such as periosteum, subchondral bone, synovium, menisci, ligaments and muscles 
(Brandt et al., 1991).  It is thought to be enhanced by inflammation and angiogenesis which are both 
interconnected.  It has been postulated (Dieppe et al., 2005) that angiogenesis can lead to the innervation of 
normal articular insensate cartilage, thus being the source of pain.  Vascularisation of non-calcified 
articular cartilage is a common feature in OA but the mechanisms driving it remain incompletely 
understood.  Sensitisation of sensory nerves by inflammatory mediators can also cause pain and these 
sensitized nerves can therefore contribute to neurogenic inflammation and initiate new vessel growth.   
 
Radiographically visible changes are narrowing of the joint space with osteophyte growth at joint margins 
and advancement of the subchondral bone (Goldring et al., 2007).  Depletion of proteoglycans and collagen 
II have been found alongside fibrillation of the articular surface, fissures, thinning of the cartilage and 
tidemark duplication (Lorenz et al., 2006).  Blood vessels cross the tidemark from the subchondral bone 
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into the avascular articular cartilage.  Synovial inflammation is observed accompanied by thickening of the 
synovial lining, angiogenesis and synovial effusion, all leading to joint swelling. 
 
1.3.3 Pathophysiology 
In the osteoarthritic joint, gradual loss of articular cartilage is observed, where osteoarthritic cartilage loses 
its smooth appearance.  Initial degenerative changes in the articular cartilage lead to cartilage softening, 
fibrillation, fissuring and diminished cartilage thickness.  These changes become more pronounced with 
time, eventually exposing the underlying subchondral bone plate.  Pathology in the articular cartilage is 
referred to as chondropathy (Figure 1.4).  In the case of the knee joint, structural changes are more marked 
in the tibial cartilage, particularly in the medial compartment.  Cartilage loss in OA results from the 
degradation of ECM by chondrocytes and activation of extracellular matrix metallaproteinases (MMPs).  
Additionally, metabolic activity of the chondrocytes is shifted towards a state where new matrix synthesis 
is outweighed by a breakdown of matrix constituents (Rousseau et al., 2007).  Chondrocytes show a 
reduced expression of type II collagen, and aggrecan, the major cartilage proteoglycan.  Upregulation of 
MMPs such as collagenases (MMP-1, -8 and -13), gelatinase (MMP-2) and stromelysin (MMP-3) is also 
apparent.  These enzymes are synthesized by chondrocytes and released into the ECM where they are 
activated and cause degradation of collagen and proteoglycans (Murphy et al., 2005; Pardo et al., 2005; 
Cawston et al., 2006) but these are not dominant aggrecanase enzymes, and instead the major protease 
responsible are two members of the A-Disintegrin And Metalloproteinase with Thrombospondin-like 
Repeats (ADAMTS) family-ADAMTS-4 and ADAMTS-5 (Murphy et al., 2005).  The activity of MMPs is 
controlled by tissue inhibitors of metalloproteinases (TIMPS).  TIMP-1 is most effective in inhibiting 
MMP-1 and is the most highly expressed protease inhibitor in normal cartilage (Davidson et al., 2006).  
TIMP-3 is the only TIMP that can inhibit aggrecanases ADAMTS-4 and -5, and in addition is sequestered 
rather than released freely into the ECM, allowing for a precise control over its cellular localization, which 
is very useful in the carefully localized process of angiogenesis (Kashiwagi et al., 2001; Murphy et al., 
2003).  Disturbances in the regulation of MMPs and TIMPs increase cartilage degredation (Franses et al., 
2010).  Serine protease inhibitors, secretory leukocyte proteinase inhibitor (SLPI) and the plasminogen 
activator inhibitor (PAI)-1 are also responsible for cartilage matrix degradation.  PAI-1 regulates the 
activation of of the serine protease plasmin via urokinase plasminogen activator (uPA) or tissue 
plasminogen activator (tPA), contributing to cartilage turnover by activating pro-MMPs (Cawston et al., 
2006).  SLP-1 inhibits many cartilage degrading proteases, and is implicated in reducing angiogenesis by 
inhibiting endothelial cell (EC) migration (Franses et al., 2010).  Therefore a compromised articular matrix 
composition through an interplay of various promoters and inhibitors leads to abnormal matrix turnover 
and hence cartilage degradation. 
 
Concomitant changes in bone are less well understood.  OA is characterized by an increase in anabolic 
activity in the subchondral bone.  Osteoblastic and Osteoclastic activities become unbalanced and increased 
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bone deposition results in subchondral bone sclerosis and formation of osteophytes.  Osteophytes (new 
bone formation) appear at the joint margins, subchondral bone thickens, joint capsule enlarges, mild 
synovitis and effusion are also observed (Pelletier et al., 1995).  It remains yet to be confirmed whether 
subchondral bone sclerosis is a cause of or consequence of cartilage loss in OA.  The increased thickness 
and density of the subchondral bone and osteophyte formation may be a result of a disordered repair 
process to increase joint stability.  Evidence suggests that sclerosis may be the initial pathological event in 
OA initiating subsequent cartilage loss through preventing the flow of nutrients from underlying 
subchondral bone to the cartilage (Hunter et al., 2003).  Fragments of damaged joint cartilage detach and 
fall into the articular cavity as a result of fissuring and float in the synovial fluid causing the upregulation of 
inflammatory mediators like interleukin (IL)-1 and tumour necrosis factor (TNF)-Į(Hedbom et al., 2002).  
This pathological process leads to compromised function of the cartilage to effectively distribute forces in 
the weight bearing joints (Maroudas 1976).    
 
OA is largely thought of as a non-inflammatory disorder; however research has shown that inflammation is 
an integral component of OA progression contributing to the development of its symptoms (Bonnet et al., 
2005).  Inflammation may be caused by phagocytosis of shed cartilage fragments by synoviocytes.  The 
inflamed synovium releases pro-inflammatory cytokines such as TNF-Į DQG ,/-1 and -6 (Smith et al., 
1997).  These cytokines can bind to chondrocyte receptors leading to further release of MMPs as well as 
inhibiting type II collagen production, hence enhancing cartilage degradation (Stannus et al., 2010). 
 
Synovial and subchondral bone changes are now being regarded as essential in understanding the 
pathogenesis of progressive joint destruction, but whether events in cartilage precede those in bone and 
synovium or vice versa or they actually occur around the same time in cartilage, synovium and the 
subchondral bone are all topics of immense interest.   
 
Meniscal degeneration is commonly seen in OA, where menisci appear torn, fissured, fragmented, 
macerated or completely destroyed (Bennett et al., 2002; Englund 2009).  Proteoglycan loss, collagen 
alteration, degradation of the meniscal ECM, peri-meniscal synovitis, calcification and increased blood 
vessel growth not limited to the outer peripheral portion of the menisci (Burman et al., 1933; Herwig et al., 
1984; Kapadia et al., 2000; Grainger et al., 2007; Sun et al., 2010) all contribute to meniscal degeneration 
and reduced meniscal tensile strength.  The meniscus is less able to withstand loading and force 
transmission during normal movements of the joint, further leading to degenerative tears (Bhattacharyya et 
al., 2003) and exacerbating OA structural damage.   
 
Degenerative tears occurring in OA are distinct from traumatic tears which usually occur in younger people 
as a result of a specific trauma to the joint in which the meniscus becomes trapped under excessive force 
between the femoral and tibial condyles (Englund 2009).  Joint space narrowing as a result of OA displaces 
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the meniscus, exposing the underlying articular surfaces (Gale et al., 1999).  The loss of normal functioning 
meniscus due to tears or displacement contribute to articular cartilage loss and further progression of OA 
(Hunter et al., 2006).   
A strong association between meniscal degeneration, articular cartilage damage, subchondral bone changes, 
synovitis and joint space narrowing is reported in enhancing the experience of pain in OA (Gale et al., 
1999; Hunter et al., 2006; Yusuf et al., 2010).   
 
 
 
 
Figure 1.4: Comparison of osteoarthritic and normal joint.  Changes occur in the cartilage (loss of 
proteoglycans, fibrillation/erosion), subchondral bone (osteophytosis, sclerosis, remodeling) and synovium 
(inflammation).  (Smith et al., 2002). 
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1.3.4 Diagnosis and Detection 
To a certain degree like other complex clinical syndromes, a poor correlation is observed between the 
clinical features (symptoms), underlying mechanisms (pathology) and imaging (radiological) of OA.   
 
Standard radiography is insensitive to the earliest pathological features of OA, hence the absence of 
positive radiographic findings can not confirm the complete absence of symptomatic disease (Kellgren et 
al., 1957); radiographs have also been shown to not always complement the clinical presentation of pain 
(Spector et al., 1993).  Conversely, on some occasions people may have indication of OA through X-ray 
changes but display mild physical symptoms.  The advanced form of the disease is clearly visible on plain 
radiographs as narrowing of joint space, osteophytes and sometimes changes in the subchondral bone.  
Standard radiography, in general, provides a limited view of the disease process in subchondral bone (Ding 
et al., 2007). 
 
Ultrasound can be used to measure synovial thickness and Doppler imaging can be used to reveal synovial 
blood flow and hence indirectly angiogenesis and synovitis, which encompass some of the early changes 
observed in OA.  Magnetic Resonance Imaging (MRI) is now permitting serial assessment of subchondral 
bone, both in early and established OA as well as in normal joints.  This whole-organ evaluation approach 
has demonstrated frequent abnormalities of cartilage, menisci, bone (bone marrow lesions and 
osteophytes), synovium and ligaments even when no radiographic changes are present in patients with OA 
(Conaghan et al., 2006) such as bone marrow lesions in early OA, which are not detectable with plain 
radiographs (Conaghan et al., 2004; Carrino et al., 2006).    
 
Arthroscopy can reveal cartilage damage before changes in bone become evident however it is invasive so 
it is not a method of choice for diagnosis of OA.  No reliable laboratory test for diagnostic purpose is 
available.  Erythrocyte sedimentation rate and levels of C - reactive protein provide useful information 
about inflammation in some patients with OA but they correlate poorly with pathology of cartilage damage.   
 
The 2009 European League Against Rheumatism (EULAR) recommendations for diagnosing knee OA 
state that when the following 3 symptoms and 3 signs are detected, it is sufficient to correctly diagnose 
99% of knee OA (Altman 2010).  The 3 symptoms are persistent knee pain, limited morning stiffness and 
reduced function, and the 3 signs are, crepitus, restricted movement and bony enlargement (Zhang et al., 
2010).  American College of Rheumatology (ACR) describe OA based on clinical examination of knee 
pain in addition to 3 of the following 6 criteria: > 50 years of age, < 30 minutes of morning stiffness, 
crepitus, bony tenderness, no enlargement, or an absence of palpable warmth (Altman et al., 1986).  
Sensitivity for these criteria is 95% with 69% specificity (Altman 2010).   
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Patients presenting in the clinics normally have severe OA so early detection and analysis of OA in patients 
need to be the prime research focus to fully understand the mechanisms in disease progression from start to 
finish.   
 
1.3.5 Treatment 
OA is not a curable disease.  Mechanisms by which OA arises remain incompletely understood.  At present 
therefore treatment is tailored according to risk factors, severity of pain, presence or absence of joint 
effusion and degree of osteoarthritic damage.  Because no single therapy is adequate in OA, it comprises of 
both non-pharmacological and pharmacological therapies.  Therapy focuses on alleviating the signs and 
symptoms of the disease especially pain and inflammation, to improve quality of life, mobility, walking 
and if possible, to slow the progression of OA (Altman 2010).  Physical therapy and exercise are employed 
to improve stiffness by increasing movement and strengthening muscles that support the affected joints.  
Joint replacement surgery is the end result in those in whom conventional management has failed.  
Currently, analgesics (paracetamol, acetaminophen, opioids and capsaicin), anti-inflammatory agents with 
analgesic properties (non-selective non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase 
[COX]-2 inhibitors, topical NSAIDs and intra-articular corticosteroids), symptomatic-slow-acting drugs 
and anti-cytokine therapy are used to treat OA of the knee (Michael et al., 2010) (Figure 1.5).  These drugs 
are not without their associated side effects.  The specific risk factors associated with the use of classic 
NSAIDs are due to their mechanisms of action on prostaglandin secretion.  These drugs act by inhibiting 
the secretion of prostaglandins through COX-1 and/or COX-2 inhibition.  Specific COX-2 inhibitors have a 
selective anti-inflammatory effect but are still markedly nephrotoxic, whereas non-selective COX inhibitors 
also have renal side effects.  Intra-articular glucocorticoid injections can markedly reduce joint effusions 
but are used with caution in diabetic patients who are already hyperglycaemic.  Slow-acting drugs for 
osteoarthritis (SADOA) which can be further subdivided into either symptomatic-SADOA or disease 
modifying osteoarthritis drugs (DMOAD) include hyaluronic acid, D-glucosamine sulphate, chondroitin 
sulphate and diacerein (Michael et al., 2010).  Their specific mechanisms of actions are yet to be elucidated 
but they range from curtailing inflammation to nociceptor blockade and targeting matrix destroying effects 
of cytokines.  Antibodies against TNF-ĮRU the use of anti-inflammatory cytokines such as IL-1, -10, -13 
and TNF-ȕDUHDOVRDYDLODEOH(Michael et al., 2010). 
 
Inflammation and Angiogenesis both contribute to the symptoms and pathology of OA, therefore further 
analysis of their role can lead to more effective therapies. 
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Figure 1.5: Therapeutic approach for OA.  After the diagnosis of OA, a non-pharmacological 
approach is initiated.  If that is not effective, then a pharmacological approach is adopted.  Joint 
replacement surgery is the end result in those in whom conventional management has failed.  COX 
(cyclooxygenase), NSAID (non steroidal anti-inflammatory drug) (Altman 2010). 
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1.4 Pain and Osteoarthritis 
The sensation of pain alerts us to real or impending injury and triggers the appropriate protective responses 
in harmful situations.  However, in some instances, pain can exceed its usefulness and can become chronic 
and debilitating.  The theory of pain that has been carried over into the 20th Century was originally 
proposed by a scientific philosopher Descartes in the 17th Century, but in 1965 ideas about pain were 
revolutionized by Wall & Melzacks ³*DWH&RQWURO7KHRU\´(Melzack et al., 1965).  This theory states that 
the transmission of nerve impulses from afferent fibres (nociceptors) to the spinal cords dorsal horn is 
PRGXODWHGE\DVSLQDO³JDWLQJ´PHFKDQLVPZKLFKLQFUHDVHRUGHFUHDVHWKHIORZRIWKHVHDIIHUHQWVLJQDOVWR
higher processors i.e. the brain, depending on their activity.  Essentially the theory highlighted the central 
nervous system as an essential component in pain processes (Melzack 1993).  The current beliefs of pain 
DUHODUJHO\EDVHGRQWKLV³JDWHFRQWUROWKHRU\´RXWOLQHGRYHU\HDUVDJR 
 
The tissues of healthy joints appear to have a relatively high threshold in order to prevent normal 
movements generating pain (Dieppe et al., 2005).  Pain arising from damage to tissue that the nerves serve 
is known as inflammatory pain, whereas, neuropathic pain arises from changes in damaged nerve endings 
(Dickenson 2002).  Pain, the predominant feature of OA, is one of the main reasons of patients seeking 
medical advice.  The precise causes of this pain are not fully understood as the pain experienced in OA 
varies widely in nature, severity and location between patients, hence it is plausible to assume that the 
sources of pain also differ between patients (Creamer 2000).   
 
It is the sensory neurons (nociceptors) that transmit the information that is portrayed as pain, of which the 
$į-fibres transmit the sharp pain of an acute injury and the C-fibres produce the dull, aching pain of a 
deeper, more persistent injury and the burning quality of neuropathic pain (Julius et al., 2001; McCabe 
2004).  Afferent sensory nerves terminate at the dorsal horn in the spinal cord, here information from the 
periphery is interpreted and acted on through interaction with the central nervous system (CNS) (Schaible 
et al., 1993; Felson 2005; McDougall 2006).  Nociceptors in the joint normally respond only to movement 
of the joint beyond its working limits, however following joint damage, physical changes (joint effusion, 
tissue oedema, and structural changes) in the joint, alongside the introduction of inflammatory mediators 
released into the damaged tissues, result in a reduction of the mechanical threshold for the activation of 
articular nociceptors.  In this instance, manipulation and movement of the joint within its normal range is 
easily sufficient to activate them and cause allodynia (pain in response to a normally innocuous stimuli) 
and hyperalgesia (heightened pain intensity in response to a normally painful stimuli) (Schaible et al., 
1985).   
 
It has been reported that nociceptors in the joint do not always signal pain when stimulated by mechanical 
pressure, explaining why some patients with extensive radiographic changes of OA fail to report pain 
whilst others having normal radiographs experience pain (Hannan et al., 2000; Felson et al., 2001).  
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Inflammation has been strongly linked to hyperalgesia and persistent pain in OA (Hill et al., 2001; Hill et 
al., 2007)  $QRWKHU PHDQV E\ ZKLFK SDLQ PD\ EH JHQHUDWHG LQ MRLQWV LV YLD WKH VWLPXODWLRQ RI ³VLOHQW
QRFLFHSWRUV´7KHVHVHQVRU\QHUYHILEUHVDUHTXLHVFHQWLQ normal joints.  However, following injury and/or 
inflammation these become activated and start to send nociceptive information to the CNS (Grigg et al., 
1986; Schaible et al., 1988).  Persistent pain (chronic inflammation) can alter both peripheral and central 
signaling mechanisms.  Effectively, peripheral sensitization will, over a period of time lead to central 
VHQVLWL]DWLRQ DORQJVLGH ³1HXUDO SODVWLFLW\´ ZKLFK PD\ SOD\ D ODUJH UROH LQ WKH SDLQ H[SHULHQFHG GXULQJ
arthritis.  Whereby, the normal neural circuits that feed in to the pain pathways can reconfigure in response 
to the stimulus they receive.  Here, persistent pain transmission, as in chronic inflammation can lower the 
WKUHVKROGRIWKH$įDQG&ILEUHVIURPMXVWGHWHFWLQJQR[LRXVVWLPXOLWRGHWHFWLQJQRQ-noxious stimuli, such 
as normal knee joint movements (McCabe 2004).  Overall, nociceptors not only signal acute pain, but also 
contribute to persistent and pathological pain conditions that occur after injury or inflammation, wherein 
pain is produced by normally innocuous stimuli resulting from either the lowering of nociceptor activation 
thresholds (peripheral sensitization) and/or the increased responsiveness of spinal cord neurons that are 
responsible for pain transmission to the brain (central sensitization) (Coggeshall et al., 1983; Schaible et 
al., 1986; Dieppe et al., 2005).   
 
1.4.1 Joint pathology contributing to pain in OA 
The source and cause of osteoarthritic pain is still largely unknown but is believed to involve multiple 
interactive pathways, and could be caused by the structural damage occurring in the joint such as 
degradation of the articular cartilage, joint space narrowing, osteophyte formation, subchondral bone 
changes, meniscal changes and/or inflammation in the joint.   
 
Articular cartilage is both avascular and aneural, incapable of directly generating pain.  In contrast, 
nociceptors are found primarily in the tissues of subchondral bone, periosteum, ligaments, muscle, joint 
capsule, synovium and the menisci and may be implicated in the genesis of pain in OA (Felson 2005).   
 
Synovial hyperplasia, fibrosis, thickening of synovial capsule, activated synoviocytes and in some cases 
lymphocytic infiltrate (B- and T-cells as well as plasma cells) are characteristic features of osteoarthritic 
synovium (Hunter et al., 2008).  Synovium contributes to osteoarthritic pain as a result of irritation of 
sensory nerve endings within the synovium from osteophytes and synovial inflammation that is due in part 
to the release of prostaglandins, leukotrienes, proteinases, neuropeptides and cytokines (McDougall 2006).  
Using non-contrast MRI, inflamed infrapatellar fat pad, has also been implicated in the pathogenesis and 
hence a source of pain in OA (Fernandez-Madrid et al., 1995; Hill et al., 2007). 
 
It has been shown that blood vessels grow up from the subchondral bone, breaching the tidemark and 
invading the normally aneural and avascular articular cartilage in OA (Suri et al., 2007).  The route by 
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which they do this is usually within the vascular channels that extend up from the subchondral bone 
marrow spaces through the calcified cartilage and into the non-calcified articular cartilage (Clark 1990), 
which effectively provide a direct connection between the subchondral bone marrow spaces and articular 
cartilage.  Such invasion has also been linked to the loss of proteoglycans from the cartilage providing less 
resistance to vascular invasion.  Alongside the growth and invasion of new vessels, accompanying afferent 
fibres have also been observed, which may be attributed to some of the pain experienced in OA.  
Experiments have indicated that neovascularisation precedes nerve growth forming a pathway for 
innervations of the surrounding tissue (Gu et al., 1995).  If this is the case at the osteochondral junction, 
neovascularisation in OA from underlying subchondral bone and the subsequent invasion of the overlying 
articular cartilage may also form a pathway in which these sensory nerves can grow.  As well as the 
sensitization of joint nociceptors, both in the synovium and within the subchondral bone, such as those 
growing through vascular channels, there are other peripheral components in joint pain suffered in OA, 
including bone pain caused by rapid bone turnover and subchondral bone plate thinning (due to high 
osteoclast activity and an acidic pH), the ossification of chondrocytes to form osteophytes and the 
formation of osteophytes, attributing to joint space narrowing.  Source of pain in OA has been attributed to 
bone pathologies such as subchondral bone sclerosis, microfractures, raised interosseous pressure and 
decreased blood flow leading to bone angina and stretching of periosteum by osteophyte formation 
(Arnoldi et al., 1975; Szebenyi et al., 2006; Hunter et al., 2008).  Bone marrow lesions detected using MRI 
are also strongly associated with pain in OA (Felson et al., 2001).   
 
However, the use of bone pathology as an explanation for pain in OA is limited since only a weak 
relationship exists between radiographic joint changes and the level of pain experienced.  Patients suffering 
from joint pain may have periarticular syndromes; soft tissue lesions that are painful and often disabling 
HJ%DNHU¶VF\VWRU,QIUDSDWHOODUEXUVLWLVFDXVHGE\LQIODPPDWRU\PHGLDWRUVWKDWEXLOGXSLQWKHVRIWWLVVXH
The above mentioned studies on sources of pain in OA rely on correlation between particular tissue 
pathologies and presence of pain.  From these studies it can not be confirmed whether a particular 
pathological process in OA is the cause of pain, it can only be deduced that the two are associated. 
 
Another source of joint pain in OA may be directly due to the nerves themselves.  Following joint injury, 
the nerves which re-innervate the healing tissue may show a disorganized and abnormal morphology, 
containing an over abundance of chemicals such as Substance P and CGRP (McDougall et al., 2000) 
indicating that injured joints could develop neuropathic pain post-trauma which has been successfully 
treated with the neuropathic pain analgesic gabapentin to relieve arthritis (Hanesch et al., 2003). 
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1.4.2 Neuropeptides, Sensory Nerves and Inflammation 
Inflammation in OA, whether it is in the synovium or bone is a substantial contributor to joint pain.  
Neuronal activity in the pain pathway is ultimately responsible for the generation and exacerbation of joint 
pain.  Release of inflammatory mediators such as bradykinin, prostaglandins, histamine, lactic acid, 
substance P, CGRP and vasoactive intestinal peptide into the joint sensitizes nociceptors to otherwise 
normal innocuous joint movements to elicit a painful response (Hunter et al., 2008).  With time, in OA, 
inflammation and increased neuronal activity from the periphery can cause plasticity changes in the CNS.  
Second order neurons in the spinal cord increase their firing potential such that the transmission of pain 
information to the somatosensory cortex is enhanced.  This central sensitization intensifies pain felt and can 
even lead to pain responses in other regions of the body remote from the inflamed joint (referred pain) 
(Hunter et al., 2008).  As the disease progresses, more of these mediators accumulate in the affected joint, 
thereby stimulating a self-perpetuating cycle of pain generation.     
 
Neuropeptides are a family of chemical mediators, stored and released from the terminals of autonomic 
nerves and slowly conducting joint afferents.  Local axon reflexes are responsible for the peripheral release 
of neuropeptides from sensory nerves, leading to neurogenic inflammation (McDougall 2006).  Numerous 
neuropeptides are localized in nociceptive afferent nerve fibres, including the thin un-myelinated A and C-
fibres, both of which are found in the joints.   
 
CGRP and substance P are both well known neuropeptides markers for primary afferent fibres.  CGRP is a 
37 amino acid peptide known to exist in two forms, alpha and beta, that activates intracellular adenylyl 
cyclase and protein kinase A through G protein-coupled receptors including the CGRP1 receptors (Bird et 
al., 2006).  CGRP coexists with Substance P in small-diameter afferent fibers and are important mediators 
in the pathogenesis of arthritis (Chen et al., 2008).  It has been reported that sensitization of sensory nerves 
lead to the untimely, abnormal and excessive release of neuropeptides in some areas and depletion in 
others, leading to neurogenic inflammation, causing vasodilatation, increased vascular permeability and 
plasma extravasation into the surrounding tissues, all of which are characteristic features of an acute 
inflammatory response (Garrett et al., 1992; Konttinen et al., 2006).  Substance P has been shown to induce 
plasma extravasation into the joint and stimulate the function of various inflammatory cells whilst CGRP 
has been reported to both increase blood flow to the joint, and also potentiate the effects of Substance P 
(Mapp et al., 1996).  Hyper-responsiveness of CGRP was blocked in acute synovitis following 
administration of a selective CGRP antagonist, indicating that CGRP plays an important role in the central 
neurotransmission of painful mechanosensory information arising from the knee (Neugebauer et al., 1996).  
CGRP is also referred to as a ³ERQH QHXURSHSWLGH´ ZKLFK KDV EHen shown to inhibit osteoclastic bone 
resorption and may be implicated in the bone remodelling seen in OA (Konttinen et al., 1996).  The release 
of neuropeptides also has a powerful effect on cytokine production such as the interleukins which can 
further lead to the up regulation of these neuropeptides, hence potentiating the inflammatory effect as well 
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as pain behaviour (Konttinen et al., 2006).  Taken together, previous literature indicates that sensory 
neuropeptides, of which CGRP and substance P are most well studied, contribute towards generating and 
promoting joint pain in OA. 
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1.5 Angiogenesis and Osteoarthritis 
The complex process of angiogenesis is defined as the growth of new blood vessels from pre-existing 
vasculature (Risau 1997).  Under normal conditions angiogenesis is tightly regulated by various activating 
and inhibitory factors.  Angiogenesis is fundamental to many physiological events including 
embryogenesis, growth, wound healing and female reproductive system (Walsh 1999).  Unregulated 
angiogenesis can result in numerous pathologies including chronic inflammation, tumour growth and 
metastasis, arthritis (Walsh et al., 2001), diabetic retinopathy, psoriasis, and juvenile haemangioma (Powell 
1999).   
 
1.5.1 Process of Angiogenesis 
Angiogenesis is viewed as a multi-step process rather than just a single event (Bonnet et al., 2005) 
involving intensive interplay between cells, soluble factors, ECM components, activating and inhibiting 
factors (Liekens et al., 2001).  These vary depending on the tissue involved, between different 
physiological and pathological conditions as well as during the different phases of a continuous disease 
process such as synovitis (Bonnet et al., 2005). 
 
Angiogenesis is rapidly initiated upon receiving an activating signal, also known as the angiogenic 
stimulus.  Hypoxia, ischemic conditions, diseased or injured tissues producing and releasing angiogenic 
promoters can all trigger angiogenesis.  Vascular relaxation mediated by Nitric Oxide (NO) can enter ECs 
in the angiogenic cascade (Griffioen et al., 2000).  Vascular endothelial growth factor (VEGF) has also 
been implicated in the initiation of angiogenesis.  VEGF can induce vasodilation via endothelial NO 
production, increase EC permeability and prevent EC apoptosis (Brown et al., 1997) as well as inducing 
proteases and various receptors important during cellular invasion and tissue remodelling.  It is abundantly 
released by hypoxic tumour cells, macrophages and various other cells of the immune system (Ziche et al., 
1997).  VEGF-receptor is upregulated under hypoxic and ischemic conditions, emphasising its role in the 
early phases of angiogenesis (Forsythe et al., 1996).  Angiogenesis initiation however does not solely 
depend on VEGF production.   
 
The first process to take place after receiving the angiogenic stimulus is the activation of ECs.  This 
involves their detachment from the tight configuration with adjacent ECs by the alteration of vascular 
endothelial cadherin junctions that link them together (Bonnet et al., 2005), leading to increased vascular 
permeability.  The underlying endothelial basement membrane (BM) is degraded by proteolytic enzymes 
such as MMPs and plasminogen activators, releasing matrix bound angiogenic factors (Pepper 2001) 
enabling the migration and proliferation of ECs into the stroma of neighbouring tissues.    
 
Following the proteolytic degradation of the BM, ECs start to migrate through the degraded matrix into the 
surrounding areas.  This migration is aided by a variety of cell surface associated integrins, allowing 
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specific cell matrix adhesions as they move through the ECM to reach the site of new vessel formation 
(Carmeliet 2000).  ECs proliferate to provide adequate capillary perfusion to the target site, if for any 
reason proliferation is halted then the angiogenic response fails to progress beyond the initial stage of 
neovascularisation which is vascular sprouting.   
 
Capillary tube formation and deposition of new BM are critical steps in the formation of new, fully 
functional capillaries and requires the re-establishment of the vascular endothelial cadherin and adherin 
junctions that were initially disrupted.  This requires the tight cell-cell adhesions to form; platelet 
endothelial cell adhesion molecule-1 (PECAM-1) plays an important role in this.  EC interactions with 
ECM and mesenchymal cells are an essential requirement for the formation of a stable vasculature.  Hence 
when the capillary tube formation is completed and the BM is laid down, surrounding vessel layers 
composed of mural cells (Hirschi et al., 1997) need to be recruited.  This is accomplished by the synthesis 
and secretion of growth factors like platelet derived growth factor (PDGF) which is a mitogen and 
chemoattractant for a variety of mesenchymal cells (Griffioen et al., 2000).  Mural precursor cells then 
differentiate into pericytes and smooth muscle cells (SMC) through the cell-cell contact dependent process.  
Anastomoses are then created and blood flow is established leading to the development of vasoregulatory 
system and a fully functional microvasculature through the expression of vasoactive peptides and their 
receptors (Walsh 1999) whilst redundant vessels regress as a result of EC proliferation (Bonnet et al., 2005) 
(Figure 1.6). 
 
Figure 1.6: Process of angiogenesis.  Activating signal/angiogenic stimulus leads to the release of 
angiogenic promoters including vascular endothelial growth factor (VEGF) and fibroblast growth factors 
(FGFs) which assist in the development of new blood vessels (angiogenesis). 
Activating Signal/Angiogenic Stimulus 
Hypoxia, Ischemia, Diseased or Injured Tissue 
Angiogenic Promoters 
VEGF and FGF ANGIOGENESIS 
EC activation 
Capillary tube formation and deposition of new 
basement membrane 
EC proliferation 
EC migration 
Stable Vasculature 
 39 
1.5.2 Factors regulating Angiogenesis 
Angiogenesis is regulated by numerous inducers and inhibitors produced by a large number of cells under 
various conditions.  VEGF, FGF, epidermal-derived growth factor (EDGF), PDGF, angiopoietins as well as 
chemokines and cytokines are some of the well known pro-angiogenic factors (Walsh 1999; Liekens et al., 
2001; Bonnet et al., 2005).  Perhaps the most well described of these pro-angiogenic factors is VEGF 
(Klagsbrun et al., 1999).  These regulatory mediators are either soluble, ECM or membrane bound growth 
factors (GF) or components of ECM itself.   
 
VEGF family and the angiopoietins specifically act on ECs.  VEGF is produced in response to certain 
growth factors, cytokines and in response to low tissue oxygen tension (Liekens et al., 2001).  VEGF is a 
potent angiogenic factor which also regulates chondrocyte metabolism.  It couples the invasion of blood 
vessels with hypertrophic cartilage remodelling and ossification in OA (Murata et al., 2008).  VEGF can be 
expressed by osteoblasts, hypertrophic chondrocytes, and superficial articular chondrocytes in OA, as well 
as by macrophages and fibroblasts within the synovium  (Enomoto et al., 2003).  VEGF expression is 
upregulated in OA chondrocytes compared to normal controls (Gerber et al., 1999), although increased 
VEGF expression in OA articular cartilage is predominantly localised to the superficial zones rather than 
near sites of osteochondral angiogenesis (Pufe et al., 2005).   
 
Inflammatory cytokines, hypoxia and mechanical stress each modify chondrocyte phenotype in OA (Pufe 
et al., 2004),  including upregulated VEGF expression (Goldring 2001; Murata et al., 2008).  IL1 induced 
VEGF production was dependent on Jun N-terminal kinase (JNK) but not p38 mitogen-activated protein 
kinase (MAPK) signalling pathways (Murata et al., 2006).  The inflammation-responsive transcription 
factor Serum Amyloid A activating factor-1 (SAF-1) may regulate VEGF expression in chondrocytes 
during arthritis (Ray et al., 2007).  Knock-down of endogenous SAF-1 inhibited IL-ȕDQGtumour growth 
factor (TGF)-ȕPHGLDWHGLQGXFWLRQRI9(*)H[SUHVVLRQLQFKRQGURF\WHV 
 
Hypoxia upregulates VEGF expression in chondrocytes through the activation of hypoxia inducible factor 
(HIF)-Į.  HIF-ĮDQG9(*)GLVSOD\VLPLODUORFDOLVDWLRQVLQ2$(Pfander et al., 2005).  Increased VEGF 
expression in hypoxic chondrocytes was dependent on the p38 MAPK pathway, indicating that 
inflammation and hypoxia regulate VEGF expression in chondrocytes through distinct signalling pathways 
(Murata et al., 2006).   
 
Upregulated VEGF expression in chondrocytes induced by mechanical overload/stress such as 
compression, shear, tension and strain may also be mediated by HIF-ĮDFWLYDWLRQ (Tanaka et al., 2005).  
HIF-ĮH[SUHVVLRQDOVRDFFRPSDQLHG9(*)H[SUHVVLRQ LQRYHUORDGHGERYLQHFDUWLODJHGLVNV (Pufe et al., 
2004).  Inflammatory mediators may also contribute to the stimulation of chondrocytes by abnormal 
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mechanical stress (Loeser 2006) and synergy between inflammatory, hypoxic and mechanical pathways 
may be key to the predilection of diarthrodial joints to develop OA. 
 
VEGF may facilitate the secretion of MMPs whilst reducing TIMP production, especially under hypoxic 
conditions (Pufe et al., 2004; Tanaka et al., 2005).  The resistance of articular cartilage to vascular 
invasion, is in part due to the generation of anti-angiogenic factors, including TIMPs, by articular 
chondrocytes (Smith et al., 2003) 9(*)¶V DELOLW\ WR VKLIW WKH MMP:TIMP balance in favour of matrix 
degradation may contribute to the loss of angiogenesis inhibition observed in OA cartilage. Modulation of 
chondrocyte function, therefore, far from being a coincidental action of VEGF, may enhance its direct 
angiogenic effects on vascular ECs. This may well be desirable in the normal growth plate, but in OA, 
where the equilibrium is already shifted to cartilage degradation, such effects may exacerbate the disease 
process. 
Angiopoietin (Ang)-1 and Ang-2 play key roles in blood vessel maintenance, growth and stabilisation 
(Carmeliet 2003).  Once VEGF has triggered the formation of immature vessels (Polverini 2002) Ang-1 
stabilises them by recruiting mesenchymal cells to the site and promoting their differentiation into vascular 
SMC (Horner et al., 2001).  Ang-2 is a natural antagonist of Ang-1, competitively inhibiting the binding of 
Ang-1 to Tie-2 receptors (Kasama et al., 2007).  In synovial fibroblasts, Ang-1 and Ang-2/Tie expression is 
modulated by hypoxia, VEGF and the proinflammatory cytokines IL-1 and TNF-Į (Scott et al., 2005).  
Osteoblasts also are an important source of Ang-1.  TNF-ĮDQGLQWHUIHURQ-Ȗ,)1ȖFR-stimulation reduces 
the secretion of Ang-1 from human osteoblasts which is mediated in-SDUWE\DQ1)ț%GHSHQGHQWSDWKZD\
leading to the induction of NO synthesis (Jimi et al., 2005).  Mice deficient in Ang-2 are unable to elicit an 
inflammatory response, perhaps suggesting an anti-inflammatory effect of Ang-1 (Fiedler et al., 2006).  
Again, complex interactions are emerging between angiogenesis, inflammation and bone formation.  
 
7*)ȕ-1, noted above to mediate osteophyte growth, has complex effects on angiogenesis. It inhibits EC 
growth, promotes BM reformation and stimulates SMC differentiation and recruitment (Carmeliet 2003).  
7*)ȕ-1 therefore may be important in vascular maturation, an essential step in developing a stable 
neovascular bed. PDGF similarly can contribute to vascular maturation through proliferation of pericytes 
and vascular SMCs (Abramsson et al., 2003).  TNF-Į DQG 7*)-ȕ FDQ H[HUW WKHLU DQJLRJHQLF HIIHFWV E\
releasing factors from macrophages, ECs and tumour cells. 
 
Fibroblast growth factor (FGF) is a family of growth regulatory proteins sharing 35% to 50% amino acid 
sequence identity that have potent mitogenic effects on various cells of mesodermal and ectodermal origin 
(Szebenyi et al., 1999).  FGF signalling is transduced through the formation of a complex, of a growth 
factor, a proteoglycan and a high affinity fibroblast growth factor receptor (FGFR), which is a 
transmembrane tyrosine kinase receptor (McKeehan et al., 1998).  Further research has shown that a 
combination of angiogenic factors such as VEGF or GF supplements containing FGF-1 can increase the 
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survival of both ECs and vascular network tremendously (Kwak et al., 1999).  Cytokines, chemokines and 
angiogenic enzymes activate a wide array of target cells besides ECs.  FGFs (mainly FGF1 and FGF-2) are 
the most well known molecules of this group inducing cell migration, proliferation and differentiation.  
Studies have shown that FGF-2 can induce tube formation in collagen gels and modulate integrin 
expressions, gap junctions and intercellular communications (Bussolino et al., 1996).  FGFs are implicated 
in the progression of OA (Daouti et al., 2005).  FGF-8 was shown to be produced by injured synovium and 
degradation of ECM was enhanced by FGF-8 (Uchii et al., 2008).  FGF-8 may therefore be involved in 
cartilage damage and exacerbation of OA.  FGF-2 has various physiological effects on bone and cartilage 
metabolism (Chuma et al., 2004), it is chondroprotective (Khan et al., 2010). 
 
1.5.3. Role of Chondrocytes in Angiogenesis    
The regulation of matrix turnover and angiogenesis also converge in articular cartilage. Normal mature 
non-calcified articular cartilage is devoid of blood vessels. Articular cartilage is normally hostile to 
vascular invasion, probably because of its matrix composition, and the generation of anti-angiogenic factors 
by articular chondrocytes (Smith et al., 2003).  These include troponin-1 (Moses et al., 1999) and 
chondromodulin-1 (Shukunami et al., 2005) amongst others such as metalloprotease inhibitors.  By 
contrast, chondrocytes may alternatively induce vascular invasion of articular cartilage. Indeed, this is a 
prerequisite for endochondral ossification. In physiological endochondral ossification during long bone 
growth, differentiated chondrocytes proceed stepwise to become hypertrophic chondrocytes, eventually 
undergoing apoptosis, leaving behind a cartilage matrix that is mineralised and replaced by new bone. 
Osteophyte formation at chondro-synovial junctions, and advancement of the subchondral bone into 
articular cartilage, both characteristic features of OA, each proceed through a process of endochondral 
ossification  (Moskowitz et al., 1987).   
 
Pharmacological inhibition of angiogenesis prevents endochondral ossification at the growth plate, leading 
to a widening of the cartilaginous growth plate in growing rodents. Similarly, angiogenesis inhibitors 
prevent new bone formation at the chondro-synovial junction in rodents subjected to experimental arthritis 
(Hashimoto et al., 2002).  Angiogenesis may also contribute to osteophyte formation by facilitating 
inflammation.  TGF-ȕ DQG ERQH PRUSKRJHQLF SURWHLQ %03-2, amongst the growth factors that are 
produced by macrophages (Bakker et al., 2001), contribute to osteophyte formation by enhancing chondro- 
and osteogenesis (Zoricic et al., 2003; van Lent et al., 2004).  Blood vessels from the subchondral bone 
penetrate into the calcified articular cartilage, and grow into the non-clacified cartilage in OA.  As vessels 
invade, new bone is formed as cuffs around the vascular channels, constituting an advancing wave of 
ossification into the osteoarthritic cartilage.  Altering the balance between inhibition and stimulation of 
angiogenesis therefore has the potential to retard pathological new bone formation in OA.  
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Convergence of molecular pathways that regulate chondrocyte function, angiogenesis and inflammation 
emphasises their interdependence in OA pathogenesis, but compromises conclusions about the specific 
contribution made by blood vessel growth. This is amply illustrated by VEGF.  Originally thought to be a 
specific modulator of EC function, albeit causing plasma extravasation as well as angiogenesis, VEGF is 
now known also to have important effects on articular chondrocytes. Evidence of efficacy of VEGF 
receptor inhibition in animal models of arthritis is consistent with, but does not prove, a contribution of 
angiogenesis to their aetiology. 
 
1.5.4 Involvement of Angiogenesis in OA 
During OA, a number of changes can be observed in the joints such as cartilage loss, osteophyte formation 
and synovitis, varying degrees of angiogenesis contributes to each of these features.    
 
The vasculature of normal joints is highly organised, with the synovium being vascular inorder to supply 
the avascular hyaline articular cartilage with oxygen and nutrients.  Study using the chick embryo chorio-
allantoic membrane (CAM) shows that osteoarthritic hyaline cartilage loses its ability to remain avascular 
when placed onto active chick CAM vasculature (Fenwick et al., 1999).  It is thought that the actions of 
anti-angiogenic molecules synthesised and released by chondrocytes inhibit the vascularisation of the 
hyaline articular cartilage and prevent endochondral ossification (Haywood et al., 2001).  Blood vessels 
penetrate the outer portion of the normal human meniscus, reaching as far as its middle third, with the 
innermost portion remaining avascular (Wilson et al., 1969; Day et al., 1985).  This property of the 
cartilage ensures that its mechanical performance is maintained.   
 
The ability of a joint to regulate its blood flow is diminished by the occurrence of synovitis and increased 
levels of synovial fluid volume associated with joint disease.  Studies have indicated that angiogenesis is 
observed more profoundly near the synovial surface of patients with OA (Walsh et al., 2007).  
Angiogenesis is a key component of chronic inflammation, the two are closely linked, supported by in-vivo 
studies showing that synovitis is inhibited by agents that inhibit angiogenesis (Storgard et al., 1999).  
Inflammatory tissue is often hypoxic which leads to angiogenesis via the regulation of factors like VEGF 
and FGF-1 (Walsh et al., 2001).   Inflammatory cells such as macrophages and mast cells (found in 
chronically inflamed OA synovium), can directly or indirectly produce angiogenic factors that can 
stimulate vessel growth in OA.   
 
Invasion of blood vessels across osteochondral junctions is implicated in contributing towards articular 
cartilage changes in OA.  Blood vessels invade into calcified cartilage from the underlying subchondral 
bone within fibrovascular channels (Bonnet et al., 2005; Suri et al., 2007).  Angiogenesis has also been 
demonstrated in association with degeneration in the fibrocartilage of the intervertebral disc (Kauppila 
1995).  Angiogenesis is thought to facilitate the progression of OA by development of osteophytes, 
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endochondral ossification, advancing of subchondral plate and the remodelling of the joint (Brown et al., 
1988).  Subchondral bone has been identified as a potential source of pain in OA.  Subchondral bone 
changes have long been recognised in early disease leading to speculation that these, rather than cartilage 
changes, may be of primary aetiological importance.  
 
Bone marrow lesions (BML), initially described as bone marrow oedema (BME) were first identified in 
association with trauma and injury (Eustace et al., 2001).  They are commonly defined as regions of 
abnormal MRI signals that histologically represent necrosis, fibrosis, bleeding and/or oedema (BME) 
(Zanetti et al., 2000).  BML  are characterised by MRI as hyperintense signalling regions on T2 weighted 
images consistent with increased water content, and exhibit increased signal after gadolinium 
diethylenetriamine pentaacetic acid (Gd-DTPA) injection, indicating increased vascularity (Hawighorst et 
al., 1999).  At least some of these changes associated with BML have long been recognised by 
histopathologists as replacement of the normal subchondral marrow by fibrovascular granulation tissue.  
Angiogenesis is an important component of subchondral fibrovascular marrow replacement in both human 
and experimental OA (Mapp et al., 2008).  This tissue is continuous with the vascular channels which 
breach the tide mark to invade the articular cartilage in OA.  BML are positively associated with knee pain, 
increased cartilage defect score and OA progression as measured by joint space narrowing, suggesting an 
importance in both symptoms and structural damage in OA (Hunter et al., 2005; Hunter et al., 2006).  
Elucidating the contribution of angiogenesis to this potentially pivotal process in the development of 
symptoms and structural damage in OA raises hope of novel and targeted therapeutic approaches for the 
future as angiogenesis is an essential part of OA pathophysiology.   
 
1.5.5 Angiogenesis and Pain 
The contribution of angiogenesis to pain is still not fully understood. Although not of itself necessarily 
painful, angiogenesis, by enabling innervation of tissues, may be permissive, and may synergise with 
inflammation to exacerbate pain (Bonnet et al., 2005).   
 
In OA blood vessels invade the calcified region of the otherwise avascular and aneural articular cartilage 
from the underlying subchondral bone and penetrate newly formed cartilage at the joint margin during 
osteophyte formation (Hashimoto et al., 2002).  Vascular turnover is even more pronounced in the inflamed 
osteoarthritic synovium.  Sensory nerves accompany this neovascularisation in all these structures (Walsh 
et al., 1996).  These fine, unmyelinated, peptide-containing nerve terminals typically mediate a sustained 
burning pain commonly described by patients with OA (Wagstaff et al., 1985).  Perivascular sensory 
nerves may contribute to pain in OA, originating in articular cartilage, periosteum, menisci, cruciate and 
collateral ligaments and in joints capsules (Suri et al., 2007).  Subchondral angiogenesis and innervation 
may be particularly important where the protective layer of articular cartilage is lost, consistent with 
observed associations between the extent of cartilage loss determined arthroscopically and reported pain 
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severity.  Compressive forces and hypoxia may activate growing perivascular nerves even before complete 
cartilage loss.  Sensory innervation of osteophytes following angiogenesis may, in part, explain the 
association between radiologically graded osteophyte severity and reported pain in OA (Neame et al., 
2003).   
 
Unmyelinated sensory nerves can also amplify the inflammatory response by releasing vasoactive 
substances (neuropeptides) (Neugebauer et al., 1995), such as substance-P and CGRP. These peptides also 
can initiate angiogenesis, as can peptides from accompanying sympathetic nerves such as neuropeptide Y 
(Zukowska-Grojec 1998).  Substance P and CGRP act on specific cell surface receptors localised on blood 
vessels thereby enhancing EC proliferation, migration and capillary tube formation in-vitro (Haegerstrand 
et al., 1990; Kahler et al., 1993) and angiogenesis in-vivo (Lee et al., 2003).   
 
Substance P release during neurogenic inflammation enhances plasma extravasation and enables EC 
proliferation through neurokinin NK1 receptors.  In animal models of synovitis, substance P, either 
exogenously applied or released from an endogenous source, can stimulate synovial angiogenesis through 
NK1 receptors during the early stages of synovitis, and selective NK1 receptor antagonists can inhibit this 
angiogenesis (Seegers et al., 2003; Seegers et al., 2004).  Endogenously released substance P can therefore 
contribute towards the early stages of angiogenesis in acute inflammation, and neuropeptides interact with 
other acute inflammogens such as bradykinin under these circumstances. 
 
1.5.6 PPI-2458, an inhibitor of Angiogenesis 
Angiogenesis inhibitors have currently been under continuous focus due to their immense potential as 
therapeutic agents.  Increasing number of anti-angiogenic compounds (synthetically created; PPI-2458 and 
naturally occurring; angiostatin and endostatin) have been identified over the years with a specific focus on 
inhibiting an individual step of angiogenesis.  As each step in the angiogenic cascade involves a great 
variety of enzymes, cytokines and receptors, numerous possible targets for therapeutic intervention are 
available.  These compounds have targeted the inhibition of ECM remodelling, adhesion molecules, 
activated ECs, angiogenic mediators or their receptors and EC intracellular signalling (Liekens et al., 
2001).  Most of these have been studied in relation to their applicability in cancer therapy and chronic 
inflammatory conditions.   
 
Development of novel therapies to manipulate angiogenesis offers a great approach to relieve the 
symptoms and severity of OA.  These therapeutic agents need to specifically target the mechanism of 
harmful angiogenesis whilst causing minimal adverse effects.  Therefore drugs that broadly inhibit 
inflammation or angiogenesis may have limited applicability in OA.  Anti-angiogenic therapy for 
inflammatory diseases has numerous advantages.  It suppresses blood vessel growth leading to reduced 
nutrient supply to the metabolically active cells present in the inflamed tissue.  It blocks the entry route of 
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inflammatory cells into the tissues, inhibits EC activation, proliferation and vascular remodelling in 
chronically inflamed lesions thereby inhibiting the production of EC-derived soluble factors such as MMPs 
and cytokines.  Application of anti-angiogenic strategies will also allow us to study in more detail the 
functional role of angiogenesis during inflammatory conditions thereby increasing our knowledge related to 
OA pathophysiology. 
 
Methionine aminopeptidase (MetAP) are metalloenzymes required to remove N-terminal methionine 
residue from proteins at the initial phase of translation.  The translation process on ribosomes is initiated 
with methionine, and the N-terminal methionine is usually removed before the newly synthesised protein is 
intracellularly transported.  The removal of the N-terminal methionine residues, leads to the exposure of a 
glycine residue onto which myristic acid is attached covalently (myristylation).  This process is required for 
the stability and correct functioning of numerous signalling molecules (Lowther et al., 2000).  Two types of 
MetAP have been identified, MetAP-1 and MetAP-2.  MetAP-2 is distinguished from MetAP-1 by the 
addition of a helical subdomain inserted into the C terminal.  MetAP-2 is expressed in proliferating cells 
such as endothelium, at the site of neo-vascularisation or B cells in the germinal centres (Priest et al., 
2009).   
 
Fumagillin and structural analogs such as TNP-470 (previously known as AGM-1470) irreversibly inhibit 
MetAP-2 (an enzyme that selectively removes initiating N-terminal methionine residues from proteins 
during synthesis) (Griffith et al., 1997; Sin et al., 1997; Bernier et al., 2004).  These molecules inhibit 
angiogenesis by blocking EC proliferation and migration (Ingber et al., 1990).  Studies using in-vivo 
models of arthritis have shown that administration of TNP-470 before the onset of arthritis prevents disease 
(Peacock et al., 1992).  Adverse neurotoxicity however has been reported with the use of TNP-470.  
Therefore less toxic MetAP-2 inhibitors are needed, of which, PPI-2458 is a strong candidate.   
 
PPI-2458 [(1R)-1-carbamoyl-2-methyl]-carbamic acid-(3R, 3S, 5S, 6R)-5-methoxy-4-[(2R, 3R)-2-methyl-
3-(3-methyl-but-2-enyl)oxiranyl]-1-oxaspiro(2*5)oct-6-yl ester], a orally active, novel fumagillin 
derivative that irreversibly forms covalent bonds with MetAP-2 and inhibits EC proliferation at the late G1 
phase of the cell cycle, a crucial step in angiogenesis (Bernier et al., 2005).  PPI-2458 has shown not to 
have any direct effects on inflammatory cytokines and chemokines, but how MetAP-2-dependent 
proliferation is regulated in PPI-2458-sensitive cells is yet to be fully understood (Bernier et al., 2004; 
Brahn et al., 2009).  However it is this direct angiogenic effect of PPI-2458 which distinguishes it from 
other agents used to treat arthritis whose actions are directed at the proinflammatory cytokine network.  
PPI-2458 has been shown to inhibit swelling in peptidoglycan-polysaccharide (PG-PS) induced arthritis 
(Bernier et al., 2004; Hannig et al., 2007) and to regress collagen-induce arthritis (CIA) in both rat and 
mice models (Bainbridge et al., 2007; Brahn et al., 2009), indicating that angiogenesis might be an 
important target in treatment of arthritis.  PPI-2458 has fewer toxic side-effects compared with its parent 
 46 
molecule TNP-470 (Figure 1.7).  PPI-2458 is under development for the treatment of cancer, including B 
cell non-+RGJNLQ¶VO\PSKRPDSKDVHDQGDUWKULWLV(Cooper et al., 2006; Hannig et al., 2006; Priest et al., 
2009). 
 
 
 
Figure 1.7: Structure of parent molecule, fumagillin and modification of side chains (box) for TNP-
470 and PPI-2458 (Bernier et al., 2004; Brahn et al., 2009). 
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1.6 Inflammation and Osteoarthritis 
Inflammation is a protective pattern of response controlling tissue damage occurring as a result of 
pathogenic, traumatic or toxic injury.  The inflammatory process is governed by both pro- and anti-
inflammatory molecules requiring distinct cell types and various factors which act in a co-ordinated manner 
to regulate cell chemotaxis, migration and proliferation leading to tissue repair (Benelli et al., 2006).   
 
Under normal physiological conditions inflammation is tightly regulated to maintain homeostasis which is 
achieved by the actions of soluble proteins (cytokines and growth factors) acting between inflammatory 
cells, fibroblasts and vascular ECs within the affected site.  When inflammation is not properly regulated 
the balance is shifted away from the initiation of the healing process and towards the occurrence of 
persisting inflammation (Charo et al., 2006).  Thus the initiation and the control of inflammation are crucial 
elements.  Inflammation can be classified as either acute or chronic.   
 
1.6.1 Acute Inflammation 
This is the initial response to cellular injury characterised by its sudden onset.  The series of events 
involved in acute inflammation are coagulation, increased blood flow and vascular permeability at the 
affected site as a result of the dilatation of arterioles, capillaries and venules, oedema, localised pain, 
migration and accumulation of inflammatory cells and the formation of granulation tissues, all contributing 
to tissue repair.  Hence the classical symptoms observed in inflammation are redness, swelling, heat and 
pain which occur within minutes of tissue trauma (Dallegri et al., 1997). 
 
The initial step in acute inflammation is to contain the blood flow and repair the damaged blood vessels. 
This is done by activating the blood clotting system which eventually leads to the release of inflammatory 
mediators that control the vascular response, causing changes in permeability, blood flow and 
adhesiveness. 
 
Movement of cells and tissues is important in diluting toxic factors at the sites of trauma/infection and also 
to allow the influence of proteins which promote anti-bacterial activity.   
 
ECs are an active part of the inflammatory response.  They expose adhesion molecules on their surface 
after receiving stimulatory signals from pro-inflammatory cytokines and aid the movement of leukocytes 
(neutrophils) in the inflamed tissue.  This is an essential mechanism for the destruction of microbial agents 
and removal of tissue debris by phagocytosis, representing a key step in the resolution of inflammation 
(Wahl et al., 1996). 
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Following clearance of the pathogens it is necessary to suppress the inflammatory response (infectious 
stimulus is eliminated and acute inflammatory response fades) and enhance tissue repair.  If an acute 
response fails to resolve the cellular injury, it leads to chronic inflammation.   
 
1.6.2 Chronic Inflammation 
Chronic inflammation results from a persisting irritant that fails to be eliminated during the acute 
inflammatory response.  It can also be caused by autoimmune response to self antigens or due to an 
innately chronic irritant of low intensity which does not evoke a significant acute inflammatory reaction.  In 
this process the continuous inflammation and attempted tissue healing by repair occur simultaneously 
rather than consecutively.   
 
It is characterised by the recruitment of a large number of macrophages which lead to a less pronounced 
exudative response and increased inflammatory cellular recruitment and proliferation compared to the acute 
inflammatory response.  Different profiles of the inflammatory mediators and GFs are released depending 
on the nature of the pathogens encountered, giving rise to different morphological patterns of chronic 
inflammation.  Systemic effects however are more pronounced and contribute towards clinical 
consequences.   
 
Chronic inflammatory conditions have been found to mediate numerous diseases including psoriasis, 
GLDEHWHV DWKHURVFOHURVLV $O]KHLPHU¶V UKHXPDWRLG DUWKULWLV 5$ 2$ RFXODU GLVRUGHUV &URKQ¶V GLVHDse 
and cancer (Costa et al., 2007). 
 
1.6.3 Inflammatory Process 
When blood vessels are damaged during tissue trauma, clotting enables the containment of blood flow.  
Platelets release coagulation factors (essential in haemostasis) and leukocyte recruitment factors (facilitate 
the rapid influx of leukocytes and GFs to the affected site) so that the healing process can commence, a part 
of this healing process is inflammation. 
 
Inflammation includes a complex network of chemical signals and cell interactions that instruct and 
maintain the host response against tissue damage.  These include allergic, cytotoxic antibody mediated, 
immune complex mediated and delayed hypersensitivity responses.  Usually immune complexes eliminate 
antigens without producing any detectable inflammation (governed by a balance between pro-inflammatory 
and anti-inflammatory factors) but if the inciting agent is too difficult to remove, it will produce amplified 
effects.   
 
The cells that are initially activated during this process are leukocytes, neutrophils and eosinophils (Charo 
et al., 2004).  Leukocytes are normally restricted to the centre of the blood vessels but as a result of 
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inflammation they interact with the vascular endothelium.  Once in damaged tissues, leukocytes proceed to 
remove the injurious agents and initiate tissue repair.  Changes in the adhesion molecules on ECs and 
leukocytes enable a large number of circulating leukocytes and neutrophils to be further recruited.  
Neutrophils are the earliest phagocytic cells to be recruited, they engulf and destroy debris, dead and dying 
tissues, they are able to phagocytose many pathogens.  As inflammation progresses even monocytes 
contribute towards its actions.  
 
Monocytes migrate to the inflamed areas guided by chemotactic signals (Philip et al., 2004) where they 
differentiate into dendritic cells (DC) and macrophages.  Macrophages in turn provide GFs (PDGF, FGF, 
7*)ȕDQGF\WRNLQHVWKDWHQJDJHQXPHURXVUHVSRQVHVLQGLVWLQFWFHOOW\SHVLQFOXGLQJ(&VHSLWKHOLDOFHOOV
and cells of mesenchymal origin at the inflamed region (Costa et al., 2007).  Macrophages and mast cells 
release cytokines that result in tissue remodelling and recruitment of additional leukocytes.  They help 
lymphocytes to proliferate, further enabling cytokine production and orchestration of tissue repair through 
their release of fibroblast recruitment, growth and matrix inducing molecules.  
 
DCs then capture antigens, mature and eventually migrate to lymph nodes stimulating adaptive immune 
cells.  DCs are further activated by natural killer (NK) cells which interlink innate and adaptive immunity, 
in response to this, B cells, CD4+T cells and CD8+T cells are attracted to a specific antigen and clonally 
expanded to elicit a large immune response (de Visser et al., 2006) thereby eliminating the pathogen.  This 
result in the increased vascular permeability, blood flow and vascular adhesiveness observed during 
inflammation.  
  
Mast cells are also involved in the early steps of the inflammatory process, they release cytokines, 
histamine, proteases and eicosanoids (Coussens et al., 2002) which also mediate vasodilatation and fluid 
extravasation promoting endothelial adhesion and further recruitment of inflammatory cells (Nathan 2002).   
 
Eosinophils are not normally associated with inflammation; they are not as sufficient as neutrophils in 
phagocytosis.  Eosinophils are mainly involved in the destruction of organisms that are too large to be 
phagocytosed efficiently.   
 
Pro-inflammatory cytokines and chemokines including interleukins, TNF-ĮDQG,FNs are also released by 
several cell types at the inflamed sites, they bind and activate G-protein coupled receptors on immune cells 
(Charo et al., 2004; Charo et al., 2006) stimulating signalling transduction cascades within the cells, 
inducing changes in cell morphology and migration.     
 
Hence the immunological mediated elimination of foreign material is the result of antigen recognition by 
specific mechanisms (antibodies) or non-specific mechanisms (phagocytes).  This activates an 
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amplification cascade, producing pro-inflammatory substances resulting in altered blood flow, increased 
vascular permeability, augmenting the adherence of circulating leukocytes to vascular endothelium, 
promoting the migration of leukocytes into tissues and stimulating the leukocytes to destroy the inciting 
agent.   
 
1.6.4 Involvement of Inflammation in OA 
Inflammation is increasingly thought to enhance structural severity in OA, whether it is the bio-chemical 
changes within the cartilage and the release of the cartilage breakdown products in the synovial fluid (Attur 
et al., 2002) or the subchondral bone changes.  Acute flares are proposed to occur on the background of 
chronic synovitis or in non-inflamed joints leading to elimination of the irritant followed by resolution to 
the original state (Bonnet et al., 2005).   
 
In osteoarthritic synovium, the inflammatory changes that are observed include synovial hypertrophy and 
hyperplasia with the sublining tissue being infiltrated with a mixed population of inflammatory cells 
(Pelletier et al., 2001).  Synovitis contributes towards dysregulation of chondrocyte function in remodelling 
the cartilage ECM (Loeser 2006).  Chondrocytes obtained from patients with OA have been shown to 
produce pro-inflammatory mediators and are thought to act in the cartilage in an autocrine or paracrine 
manner to promote a catabolic state which leads to a progressive cartilage damage in OA (Attur et al., 
1998).   
 
Various researchers have implicated T cells in producing pro-inflammatory cytokines and MMPs within the 
inflamed synovial membranes (McInnes et al., 2000) as well as increased mononuclear cell infiltrates and 
over expression of mediators of inflammation in early OA (Benito et al., 2005). 
 
Considerable amounts of evidence involving in-vitro and in-vivo studies support the view that a link exists 
between increased levels of catabolic enzymes and inflammatory mediators in OA synovial fluid and joint 
tissue (Goldring et al., 2007).   
 
Mechanical forces in OA may also produce metabolic changes that result in cytokine production by the 
synovium (Abramson 2004).  Persisting mechanical stress results in inflammation, as cartilage is not 
vascularised or innervated, joint swelling or pain may not be observed, but a host of mediators normally 
seen in inflammatory arthritis are produced and act in a paracrine and autocrine manner to endow the 
chondrocytes with a catabolic phenotype.  Prostaglandins (PG) are one of the key mediators of 
inflammation; these mediators can be produced by synovial cells and the chondrocytes themselves.   
 
A number of biological markers are believed to be associated with synovitis in OA, such as cartilage 
oligomeric protein (COMP), serum level of C reactive protein (CRP) and hyaluronic acid (HA).  COMP is 
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found in the articular cartilage during increased levels of synovitis.  CRP is predictive of radiographic 
progression of long term knee OA whereas HA levels have shown to increase in OA (Thonar et al., 1995).  
These markers are elevated in OA, indicating the presence of subclinical inflammation in the absence of 
acute inflammatory flares.  Excessive production of cytokines and GF by the inflamed synovium and 
activated chondrocytes functionally alter the synovium, cartilage and subchondral bone (Pelletier et al., 
2001).  They appear to be first produced by the synovial lining and then they diffuse into the cartilage 
through the synovial fluid. Here they act in an autocrine/paracrine fashion (Goldring et al., 2007) activating 
chondrocytes that in turn display enhanced and co-ordinated expression of proteases and their catabolic 
factors such as NO and pro-inflammatory cytokines that are further responsible for cartilage destruction, 
chondrocyte apoptosis and other structural changes associated with the disease process (Pelletier et al., 
2001).   
 
Pro-inflammatory cytokines contribute towards cartilage destruction (Shalom-Barak et al., 1998; Olee et 
al., 1999; Goldring et al., 2007).  Studies in animal models have shown that cartilage destruction is mainly 
GULYHQ E\ WKH DFWLRQV RI ,/ ZKHUHDV 71)Į LV LQYROYHG LQ WKH RQVHW RI DUWKULWLV (Goldring et al., 2004).  
Human articular chondrocytes when stimulated by IL1 increase the expression of MMP but inhibit the 
biosynthesis of cartilage PG and collagens (Tetlow et al., 2001).  Chronic synovitis is also associated with 
the changes in the synthesis and release of neurotransmitters and modulators (Bonnet et al., 2005).   
 
In the inflamed synovium fibroblasts and blood vessels proliferate, macrophages are recruited and there is 
an increased cellular apoptosis.  Inflammatory mediators stimulate sensory nerves causing pain in the joint.  
Fine unmyelinated sensory nerves containing neuropeptides like substance P and CGRP have been 
localised in the joint.  Inflammation exacerbates cartilage degradation in OA (Bonnet et al., 2005).  Under 
normal circumstances, if damaged matrix proteins were removed, the proteolytic process would be turned 
off and chondrocytes would work to replace the lost matrix, however in OA this phase of matrix 
remodelling is insufficient or defective.  Abnormal mechanical forces stimulate the chondrocytes to 
produce a host of inflammatory mediators many of which are normally produced by macrophages during 
response to injury and infection increasing the catabolic activity of the chondrocytes, resulting in the 
release of proteolytic enzymes including aggrecanase and MMPs that cause the destruction of the cartilage 
matrix (Lisignoli et al., 1999).  Fundamental events resulting in the destruction of articular cartilage in OA 
arises from the imbalance between the anabolic and catabolic pathways (Hedbom et al., 2002).  Increased 
catabolism of cartilage ECM is the main pathologic process leading to the degeneration of articular 
cartilage in OA (Tetlow et al., 2001).   
 
1.6.5 Synovial Macrophages and Inflammation in OA 
Activated synovial macrophages are important mediators of synovitis and promoting OA pathology.  
Clinically, patients with OA have a variable degree of synovitis.  Synovial inflammation has been 
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implicated in many of the signs and symptoms of OA including joint swelling and effusion (Pelletier et al., 
2001).  Inflammation is likely to contribute to disease progression because a strong association between 
biological markers of inflammation such as C-reactive protein and cartilage oligomeric matrix protein with 
structural damage in OA exists (Clark et al., 1999; Sowers et al., 2002).  Histologically OA synovium 
shows hyperplasia, with increased lining cells, and mixed inflammatory infiltrate mainly consisting of 
macrophages (Farahat et al., 1993; Benito et al., 2005).  In-vitro studies have indicated that macrophages 
drive the production of of several pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-Į DQG 003V 
(Bondeson et al., 2006).  As well as being involved in synovial inflammation, TNF-ĮDQG,/-1 can activate 
chondrocytes and synovial fibroblasts, stimulate their own production, induce synovial cells and 
chondrocytes to produce IL-6, IL-8 and leukocyte inhibitory factor (LIF) and stimulate protease and 
prostaglandin production (Goldring et al., 2007; Bondeson et al., 2010).  In-vivo studies where synovial 
lining macrophages were depleted have shown that, macrophage depletion was linked to fibrosis and 
osteophyte formation (van der Kraan et al., 1990; Blom et al., 2004; van Lent et al., 2004).  Therefore, 
synovial macrophages exhibit an activated phenotype in OA.  Anti-macrophage strategies to reduce OA 
seem to be an attractive avenue to explore, but if such strategies need to be feasible, they need to act locally 
in the synovium only, because macrophages are key players in protecting tissues against infectious diseases 
DQGVXFKVWUDWHJLHVFDQDOVRLQKLELWWKH³ZDQWHG´SRVLWLYHHIIHFWVRIPDFURSKDJHV 
 
1.6.6 Anti-inflammatory Therapy 
Targeting inflammation is an attractive possibility in OA.  It has the potential to retard disease progression 
and relieve symptoms of pain and stiffness.  Currently available NSAIDs are the most commonly used 
treatment in OA, reducing the symptoms observed in OA without halting disease progression.  The 
selective COX-2 inhibitors exhibit analgesic and anti-inflammatory effects equivalent or even superior to 
conventional NSAIDs.  Indomethacin is the most well studied conventional NSAID.  Intra-articular 
injections of corticosteroids (dexamethasone) provide an easy and cost effective pain relief strategy with 
minimal risk.  Hence newer DMOADs which specifically target the pathophysiological processes in OA 
offer better disease management.  Inhibiting proinflammatory cytokines which play a pivotal role in OA 
progression is an attractive possibility (Pelletier et al., 2001).  Clinical studies using anti-TNF antibody 
infliximab (Magnano et al., 2007; Fioravanti et al., 2009) and anakinra (recombinant IL-1Ra) (Chevalier et 
al., 2005; Goupille et al., 2007) showed significant symptomatic relief in patients with OA.  Steroidal and 
non-steroidal anti-inflammatory drugs are however not without their side-effects.  Their long-term use is 
associated with dverse effects such as peptic ulcers, myopathy, oedema, hyperkalemia, hypernatremia and 
hypertension.  The greatest therapeutic finding will be targeting those inflammatory processes that are 
disease specific because drugs that broadly inhibit such important biological processes can have detrimental 
side-effects.   
 
 
 53 
1.7 Inflammation, Angiogenesis, Structural damage and Pain in Osteoarthritis 
Chronic inflammation and angiogenesis are two interlinked processes where angiogenesis can occur in the 
absence of inflammation but chronic inflammation however always accompanies angiogenesis (Bonnet et 
al., 2005).  It is thought that angiogenesis does not initiate inflammation but rather perpetuates or 
potentiates it by supplying nutrients and oxygen to the cells present in the inflamed synovium (Costa et al., 
2007), and also the increase in vascular density, macrophage infiltration and VEGF expression within the 
synovium regulate the extent of EC proliferation.  Thereby highlighting that neovascularisation could be 
largely driven by synovitis.   
 
Angiogenesis itself can be stimulated directly or indirectly by inflammatory mediators, it is closely 
associated with chronic synovitis.  A considerable body of evidence suggests that this co-dependence 
involves the augmentation of cellular infiltration and proliferation as well as the overlapping roles of 
regulatory growth factors and cytokines (Jackson et al., 1997).   
 
Macrophages are abundantly present in chronically inflamed osteoarthritic synovium producing 
inflammatory mediators and increasing the production of growth factors enabling new blood vessel 
formation.  Hypoxia is viewed as a common stimulus for both angiogenesis and inflammation (Murdoch et 
al., 2005).  It occurs when tissue proliferation outstrips blood vessel growth, inducing macrophages and 
monocytes to release a large quantity of angiogenic factors (including VEGF and FGF2) which can induce 
blood vessel growth (Nathan 2002).  Normally vascular synovium provides the avascular cartilage with 
nutrients and oxygen.  In OA the association between EC proliferation and new vessel formation leads to 
an increase in EC surface area creating an enormous capacity for the production of cytokines, adhesion 
molecules and other inflammatory stimuli (Jackson et al., 1997).  It is proposed that VEGF and FGF-2 may 
also be produced by lymphocytes and neutrophils in the early induction of angiogenesis (Bonnet et al., 
2005) however their exact involvement is still under investigation.  Many inflammatory mediators are also 
angiogenic (Form et al., 1983).  These findings are mainly based on research carried out using Cornea and 
Chicken CAM Assays.   
 
The interplay between chronic inflammation and angiogenesis is accomplished by the activation of iNOS 
which leads to NO production from inflammatory cells (macrophages) and endothelium, thereby 
stimulating vessel dilatation and permeability to macromolecules facilitating oedema formation and 
immune cell extravasation (Morbidelli et al., 1996).  Adhesion of immune cells to endothelium is a crucial 
step in activating neighboring EC to attract blood derived inflammatory cells.  Adhesion molecules such as 
E-selectin are highly expressed by new vessels and facilitate inflammatory cell infiltration (Cid et al., 
2000).  Inflammatory mediators produced by immune cells can target fibroblasts and ECs to release 
angiogenic factors and can themselves release angiogenic factors (VEGF and FGF-2) (Ziche et al., 1997).  
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Inflammatory response on the other hand can be maintained by new vessels transporting inflammatory 
cells, nutrients and oxygen to the site of inflammation.   
 
Recent finding show that anJLRJHQHVLVDQGLQIODPPDWLRQUHO\RQFURVVWDONEHWZHHQ1)ț%DQG$QJ-Tie 2  
signaling pathways (Pacifico et al., 2006).  Ang-2 has both an angiogenic role and is also involved in 
upregulating pro-inflammatory cells (Fiedler et al., 2006).   
 
It has also been postulated that neuropeptides such as substance-P and CGRP enhance EC proliferation, 
migration and capillary tube formation in-vitro and angiogenesis in-vivo (Bonnet et al., 2005), it has been 
revealed that endogenously released Substance P contributes to early stages of angiogenesis in capsaicin 
and carrageenan induced synovitis (Walsh et al., 1998).  
 
Hence inflammatory cells that are abundant in the inflamed OA synovium can induce angiogenesis directly 
by producing angiogenic factors and/or by secreting cytokines that indirectly stimulate ECs and fibroblasts 
to release angiogenic factors, which in turn contribute to neovascularisation and inflammation by inducing 
immune cell mobilization.  Expression of angiogenic factors is further enhanced by the hypoxic conditions 
that are evident in OA.  
 
Angiogenesis and inflammation are important processes in OA pathophysiology, both are interlinked; 
evidence in the literature has demonstrated that they are upheld by the same stimuli.  We need to further 
understand their cross-talk and intricate interplay to develop effective therapies. 
 
Even-though it is not fully understood as to how angiogenesis contributes to pain in OA, it is however 
recognized that it may synergise with inflammation to exacerbate pain (Bonnet et al., 2005).  In OA blood 
vessels invade the calcified region of the otherwise avascular and aneural articular cartilage from the 
underlying subchondral bone, breaching the tidemark and penetrating newly formed cartilage at the joint 
margins during osteophyte formation (Hashimoto et al., 2002).  Sensory nerves have been shown to 
accompany neovascularisation occurring in OA (Walsh et al., 1996) and are implicated in mediating the 
sustained burning pain sensation described by patients suffering with OA (Wagstaff et al., 1985).  Pain in 
OA can originate from periosteum, subchondral bone, synovium, ligaments and muscles (Suri et al., 2007).  
A current study shows that perivascular localisation of nerve; sensory and sympathetic, in articular cartilage 
contributes to tibiofemoral pain in OA (Suri et al., 2007).  Implying that vascularisation is the driving force 
behind innervation.  Compressive forces and hypoxia are also thought to stimulate these new nerves to 
release neuropeptides in a temporally and spatially regulated manner, contributing towards persistent pain 
and structural damage in OA.   
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Unmyelinated sensory nerves can also amplify the inflammatory response by releasing vasoactive 
substances (neuropeptides) (Neugebauer et al., 1995), such as substance-P and CGRP.  These peptides can 
also initiate angiogenesis, as can peptides (neuropeptide Y) from accompanying sympathetic nerves 
(Zukowska-Grojec 1998).   
 
Substance P and CGRP are thought to act on specific cell surface receptors localised on blood vessels 
thereby enhancing EC proliferation, migration and capillary tube formation in-vitro (Haegerstrand et al., 
1990; Kahler et al., 1993) and angiogenesis in-vivo (Lee et al., 2003). 
 
Substance P release during neurogenic inflammation enhances plasma extravasation through the interaction 
with neurokinin NK1 class G protein coupled receptor and enables EC proliferation.  Fairly recent studies 
(Seegers et al., 2003; Seegers et al., 2004)  using in-vivo models of synovitis highlighted that substance P 
either exogenously applied or released from an endogenous source can stimulate synovial angiogenesis 
through an action on NK1  and bradykinin B2  receptors during the early stages of synovitis, selective NK1 
and bradykinin B2 receptor antagonists can inhibit this angiogenesis.  Hence, inflammation, angiogenesis 
and accompanied nerve growth can all enhance the structural damage seen in OA.   
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1.8 Animal models of Osteoarthritis 
A major problem encountered in OA research is that the disease is not presented in clinics and diagnosed 
until it has progressed to its advanced stages when pronounced alterations in the joint have led to 
radiographically detectable changes and severe pain.  Pain is the main symptom that brings patients 
suffering from OA to clinics.  Studying the early mechanisms of OA in humans is extremely difficult 
partially due to the low sensitivity of the diagnostic tools used and the low availability of the diseased 
tissue (Ameye et al., 2006).  As a result, the underlying biochemical and molecular processes leading to the 
macroscopically and histologically visible alterations are still not completely understood.  In-order to 
overcome this, a number of animal models of OA have been developed (Pond et al., 1973; Little et al., 
1996) that exhibit changes similar to those observed in human OA, however no animal model fully mimics 
the normal pathogenesis of OA in humans.  Thus controversy surrounds the issue regardin relating the data 
obtained from such animal models to human situations.  Never-the-less the advantages of these models are 
that as well as knowing the time-point and causative of the joint damage, healthy cartilage can also be 
obtained from the same subject (Lorenz et al., 2006).  Henec animal models complement human 
investigations to study in detail pathogenic hypotheses and therapeutic strategies. 
 
There are numerous classical animal models of OA involving a number of animal species, rabbits, dogs, 
sheep and rodent (rats and mice) models of OA which were first developed in the late 1970s (Schwartz et 
al., 1979).  Most recently cats and guinea pigs have also been used as research tools.  OA in these animals 
can occur spontaneously with aging (Wilhelmi et al., 1976) but it can also be induced surgically to produce 
mechanical joint instability.  Other chemical and enzymatic methods are also employed to induce OA, 
whereas more recently genetically modified; transgenic or knockout animals have come under the limelight 
too (Goldring et al., 2007). 
 
Spontaneous/naturally occurring models of OA (Dunkin-Hartley guinea pig, STR/ort and STR/1N mouse 
strains) are more like human OA with slower onset and progression.  Osteoarthritic pathology (synovitis, 
chondropathy, osteophytosis, subchondral bone changes and pain) is seen in these animals by 6 months 
(Bendele et al., 1989; Blaney Davidson et al., 2006).  Like human OA, these models are not very sensitive 
when identifying the initiating events but they however are viewed as effective screening models despite 
being time consuming.   
 
Chemically induced models of OA, where induction of OA is achieved by injection of a noxious substance 
cause joint pathology through inhibition of chondrocyte metabolism (papain and monosodium-iodoacetate 
[MIA])  and damage to ligaments and tendons (collagenase) (van der Kraan et al., 1990; Fernihough et al., 
2004).  The MIA model has emerged as a good model to study osteoarthritic pain and the effects of 
analgesic drugs because it is reproducible and mimcs pathological changes and experience of pain as seen 
in human OA.  Intra-articular injection of MIA produces progressive joint degeneration through inhibition 
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of glycolysis and subsequent chondrocyte death that develops over several weeks.  Similar to human OA, 
joint pathology is characterised by chondrocyte necrosis resulting in decreased thickness of the articular 
cartilage and fibrillation of the cartilage surface, exposure of the underlying subchondral bone, swelling 
and reduction in bone mineral content and density (Kobayashi et al., 2003).  However, since iodoacetate is 
a metabolic poison, chondrocyte cell death in the model is extensive, unlike that observed in human OA.   
 
Genetically modified animals (knock out or transgenic mice) are a major tool to investigate genetic 
predispositions/contributions to OA.  They are well defined and allow insight into mechanisms of tissue 
formation and maintenance, matrix assembly, signalling proteins and molecular interactions in OA but their 
usefullness for the study of the pathophysiology of OA is debateable (Saamanen et al., 2000; Ameye et al., 
2006; Dinser 2008).  The genetic approach allows important insights into the multitude of factors affecting 
the pathogenesis of OA.  However each model describes a distinct molecular entity making it difficult to 
study the effects of different treatment approaches.  Longer time is needed for OA to develop in genetic 
models compared to surgical and enzymatic models that are faster and consistent but they are considered to 
be more relevant to the traumatic than classical forms of degenerative OA.   
 
Surgical models (structural alteration to the tendons muscles or ligaments) of mechanical instability 
represent the chronic traumatic form of OA.  Initially, experiments employed models in which OA was 
induced in the temporomandibular joint but with time these models were developed to involve other 
synovial joints, including the knee (Schwartz 1987).  Mechanical instability can be induced using various 
surgical methods such as: Anterior Cruciate Ligament Transection (ACLT) and menisectomy.  ACLT was 
first used in dogs and the partial menisci resection model in rabbits (Bendele 2001) since then both of these 
procedures have been widely used in other species like mice, guinea pig, rats, and cats.   
 
Substantial research has been conducted by numerous researchers on these animal models to fully 
understand the various aspects of OA.  Some of the research has focused on the relationship between 
symptoms (pain) and bone morphology in OA (Bove et al., 2006; Vermeirsch et al., 2007), analysis of gene 
expression changes in animal models and their relevance in early human OA (Appleton et al., 2007; 
Dell'accio et al., 2008).  Recently, it was shown that using a combination of ligament transection and 
menisectomy in knees of mice, varying degrees of OA (mild, moderate, severe) with direction of instability 
(anterior versus medial) could be created (Kamekura et al., 2005).  The researchers successfully showed the 
development of OA and osteophyte formation up to 8 weeks post surgery using a rapid, cheap and 
applicable model.  To elucidate the understanding of the metabolism of cartilage and bone, knees of two rat 
models were subjected to ACLT and/or medial menisci resection (Hayami et al., 2006), results obtained 
from this study highlight the role for bone remodelling in OA pathogenesis.  Research carried out using the 
rat and rabbit meniscal transection models (Mapp et al., 2008) has further clarified the role of 
osteochondral and synovial angiogenesis in human OA.   
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The above mentioned research collectively illustrates the popularity of these two methods of surgical 
intervention amongst scientists to induce OA in animal models.  The disadvantage of the surgical models is 
that only knee damage can be studied and also use of smaller animals like mice is technically demanding. 
 
Currently no consensus exists on the most relevant animal model of OA.  However the diversity of animal 
models available provide a wealth of valuable information on joint biology and OA pathology, having said 
that each model has various advantages and disadvantages associated with its use.  
 
The rate of disease progression between species of the same model has been seen to increase as size and 
lifespan of the animal is reduced, development of OA in different species thus varies.  It has been reported 
that in animal models like dogs, cats and sheeps their large size and the lack of availability of biochemical 
reagents to study the molecular dynamics in affected joints has reduced the usefulness of these models in 
evaluating potential disease modifying agents (Goldring et al., 2007). It takes 1 year for significant 
cartilage loss and osteophyte formation to be apparent in ACLT dogs and at least 3 years to display 
alteration to advanced OA (Lorenz et al., 2006) compared to rats and rabbits.  Moderate OA has been 
observed in rabbits as early as 10 days after ACLT, severe OA developed by 2-4 months post surgery 
(Pfander et al., 1999), the follow-up however proves to be problematic because of the long time needed.  
Smaller animal like rats, mice and guinea pigs thus enable low cost studies to be carried out due to their 
small size and shorter time frame of OA development.  As a result our current understanding of the 
metabolism of cartilage and bone in the larger models is limited. 
 
Animals also display different patterns of joint loading, being quadrupeds as opposed to bipeds, joints are 
smaller and the cartilage in animals is thinner in contrast to humans, enabling only a small quantity of 
cartilage to be analysed.  Therefore differences between animal models make comparison between various 
studies difficult; this in turn makes the extrapolation of animal data to humans slightly problematic.  It is 
therefore essential to further conduct comparative studies to address the issue of whether it is possible to 
find a suitable single animal model or if the development and comprehensive characterisation of pre-
clinical animal models is more feasible to further enhance our understanding on OA pathology and 
intervention mechanisms.  It has been postulated that for future studies comparing the effects of structure 
modifying drugs on different animal models can perhaps clarify the response of these models to therapy, 
suitability as preclinical models (fast or slow disease progression models, species of choice etc.) and the 
relevance to human OA (Ameye et al., 2006).  Overall animal studies have never-the-less provided new 
insights into OA pathogenesis despite their limitations. 
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1.9 Summary 
OA is the commonest joint disease but is of unknown aetiology (Walsh 2004).  It is the major cause of pain 
and disability in the ageing population (Walsh et al., 2007).  Current therapeutic agents focus on 
symptomatic relief because pharmacological interventions that halt disease progression are not available 
(Daouti et al., 2005), and, although the clinical course of OA is highly variable, it too often progresses to 
total joint replacement surgery (Dixon et al., 2004).  A greater understanding of early OA may help achieve 
the goal of disease modification. 
 
OA is associated with articular cartilage loss, synovitis, fibrosis, subchondral bone remodelling and 
osteophyte formation. Angiogenesis, the growth of new blood vessels from old, may contribute to each of 
these features (Bonnet et al., 2005).  Angiogenesis is highly regulated under normal conditions (Risau 
1997) by various activating and inhibiting factors (Otrock et al., 2007), and is fundamental to many 
physiological events including embryogenesis, growth, wound healing and female reproductive cycle 
(Walsh 1999).   
 
Pain, the main symptom of OA can originate from several sources (Dieppe et al., 2005).  Hypoxia, 
compressive forces and inflammation have all been implicated in sensitising sensory nerves that grow 
alongside blood vessels in articular cartilage and osteophytes (Wagstaff et al., 1985).  These sensitised 
nerves may reciprocally contribute to neurogenic inflammation and initiate new vessel growth.  
 
Angiogenesis may therefore contribute both to the symptoms and pathology of OA, and further analysis of 
its role should lead to more effective therapies. 
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1.10 Hypothesis and Aims 
The overall aim of this thesis was to investigate the role of angiogenesis and inflammation in structural 
damage and pain in osteoarthritis.  It was hypothesised that: 
x Angiogenesis during the early phase of synovitis could be a key factor in determining its 
persistence, and, where this is the case, treatment with the angiogenesis inhibitor (PPI-2458) could resolve 
this persistent synovitis. 
x Anti-inflammatory (dexamethasone, indomethacin) and anti-angiogenic (PPI-2458) drugs could 
reduce structural damage and pain in the rat meniscal transection (MNX) model of OA by targeting 
synovitis and synovial and osteochondral angiogenesis.  
x Increased angiogenesis in the human meniscus could be associated with increased sensory nerve 
growth leading to pain in OA. 
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2 MATERIALS AND METHODS 
 
2.1 Introduction 
This chapter outlines the general methods employed in this thesis.  The source of human and animal tissues 
is described.  All in-vivo animal experiments were carried out in accordance with UK Home Office 
regulations and were performed on either male Lewis or Wistar rats (Charles River, Margate, Kent, UK) 
weighing between 250-280 or 150-180 gm respectively.  Pilot dose- and time-ranging experiments were 
carried out on sample animals in accordance with good practice and the 3 Rs: reduction, refinement and 
replacement.  All procedures involving the use of human tissues were approved by Nottingham Research 
Ethics Committee (08/H0403/132), the tissues were obtained post mortem (PM) from patients following 
consent from next of kin (Walsh et al., 2003).  A sample of PM consent form, buffer recipes, reagents and 
materials used and details of primary and secondary antibodies are all listed in the appendix (Section 8). 
 
2.2 Animal Models 
 
2.2.1 Anaesthesia  
General inhalant anaesthesia was administered via an anaesthetic machine on rats undergoing recovery 
experiments as recommended in schedule 2A of the Animals Scientific Procedures Act 1986 (ASPA) 
(Gotoh et al., 2004).  Isoflurane an inhaled anaesthetic is a volatile compound, delivered using oxygen (O2) 
as the carrier.  When isoflurane is allowed to vaporise, the inspired vapour has specific effects on the CNS.  
Anaesthesia is achieved when there is a gradual increase in concentration of isoflurane in the CNS and it 
reaches the same levels as that in the lungs.  Isoflurane is less soluble in blood so induction of, and 
recovery from anaesthesia is more rapid.  The fall in blood pressure observed with the use of isoflurane is 
primarily due to vasodilation rather than myocardial depression, making isoflurane the agent of choice for 
the induction of anaesthesia (Eger 1984).  Each animal was placed in a transparent, acrylic induction 
chamber, the top was sealed and O2 flow rate was turned on to 2 L/min.  Isoflurane vaporiser was set at 3% 
concentration and the scavenger system was activated.  Once the animal was anaesthetised, judged by lack 
of movement and reflexes and monitoring the rate and depth of breathing, it was removed from the 
chamber and anaesthesia was further maintained via a facemask.  As soon as anaesthesia was achieved, the 
inspired concentration (3%) was reduced to a maintenance concentration of 2% isoflurane in O2 (Gotoh et 
al., 2004).  This gave precise control on the amount of anaesthetic agent given and hence the depth of 
anaesthesia.  Elimination of the agent by the lungs meant more rapid recovery from procedures, which is 
vital in regaining normal physiology, to control post-operative hypothermia and fluid or electrolyte 
imbalance.  When the procedure was completed, the anaesthetic machine was turned off and the animal 
was monitored until it regained consciousness before being returned to its cage. 
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2.2.2 Euthanasia 
Each animal was killed by asphyxiation in carbon dioxide (CO2) as recommended in schedule 1 
(appropriate methods of humane killing) of the Animals Scientific Procedures Act 1986 (ASPA).  Each 
animal was placed in an empty, acrylic chamber with a transparent lid, which was not sealed or clamped 
down in order to allow air to escape from around the rim.  Flow of CO2 was turned on to 2 L/min, gradually 
introducing 100% CO2 to result in the replacement of 20% of the chamber volume per minute (Hewett et 
al., 1993).  Exposure to a rising concentration of CO2 caused unconsciousness due to a direct narcotic 
effect of CO2 and eventual death from hypoxia.  After 6 minutes the flow of CO2 was turned off, the 
chamber was inverted to tip out all the residual CO2 which is heavier than air and would otherwise have 
sunk to the bottom of the chamber (Smith et al., 1997).  If this is not done and the next animal is put into 
the chamber when the concentration of CO2 is already high, the animal will exhibit respiratory distress 
(Danneman et al., 1997).  Death was confirmed by placing a spatula firmly across the back of the neck of 
each animal and taking a firm grasp of the tail of the animal and pulling sharply to dislocate the neck.   
 
2.2.3 Intra-articular injections into rat knee joint cavities 
Each animal was anaesthetised with isoflurane (2% in O2) (section 2.2.1).  The skin over the joint was 
shaved and swabbed with 70% ethanol.  Injections of a total volume of ȝO were given into the knee 
joints of approximately 200g animals using a 27-gauge 12.7-mm needle inserted through the suprapatellar 
ligament whilst the joint was held in 90° flexion (Mapp et al., 1996; Walsh et al., 1998; Seegers et al., 
2003).  Sequential injections LQMHFWLRQVHDFKȝOLQYROXPHwere given in a similar manner. A delay 
of 30 minutes between injections allowed the solution to disperse, after which the carrageenan injection 
was administered.  Carrageenan was dissolved in sterile 0.9% normal saline (pH 7.4).  FGF-2 was prepared 
in 10 mM Tris (pH 7.6) containing 0.1% bovine serum albumin (BSA).  Naïve rats were used as controls 
(Figure 2.1). 
 
Figure 2.1: Intra-articular injection into knee joint cavities.  Animals were anaesthetised judged by 
lack of movement and reflexes and monitoring the rate and depth of breathing (A) (section 2.2.1).  The skin 
over the joint was shaved and swabbed with 70% ethanol (B).  Injections were given using a 27-gauge 
12.7-mm needle inserted through the suprapatellar ligament whilst the joint was held in 90° flexion (C) 
A B C 
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2.2.4 Subcutaneous injections 
Prior to meniscal transection surgery (section 2.2.6), each animal was anaesthetised (section 2.2.1) and 
given subcutaneous injection of &HSRUH[.005ml/100gm; Schering-Plough Animal Health, Middlesex, 
8. DQ DQWLELRWLF IROORZHG E\ D VLQJOH GRVH RI 5LPDG\O POJP 3IL]HU /WG .HQW 8. WR
reduce post-operative pain.  This was done by lifting a fold of the skin using the thumb and first two fingers 
of one hand in the lower left or right quadrant of the abdomen.  There are no vital organs in this area.  The 
needle was then passed through the skin at the base of the fold parallel to the body, to avoid penetrating 
deeper tissues.   
 
2.2.5 Oral gavage 
Gavage or stomach tubes are used to instil liquids directly into the stomach of animals.  They are stainless 
steel needles with a protective rounded tip to prevent any internal damage to the animal during oral dosing.  
The animal was restrained with its neck extended, so that the head was well controlled and the forelimbs 
immobilised (Wolfensohn et al., 2003).  Care was taken to avoid excessive tight grip on the animal which 
would otherwise induce a panic response.  Distance between the oral cavity and the end of the xyphoid 
process was measured on outside of the animal with the needle to ensure that the needle to be used was of 
appropriate size and at the same time giving an idea of how far to insert the needle when dosing.  
Inappropriate sized needles could cause internal damage to the animal as well as resulting in the drug being 
delivered to site other than the stomach.  The needle attached to a 1ml syringe containing the appropriate 
GUXJ LQ D  ȝO YROXPH was passed gently down the oesophagus.  To achieve correct positioning, the 
needle was used as a lever to move the animal¶VKHDGVOLJKWO\XSZDUGVDQGEDFNDSSUR[LPDWLQJDVWUDLJKW
line.  Positioning the tube to either the right or the left of the animal¶VPRuth facilitated the passage of the 
needle into the oesophagus with ease.  Care was taken not to force the needle down as this could damage 
the oesophagus, or put the needle into the trachea.  When the contents of the syringe were injected into the 
oesophagus, the needle was gently removed and the animal returned to its cage and observed for any signs 
of distress, such as gasping and frothing at the mouth or nose.  Resistance to insertion of the needle, or a 
struggling animal indicated a problem.  The procedure was stopped and carefully restarted.   
 
2.2.6 Meniscal transection (MNX) model of Osteoarthritis 
Animal models have been developed which resemble various aspects of the osteoarthritic human knee 
whilst being amenable to potential pharmacological manipulation (Ameye et al., 2006).  MNX model of 
OA in the rat displays changes within the articular cartilage, osteophyte formation and angiogenesis, both 
within the synovium and at the osteochondral junction, which resembles human tibiofemoral OA (Mapp et 
al., 2008).  It has a mild to moderate severity, sufficient to enable the exploration of factors which may 
either exacerbate or relieve OA. 
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OA was induced on day 0 by medial meniscal transection as described previously (Janusz et al., 2002; 
Mapp et al., 2008).  Briefly, prior to surgery, each animal was anaesthetized (section 2.2.1) and given 
subcutaneous injections (section 2.2.4).  The left leg was closely shaved and surgically prepared with 
Vetasept Povidone-Iodine scrub (Animalcare Ltd, Dunnington, York) to provide a sterile area to operate 
on.  The scrub was applied from the middle of the clipped area towards the outside to prevent any dirt being 
dragged from the fur at the edge on to the skin where the incision was to be made.  The animal was then 
appropriately positioned over a heat blanket to keep it warm during surgery.  A sterile op-cover (Kruuse 
Ltd, Sherburn in Elmet, North Yorkshire) was placed over the leg to be operated on, covering all but the 
surgical field, reducing the risk of sterile items coming into contact with non-sterile areas close to the 
surgical field.  All instruments were sterilized prior to surgery.  A large section of the skin over the knee 
joint was grasped using straight forceps (InterFocus Ltd, Linton, Cambridge, 11370-40).  The skin was cut 
on the medial side of the knee joint with a single cut just underneath the joint cavity using straight iris 
scissors (InterFocus Ltd, Linton, Cambridge, 14558-11).  The white shadow of medial collateral ligament 
(MCL) was seen at this point buried under the muscle layers.  Hemorrhage from the skin edge was arrested 
by applying firm pressure from a sterile swab. Connective tissue (CT) was grasped with straight forceps 
and cauterized using small vessel cauteriser (InterFocus Ltd, Linton, Cambridge, 18000-00) edged in a 
straight line from one corner of the cut to the other.  The muscle layers were then held before being 
cauterized in a similar manner as that of the CT to expose the MCL.  To prevent excess blood loss from the 
surgical site, hemorrhage was arrested by cauterizing the bleeding vessel during the course of surgery.  This 
minimized post-operative swelling, surgical shock and risk to the animal.  The MCL was grasped with 
micro-forceps with teeth (InterFocus Ltd, Linton, Cambridge, 11084-07).  Using the straight spring scissors 
(InterFocus Ltd, Linton, Cambridge, 15000-00) held flat to the joint, the MCL was cut and part removed 
(3mm) to uncover the meniscus.  The procedure was stopped at this point and the wound sutured if SHAM 
surgery was being performed.  Otherwise the procedure was continued and the meniscus was freed from its 
surrounding tissues by making two cuts either end of the meniscus at the top and two cuts at the bottom 
using straight spring scissors.  The ankle of the animal was twisted gently to clearly visualize the joint 
space and the meniscus was grasped using straight forceps before being cut through the full thickness at its 
narrowest point using straight spring scissors.  The meniscus separated in to two parts.  Care was taken to 
ensure that the underlying articular cartilage did not suffer any forced damage whilst the meniscus was 
being cut during the surgery.  The safety of the underlying articular cartilage was ensured in several ways, 
by twisting the ankle of the animal to create a space between the meniscus and the two bone ends.  This 
enabled the free meniscus to be grasped easily by the forceps and to be pulled up slightly without touching 
the two bone ends before the cut was made.  Also, after the meniscus was cut, the two bone ends were 
inspected thoroughly under the microscope to ensure no damage was sustained.  The site was flushed with 
saline and dabbed using sterile swabs to remove excess blood.  To stop tissues from drying out during 
surgery, they were dabbed at regular intervals with sterile swabs soaked in saline.  Instruments were re-
sterilised between animals using Novasapa Cold Steriliser (Pfizer Animal Health, Walton Oaks, Surrey).  
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Sutures were placed using micro needle holder with cutter (InterFocus Ltd, Linton, Cambridge, 12075-14) 
and suture tying forceps (InterFocus Ltd, Linton, Cambridge, 18025-10) to pass curved needles through 
tissues and to tie knots after suturing. The CT layer was closed with interrupted stitches using Ethicon 
coated vicryl 8/0 sutures.  The skin was closed using subcutaneous continuous stitches with Ethicon coated 
vicryl 4/0 sutures to appose the tissue margins and allow healing (Figure 2.2). 
 
 
 
Figure 2.2: Meniscal transection surgery.  Medial collateral ligament was exposed (A) and partly 
removed to access the meniscus.  The meniscus was cut through the full thickness at its narrowest point 
(B).  The connective tissue layer was closed first (C) followed by the skin (D).   
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2.3 Behavioural Testing 
 
2.3.1 Pain Behaviour 
Knee joint pain can be measured indirectly as weight-bearing asymmetry (Neugebauer et al., 2007).  This 
method is used in the clinical setting to assess pain in the arthritic patients.  Most commonly, the weight 
bearing asymmetry is measured between the two hind limbs as the force exerted by each limb on a 
transducer pad over a given period of time.  Weight borne by each hind limb is expressed as the percentage 
difference of weight distribution (force) between each hind limb (Bove et al., 2003; Mapp et al., 2010).  A 
significant shift of weight from the ipsilateral (operated) to the contralateral (control) limb (a weight-
bearing deficit) is taken as a pain measure. 
 
A Perspex tube instead of a Perspex box was used to house the animals in order to carry out the pain 
behaviour testing because animals seemed calmer and stayed relatively still in the tube compared to when 
they were in the box, enabling consecutive readings to be obtained.  However when the animals were 
housed in the Perspex box, they tended to move around a lot and appeared more stressed.  Animals were 
able to climb out of the Perspex box via the removable lid.  This interfered with obtaining consecutive 
readings.  Animals were first habituated in the Perspex tube/Incapacitance Meter prior to when the actual 
pain behaviour measurements were supposed to be taken.  This enabled the animals to get used to their 
surroundings, reducing stress levels.  Stressed animals could grossly interfere with true pain behaviour 
measurements.  Pain behaviour was measured at set time-points using the Incapacitance Meter (Linton 
Instruments, Norfolk, UK).  Each animal was placed in the Perspex tube, such that each paw rested on a 
separate transducer pad WKDW UHFRUGHG WKH DQLPDO¶V ZHLJht distribution over a period of 3 seconds.  An 
average of 5 separate readings was taken for each data point (Figure 2.3).   
 
 
Figure 2.3: Measuring pain behaviour.  Incapacitance meter having Perspex box (A) or Perspex tube 
(B) to house the animals.  Animals were placed on the incapcitance meter such that each hind paw rested 
on a separate transducer pad of the incapacitance meter.  Over a period of 3 seconds, the amount of weight 
the animal was placing on each of its hind limb was measured in grams.   
Perspex 
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2.3.2 Weights 
Weight of each animal was measured at set time-points throughout the experiments to ensure that the 
surgical procedures and the drugs being used were not having detrimental side-effects. 
 
2.4 Joint Swelling 
Joint swelling was measured at set time-points with a digital electronic caliper (Miyutoyo UK Ltd., 
Andover, UK) as asymmetry in knee diameters (millimeters) between ipsilateral (operated) and 
contralateral (control) knee joints (Figure 2.4).   
 
 
Figure 2.4: Knee joint swelling.  Each animal was held by an assistant and the knee joint diameter 
was measured using a digital electronic calliper.  
 
 
 
 
 
 
 
 
 
 
 
 
Digital electronic caliper 
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2.5 Tissue Collection and Processing 
 
2.5.1 Harvesting and mounting rat synovia 
Animals were killed by asphyxiation in CO2 (section 2.2.2).  For each animal, skin was removed, synovia 
with patellae from right and left knees were dissected free from bone (Figure 2.5) and immediately 
embedded perpendicularly side on in Tissue Tek Optimum Cutting Temperature (OCT®) mounting 
medium (Raymond Lamb, Eastbourne, UK) onto cork blocks before being snap frozen in melting 
isopentane and stored at -80°C until use.   
 
 
Figure 2.5: Harvesting synovium.  A, knee joint of an animal with the skin removed.  B, synovium 
with patella dissected free from bone.  C, exposed underlying patella groove with the synovium and patella 
removed. 
 
2.5.2 Harvesting and mounting rat tibiofemoral joints  
Tibiofemoral joints were isolated by cutting mid-femur and tibia using bone cutters and excess skeletal 
muscle was removed.  The joints were preserved in either neutral buffered formalin (containing 4% 
formaldehyde) for 48 h at room temperature or Zamboni¶VIL[DWLYHVROXWLRQ>ZY@SDUDIRUPDOGHK\GH
15% [v/v] picric acid in phosphate buffer, pH 7.3) overnight at  4°C (Stefanini et al., 1967).  The sections 
were continuously agitated on a roller-mixer throughout the fixing process and subsequently decalcified.   
 
A B C Supra-patellar   
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Decalcification is the process by which heavily mineralised tissues are softened to enable thin sections to 
be obtained for histological purposes, carried out by treatment with reagents which react with calcium.  
There are two major types of such reagents; acids (formic acid) to form soluble calcium salts and chelating 
agents (ethylenediaminetetraacetic acid [EDTA]) to take up calcium ions.  Formic acid was used to rapidly 
decalcify the tibiofemoral joints to be used for histological stains (section 2.7) in order to analyse the 
structure of the joint.  EDTA decalcification was used because it was a less harsh and slower method of 
decalcification compared to formic acid having little to no effect on the stainability of the tissue, enabling 
immunohistochemistry detection of delicate structures such as nerves.   
 
Formalin-fixed tibiofemoral joints were decalcified in 10% formic acid in neutral buffered formalin 
(containing 4% formaldehyde), changed every other day, for 10 days at room temperature.  Decalcification 
was confirmed by radiography (22kV 16sec).  Coronal sections (Figure 2.6) of trimmed joint tissues were 
then cut and processed by standard histological techniques and mounted in paraffin wax blocks for 
sectioning.  Briefly, the sections were secured (flat side down) in labelled plastic cassettes.  The cassettes 
were placed in the Shandon Pathcentre enclosed tissue processor (Shandon ThermoScientific, 
Leicestershire, UK) DW .LQJ¶V 0LOO +RVSLWDO E\ DQ H[SHULHQFHG ODERUDWRU\ WHFKQLFLDQ 5oger Hill) to 
undergo a series of dehydration and clearing steps.  The sections were impregnated with molten wax for the 
final embedding stage of setting the sections in blocks of paraffin wax.  For this, metal moulds were placed 
on a hot-plate and molten wax was dispensed into them from a Tissue Tek ® embedding centre (model 
TEC5 EME2; Sakura Finetek Europe, The Netherlands).  Tibiofemoral joint sections were then placed flat 
side down into the centre of the mould using warm forceps and transferred briefly to a cold-plate to allow 
the wax to slightly solidify at the bottom of the mould.  At the same time the section was pressed down to 
enable an even flat tissue surface to be achieved with the wax.  Labelled plastic cassettes were then placed 
on top of the mould, pressed down and more wax poured on top to evenly fill the cassettes.  Moulds were 
then placed on the cold-plate for rapid cooling of the wax.  Once the wax set, the wax blocks were removed 
from the metal moulds, excess wax trimmed from the cassettes and the wax blocks were stored at room 
temperature until required for microtomy (Figure 2.6). 
 
Zamboni-fixed tibiofemoral joints were transferred to 15% [w/v] sucrose in phosphate buffered saline 
(PBS/Sucrose) solution at 4 °C for 5 days.  The PBS/Sucrose solution was changed daily until the yellow 
appearance of the solution was cleared.  Once cleared, the PBS/Sucrose was replaced with decalcification 
fluid (10% EDTA in 10mM Tris buffer with 7.5% [w/v] polyvinylpyroolidene [PVP], pH 6.95).  The joints 
were decalcified for approximately 5 weeks at 4°C.  The decalcification fluid was changed every other day.  
Radiography (22kV 16secs) was used to detect the extent of decalcification of the tibiofemoral joints. 
When the joints were fully decalcified, coronal sections of trimmed joints (Figure 2.6 A) were cut and 
transferred to PBS/Sucrose solution for 5 days at 4°C through to 1:1 mixture of PBS/Sucrose and OCT® 
embedding matrix into 100% OCT for a further 7 days at 4 °C.  The sections were continuously agitated on 
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a roller-mixer throughout this process before being mounted onto cork blocks and then snap frozen in 
melting isopentane on liquid nitrogen and stored at -80 °C.   
 
 
Figure 2.6: Harvesting knee joints.  A, an example of a knee joint split in half from which coronal 
sections were taken.  B, sections of knee joints embedded in paraffin wax blocks. 
 
2.5.3 Human menisci 
$OOPHQLVFLVDPSOHVZHUHSURFHVVHGRQVLWHDW.LQJ¶V0LOO+RVSLWDOE\DQH[SHULHQFHGODERUDWRU\WHFKQLFLDQ
(Roger Hill) following standardised procedures.  Coronal slices (2 mm thick) from the midline of medial 
menisci were fixed in neutral buffered formalin (containing 4% formaldehyde) for 48 h at room 
WHPSHUDWXUHDQGZD[HPEHGGHGRUZHUH IL[HG LQ=DPERQL¶V VROXWLRQ >ZY@SDUDIRUPDOGHK\GH, 15% 
[v/v] picric acid in phosphate buffer, pH 7.3) (Stefanini et al., 1967) overnight at 4 °C.  Samples fixed in 
=DPERQL¶V VROXWLRQ ZHUH WUDQVIHUUHG WR  >ZY@ 3%66XFURVH VROXWLRQ DW  & IRU  GD\V DQG WKHQ
through 1:1 mixture of PBS/Sucrose and OCT® embedding matrix into 100% OCT for a further 7 days at 4 
°C before being mounted onto cork blocks and then snap frozen in melting isopentane and stored at -80 °C.   
 
2.5.4 Systemic transcardiac perfusion fixation of rat tibiofemoral joints  
Each animal was sedated 15 min prior to the procedure with intraperitoneal injection of 0.5ml sodium 
pentobarbital (Euthatal), given in the lower left or right quadrant of the abdomen as there are no vital 
organs in this area.  The quadrants are demarcated by the midline and a line perpendicular to it passing 
through the umbilicus.  The needle was angled at 45° and passed smoothly through the skin.  When both 
the corneal and hind paw withdrawal reflexes were absent, the animal was restrained on a perfusion tray 
and the rib cage was cut to expose the heart.   
 
A small incision was made in the left ventricle and a cannula was passed through it into the ascending 
aorta.  A small incision was made in the right atrium to allow drainage of returning blood and fluid from 
Tibia 
Femur 
A B 
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the systemic circulation.  PBS (500 ml) was pumped through the cannula to wash out any remaining traces 
RI EORRG LQ WKH DQLPDO  =DPERQL¶V IL[DWLYH (500 ml) was then pumped through the animal to fix the 
tibiofemoral knee joints (Hukkanen et al., 1992).  Tibiofemoral joints were isolated by cutting mid-femur 
DQGWLELDDQGSUHVHUYHGLQ=DPERQL¶VIL[DWLYHVROXWLRQUHDG\IRUWKHGHFDOFification process (section 2.5.2). 
 
2.5.5 Blood Glucose Testing 
OneTouch® Ultra® Blood Glucose Meter and Test Strips (LifeScan Inc. High Wycombe, UK) were used 
to test blood glucose levels 35 days after meniscal transection surgery (section 2.2.6).  Briefly, at the time 
of harvesting rat tibiofemoral knee joints (section 2.5.2) the code matched test strip was inserted into the 
associated meter.  Drops of blood were applied to the top edge of the test strip until the confirmation 
window was full.  The results were displayed on the meter in a range of 1.1 ± 33.3 mmol/L.  Normal blood 
glucose level was taken as 4 ± 7 mmol/L. 
 
2.6 Immunohistochemistry 
 
2.6.1 Introduction 
Immunohistochemistry is a process used to localise specific molecules (antigens) in tissue sections or cell 
preparations by the use of antibodies (Immunoglobulins) (Coons et al., 1950) for microscopical evaluation.  
These antibodies are coupled to a variety of labels such as enzymes, fluorescence molecules, isotopes and 
colloidal gold that can be visualised relatively easily.  Immunohistochemistry is readily used in research 
and in clinics as a diagnostic tool.  In addition to antibodies, other types of proteins and carbohydrates such 
as lectins can be used to detect specific molecules in tissue sections or cell preparations, using essentially 
the same method.   
 
2.6.2 Principles involved 
Tissues are first collected and processed (section 2.5) before thin sections are cut and stained with labelled 
antibodies.  This is needed not only to preserve the tissue architecture but also to prevent deterioration of 
antigens being investigated and at the same time processing the tissue so that sections can be cut for light 
microscopy.  This processing step also fixes the antigens, preventing their leakage into the 
microenvironment and into the solutions used during the processing and staining procedures.  Sections are 
cut from either fixed tissue samples embedded in paraffin wax or unfixed frozen samples which are 
followed by a fixation step using acetone.  Paraffin wax embedded tissues display superior quality of the 
morphology of cells and tissues, the antigenic determinants are however relatively poorly preserved and 
sometimes difficult to detect.  As a result, either antigen retrieval methods are used to overcome this 
difficulty or unfixed frozen tissue samples are used.  The basic principles of immunohistochemistry 
staining are the incubation of tissue sections with primary antibodies directed to antigens of interest, 
binding of these antibodies to tissue antigens and detection of the attached antibodies.  The primary 
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antibodies are either directly conjugated to a tag or unlabelled (indirect method).  In the indirect method, 
unlabelled primary antibodies bind to antigens.  Labelled biotinylated secondary antibodies (raised against 
the IgG of the animal species in which the primary antibodies are raised) react with the primary antibodies.  
The specific antigen-antibody interactions can be visualised using the avidin-biotin complex (ABC) method 
(Guesdon et al., 1979; Hsu et al., 1981).  The biotin vitamin on the secondary antibody binds with high 
affinity to the glycocprotein avidin.  Four biotin vitamins can bind with high affinity to one avidin 
glycoprotein, amplifying the antigen-antibody signal (Figure 2.7).  Biotin is labelled with either peroxidase 
(Nakane et al., 1966) or alkaline phosphatase (Mason et al., 1978) enzyme markers.  These are easily 
developed by incubation with a substrate, either diaminobenzidine (DAB) substrate to give a brown 
coloured stain or Fast Red substrate to give a red stain respectively that can easily be visualised.  The DAB 
stain can be enhanced using glucose oxidase/nickel, producing a deep purple/black colour (Shu et al., 
1988).   
 
Indirect immunohistochemistry with ABC method is more frequently used as it has several advantages.  
Firstly, it allows for considerably higher sensitivity, to antigens which are present in low amounts without 
increasing background staining.  This is also important where the cost of primary antibodies is significant.  
The high affinity of avidin and biotin ensures the user of the rapid formation and stability of the complex.  
Moreover, it is possible to localise more than one antigen with two or more primary antibodies in the same 
tissue by using separate enzyme markers or substrates. 
 
Figure 2.7: Indirect immunohistochemistry.  Primary antibody binds to the specific antigen of 
interest on the cell surface.  A biotinylated secondary antibody binds the unlabelled primary antibody and is 
detected with the performed avidin-biotin complexes (avidin biotin complex, ABC method).  Four biotin 
vitamins can bind with high affinity to one avidin glycoprotein, amplifying the antigen-antibody signal that 
is easily developed and visualised. 
Antigen 
Primary antibody 
Biotinylated 
Secondary antibody 
Avidin-Biotin   
labeled complex 
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2.6.3 Staining procedures 
For detection of CGRP positive nerves=DPERQL¶VIL[HGWLVVXHVZHUHXVHG(Stefanini et al., 1967).  Unfixed 
fresh frozen tissues were used for all other studies.  Details of primary and secondary antibodies used in 
these studies are listed in the appendix.  For staining of nerves, ȝP WKLFN tissues sections were cut to 
facilitate morphological identification of these fine delicate structures.  For all other staining, tissue 
sections were cut ȝPWKLFN.  Rat synovial tissue sections and human meniscal tissue sections from each 
OCT block were cut using a motorised cryostat, mounted on slides, and briefly air dried.  Coronal sections 
from paraffin wax blocks taken from the midpoint of the rat knee joint as identified by the presence of 
cruciate ligament insertions and sections from human menisci were cut in a Reichert-Jung rotary 
microtome were.   Preparations were mounted in Distyrene, Plasticizer and Xylene ('H3H;) except those 
to detect ECs which were mounted in PBS/glycerol (3:1).  Figure 2.8 highlights the essential steps required 
prior to carrying out the staining procedures. 
 
Sections of unfixed tissues were then fixed in acetone for 10 minutes at 4°C and washed twice in 0.01 M 
PBS, pH 7.4, each wash lasted 5 minutes.  Whereas sections from paraffin wax blocks were dewaxed in 
xylene and rehydrated from 100% ethanol, through to 70% ethanol and then into distilled water, before 
being washed in PBS.  Each step was performed twice and lasted 5 minutes.  To completely abolish the 
chances of false positive reactions occurring in frozen tissues, endogenous peroxidase activity was blocked 
by incubating the tissue sections for 30 minutes at room temperature (RT) in absolute methanol containing 
0.33% hydrogen peroxide (Streefkerk 1972) and then washed twice for 5 minutes in 0.01 M PBS.   
 
Primary antibodies diluted in 0.01M PBS with 5% BSA and 3.3% normal serum from the species in which 
the secondary antibody was raised were then applied and the tissue sections were incubated in a humid 
chamber either for 1 hour at RT, or overnight at 4°C and subsequently washed twice in 0.01 M PBS.  
Sections were then incubated in biotinylated secondary antibody diluted in 0.01 M PBS with 5% BSA and 
3.3% normal serum for 45 minutes at RT.  Sections were washed twice for 5 minutes in 0.01 M PBS and 
then incubated with avidin biotin complex (ABC) for 30 minutes at RT.   
 
$%&ZDVSUHSDUHGDQGOHIWVWDQGLQJDW57IRUPLQXWHVEHIRUHXVHȝORIVROXWLRQ%ZDVDGGHGWR
PO3%6DQGPL[HGE\VKDNLQJIROORZHGE\WKHDGGLWLRQRIȝOVROXWLRQ$DQGLPPHGLDWHPL[LQJ$IWHU
incubation with ABC, sections were washed twice for 5 minutes in PBS and incubated for a further 5 
minutes in 0.1M sodium acetate buffer, pH 4.6 before being developed with the chromogen.  Deposition of 
chromogen during development was monitored by direct visualisation under light microscopy using a ×4 
objective lens and reaction terminated by immersion in 0.01M PBS.   
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Figure 2.8: Flow diagram highlighting the essential steps involved prior to staining procedures. 
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Tissue sections immunostained by the peroxidase-conjugated ABC complex method were visualised with 
DAB using the glucose oxidase/nickel-enhanced method (Shu et al., 1988) before being either directly 
dehydrated in graded alcohols and mounted in DePeX or first counterstained with Mayers Haematoxylin 
and differentiated in 1% acid alcohol before dehydration and mounting.   
 
Glucose oxidase/nickel enhancement of the ABC-peroxidase method was employed for demonstration of 
neuronal structures (Shu et al., 1988).  It comprised of dissolving 25 mg of DAB in 25 ml of distilled water 
immediately before use and mixed with 25 ml of 0.2 M sodium acetate buffer, pH 6.0, containing 1.25 g di-
ammonium nickel (II) sulphate.6H20, 20 mg ammRQLXP FKORULGH DQG  PJ ȕ-D-glucose.  Glucose 
oxidase (0.25 ml of 0.2% in distilled water) was added with stirring and applied to sections in an incubation 
chamber. 
 
Tissues sections stained by the ABC-alkaline phosphatase method were developed using Sigma-Aldrich 
Fast Red (Poole, UK) and mounted in PBS/glycerol (3:1).  To prevent drying of sections following 
mounting, coverslips were sealed with nail varnish. 
 
For multiple sequential staining, to identify CD31-positive cells and proliferating cell nuclear antigen 
(PCNA)-immunoreactive CD31-positive cells (to identify ECs and proliferating ECs, respectively) in the 
synovia as two separate measures of the extent of angiogenesis, sections were first immunostained by the 
peroxidase-conjugated ABC complex method for PCNA (Waseem et al., 1990) and then by the ABC-
alkaline phosphatase method using a monoclonal antibody directed against CD31 for endothelium (Male et 
al., 1995)  1XFOHL ZHUH FRXQWHUVWDLQHG ZLWK IOXRUHVFHQW '1$ OLJDQG ¶-¶-diamidino-2-phenylindole 
hydrochloride (DAPI) in a humid chamber at RT in the dark for 10 minutes (Sanna et al., 1992).  Sections 
were then mounted in PBS/glycerol and coverslips sealed using nail varnish.  Staining procedures were 
similar to those previously described (Walsh et al., 1998).   
 
Macrophage infiltration was identified by immunoreactivity for the monoclonal antibody clone ED1 
(Dijkstra et al., 1985) in the synovia.  Nerves were immunolocalised using antibody to CGRP.  Vascular 
endothelium was localised using antibody to alpha actin (Kennedy et al., 2010), all labelled with avidin-
biotin complex and visualised by nickel-enhanced DAB method (Shu et al., 1988) before being mounted in 
DePeX.  
 
Lectin immunohistochemistry was performed to identify ECs using Griffonia simplicifolia (GS-1) as 
previously described (Orgad et al., 1984; Alroy et al., 1987) on paraffin wax embedded tissue sections.  
After de-waxing and rehydration, sections were incubated in neuraminidase for 3 hours in a humid chamber 
at 37°C to cleave surface sialic acids.  The sections were then washed twice for 5 minutes in N-[2-
hydroxyethyl]piperazine-1¶-[2-ethanesulfonic acid]; 4-[2-hydroxyethyl]piperazine-1-ethanesulfonic acid 
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(HEPES) buffer, pH 7.5 and incubated with lectin GS-1 in HEPES buffer overnight at 4°C in a moist 
chamber. The lectin was detected using anti-lectin followed by biotinylated antibodies with phosphatase-
ODEHOHG$%&YLVXDOLVHGXVLQJ)DVW5HG 
 
2.7 Histological Stains 
 
2.7.1 Haematoxylin and eosin  
Haematoxylin and eosin stains were used to analyse tissue architecture.  The basic dye component, 
haematoxylin, having high affinity for acidic structures such as nucleic acid, stained the cell nuclei 
blue/black, whilst eosin, an acid dye, having high affinity for basic structures, stained  cell cytoplasm and 
most connective tissue fibres in various shades and intensities of pink, orange and red (King et al., 1986).     
 
Frozen tissue sections ȝPWKLFNZHUHZDVKHGWZLFHIRUPLQXWHVLQGLVWLOOHGZDWHU:KHUHDVSDUDIILQ
wax embedded tissue sections ȝP WKLFN were first dewaxed in xylene and then rehydrated in graded 
ethanol before being washed in distilled water twice for 5 minutes.  Nuclear staining was then achieved by 
immersing WKH VHFWLRQV LQ 0D\HU¶V KDHPDWR[\OLQ IRU  PLQXWHV, rinsing in running tap water to 
differentiate the staining, dipping the sections in 1% acid alcohol solution for 10 seconds and back into tap 
water for further 3 minutes before being immersed in 1% eosin for 1 minute to stain all other tissue 
structures varying degree of red.  Staining was then differentiated with running tap water and the sections 
were dehydrated through graded ethanol into xylene and mounted in DePeX and covered with cover-slips.     
 
2.7.2 Safranin O and fast green 
Safranin O and fast green staining technique is most commonly used for studying bone and cartilage 
(McIlwraith et al., 1981; Bulstra et al., 1993).  The un-calcified cartilage stains red because of its high 
proteoglycan content, calcified cartilage stains a lighter pink shade and subchondral bone stains blue/green 
(Rosenberg 1971).  Safranin O and fast green staining technique was used to analyse the cartilage in rat 
knee joints and human menisci.   
 
)UR]HQWLVVXHVHFWLRQVȝPWKLFNZHUHZDVKHGWZLFHIRUPLQXWHVLQGLVWLOOHGZDWHU:KHUHDVSDUDIILQ
ZD[HPEHGGHG WLVVXH VHFWLRQV ȝP WKLFN ZHUH ILUVW GHZD[HG LQ [\OHQH DQG WKHQ UHK\GUDWHG LQ JUDGHG
ethanol to distilled water twice for 5 minutes  6HFWLRQVZHUH WKHQ LPPHUVHG IRUPLQXWHV LQ:HLJHUW¶V
haematoxylin, rinsed for 1 minute in running tap water, submerged in acid alcohol solution for 20 seconds 
and rinsed again in tap water for further 3 minutes.  Sections were subsequently immersed in Fast Green for 
5 minutes, dipped for 1 second in acetic acid and immersd in Safranin O for 5 minutes, followed by 
differentiation of the staining in running tap water and dehydration with graded ethanol to xylene before 
being mounted in DePeX and covered with cover-slips. 
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2.8 Image analysis and Quantification 
All image analysis and quantification was carried out whilst being blinded to the experimental details, 
using a Zeiss Axioscop-50 microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).  Images were captured 
using a 3-CCD video camera module (model KY-F55B; JVC, Japan) and analysed using KS300 image 
analysis software (Imaging Associates Ltd., Thame, UK). 
 
2.8.1 Synovia 
Using a ×20 objective lens, data was obtained from four fields of view on each synovial section that 
displayed the highest densities of either CD31-positive blood vessels, or PCNA-positive endothelial nuclei, 
or ED1-positive macrophages.   
 
To quantify vascular density and proliferating ECs in the synovium, the synovial region to be analysed was 
first chosen according to morphology.  An image was captured using a 3-CCD video camera for analysis 
with KS300 image analysis software.  Colour transmitted light images and fluorescence images of DAPI-
positive nuclei were captured and converted automatically to monochrome images.    Frame surrounding 
the synovium was delineated and measured.  The image was thresholded according to hue to include all 
CD31-positive blood vessels.  The vessels were interactively selected from a mask created to include only 
endothelium, and their combined areas measured.  PCNA-positive nuclei, falling within the endothelium 
were counted by interactively selecting each of them.  The fluorescent image of the DAPI-positive nuclei 
was overlaid by the endothelial mask automatically and the DAPI-positive nuclei were then counted 
interactively.  To quantify macrophage infiltration, colour transmitted light image of ED1-positive synovial 
region was captured and converted automatically to monochrome image.  A frame surrounding the 
synovium was delineated and measured.  The image was thresholded according to hue to include all ED1-
positive nuclei and their combined areas measured.  These procedures were similar to those previously 
described (Seegers et al., 2003).  Non-specific staining was excluded from the measurements by rejecting 
objects not fitting the morphological criteria of the structures (macrophages, blood vessels, nerves) being 
quantified.  EC proliferating index was defined as the percentage of EC nuclei positive for PCNA.  
Vascular density and macrophage fractional area was defined as the percentage of synovial area that was 
positive for CD31 and ED1 respectively.   
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2.8.2 Cartilage and Subchondral Bone 
The entire medial tibial plateaux of the mid-coronal sections stained with Safranin-O were used to assess 
chondropathy and osteophytosis through a ×10 objective lens under transmitted light. Chondropathy and 
osteophytosis were evaluated using the system of Janusz et al., as previously described (Janusz et al., 
2002).  Briefly, in this method cartilage damage was scored on a scale of 0 to 5 as follows:  
 
0 = Cartilage of normal appearance 
1 = Minimal fibrillation in superficial zone only 
2 = Mild, extends into the upper middle zone 
3 = Moderate, well into the middle zone 
4 = Marked, into the deep zone but not to the tidemark 
5 = Severe, full thickness degeneration to the tidemark  
 
The extent of medial tibial plateau involved in the damage was also taken into account.  It was estimated as 
the proportion of the section of medial tibial plateau that was involved, 1/3, 2/3 or 3/3.  The cartilage 
damage score was then multiplied by 1, 2 or 3 respectively to give an overall chondropathy score.     
 
Osteophytes were scored depending on their size on a scale of 0 to 3 using an eyepiece graticule as follows: 
 
0 = No osteophyte present 
 0LOGȝP 
 0RGHUDWHWRȝP 
 3 = SHYHUH!ȝP 
 
Total joint damage score was calculated as the sum of the chondropathy and osteophyte scores.   
 
Integrity of the osteochondral junction was measured as either the number of channels present in the 
articular cartilage of a Safranin-O stained section of the medial tibial plateau using a ×20 objective lens or 
the number of channels present per centimeter length of the medial tibial plateau.  Channels were accepted 
as being in the cartilage if they had either entered into the cartilage or were fully touching it.  To measure 
the length of the medial tibial plateau, an image was captured using a 3-CCD video camera for analysis 
with KS300 image analysis software.  Colour transmitted light image of the medial tibial plateau was 
captured and converted automatically to monochrome image.  The length was delineated using a line and 
measured.  Osteochondral vascular density was determined by counting the number of channels containing 
Griffonia simplicifolia (GS-1) lectin labelled blood vessels crossing the osteochondral junction in a section 
across the medial tibial plateau.   
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2.8.3 Human Menisci 
Meniscal degeneration was defined according to the modified Copenhaver classification based on change in 
appearance of collagen bundles (Copenhaver W 1978; Ishihara G 2009) using the following criteria: 
Grade 0 = Homogeneous eosinophilic staining.  Collagen bundles closely set with normal chondrocytes. 
Grade 1 = Mild cleft formation of collagen bundles with irregular eosinophilic staining and reduction in the 
chondrocytes. 
Grade 2 = Severe cleft and cyst formation of collagen bundles accompanied with hypocellular regions. 
 
Appearance of collagen bundles was analysed separately within the outer and inner regions of the 
meniscus.  
 
Vascularity using alpha actin staining was measured as percentage of tissue section area that was occupied 
E\ DFWLQ SRVLWLYH EORRG YHVVHOV  ȝP GLDPHWHU  9DVFXODU GHQVLWLHV ZHUH PHDVXUHG XVLQJ D î
objective lens within each of 8 consecutive fields along the entire transverse midline from the inner tip 
towards the periphery, in all fields along the sagital fibrocartilage junction between the inner and outer 
meniscal regions and within the synovium (Figure 2.9).  Each field was 1.4 mm long and had an area of 
1.68 mm2. 
 
Numbers of CGRP positive nerve profiles that were associated with blood vessels in the outer region of the 
meniscus were counted at ×40 objective lens in 6 fields of view that displayed the highest vascular densities 
with associated nerve profiles.  Each field of view FRPSULVHGDQDUHDRIȝP2.  CGRP positive nerves 
ZHUHFRXQWHGDVDVVRFLDWHGZLWKEORRGYHVVHOVLIWKH\ZHUHZLWKLQȝPRIWKHQHDUHVWYHVVHOSURILOH 
 
Synovial in-growth towards the tip of the meniscus was measured as the length (millimeter) of the 
synovium attached to the inner region of the meniscus (Figure 2.9).   To measure the length, an image was 
captured using a 3-CCD video camera for analysis with KS300 image analysis software.  Colour 
transmitted light image of the synovium attached to the inner region was captured and converted 
automatically to monochrome image.  The length was delineated using a line and measured. 
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Figure 2.9: Diagram illustrating the method of quantifying meniscal vascularisation and nerve 
growth.  Blood vessels were analysed (1) sequentially and within each consecutive field along the outer 
region of the entire fibrocartilage junction [(FCJ), vertical dashed line] separating the outer from the inner 
region, (2) along the entire midline (horizontal dashed line) of the meniscus, and (3) in the synovium (S) 
adjacent to the FCJ.  Nerve profiles associated with blood vessels were analysed in the outer region (OR) of 
the menisci.  The extent of synovial in-growth (arrows) towards the meniscal tip was measured in the inner 
region (IR).    
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2.9 Patient and sample selection for human menisci study 
All procedures were approved by Nottingham Research Ethics Committee 1 (08/H0403/132).  Knees were 
collected  PM from patients following consent from next-of-kin (person identified by the patient or those 
accompanying the patient where the patient was incapacitated) (Walsh et al., 2003).  The Academic 
Rheumatology joint tissue repository containing 288 PM cases was screened for cases displaying either 
high or low macroscopic chondropathy scores in the tibiofemoral joint as a measure of the presence and 
degree of OA (Walsh et al., 2009).  Identification of meniscal nerves required special fixation of tissues, 
available for a subgroup of 52 repository cases.  Cases did not have rheumatoid arthritis or other 
inflammatory joint diseases as determined by case notes review and interview with bereaved relatives.   
 
2.9.1 Macroscopic chondropathy score of tibiofemoral joint  
The extent and severity of loss of articular cartilage integrity for the medial and lateral femoral condyles 
and tibial plateaux were determined for each case by a single assessor, Roger Hill, at Kings Mill Hospital 
immediately following tissue harvesting (Walsh et al., 2009).  Tibial and femoral plateaux were 
photographed from a fixed distance of 23 cm using a Kaiser RS 2 XA camera stand, under standard 
illumination with a Sony DSC-s85 CyberShot digital camera fitted with a Carl Zeiss lens at ×4 zoom (Carl 
Zeiss Ltd., Welwyn Garden City, UK).  Severity of chondropathy was analysed on the photographs and 
graded 0 to 4 as follows: 
 
Grade 0 = Normal, smooth, unbroken surface, homogeneous white to off-white colour. 
Grade 1 = Swelling and softening, a light brown homogeneous colouration. 
Grade 2 = Superficial fibrillation, lightly broken surface, white to off-white/light brown in colour. 
Grade 3 = Deep fibrillation, coarsely broken cartilage surface, dark brown, grey or red in colour. 
Grade 4 = Subchondral bone exposure, stippled white and dark brown/red in colour. 
The percentage of area of each articular surface that displayed each grade was estimated by delineating 
freehand on standardised diagrams of each articular surface the extent of each grade of surface change 
(Figure 2.10).   
 
Chondropathy scores were calculated using the formula (Dougados et al., 1994; Walsh et al., 2009):  Score 
= (Grade 1*0.14) + (Grade 2*0.34) + (Grade 3*0.65) + Grade 4. 
 
The scores (possible range 0 to 100) from each articular surface were summed to give a total score 
(possible range 0 to 400) for the joint, with 0 indicating no evidence of chondropathy.  Forty cases (20 per 
group) were then selected for study of meniscal vascularity and 16 cases (8 per group) for the study of 
meniscal innervation, based on the following criteria: 
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High chondropathy group 
Knees were included on the basis of highest total joint chondropathy score plus, to maximise the likelihood 
of including cases with tibiofemoral OA, the presence of at least some grade 3 or 4 chondropathy in the 
medial compartment.  
 
Low chondropathy group 
Knees were included on the basis of lowest total joint chondropathy score plus, in order to minimise the 
risk of including cases with medial compartment OA, the absence of grade 3 or grade 4 chondropathy in 
either the medial or lateral compartment.  
 
Only medial menisci were examined for this study.  Patient criteria for choosing the samples are given in 
Figure 2.11.  Figure 2.12 shows the spread of age and the associated macroscopic chondropathy scores of 
200 consecutive PM cases within the repository from which the samples were selected. 
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Figure 2.10: Severity of chondropathy determined macroscopically on post mortem samples of 
tibiofemoral joints.  Digital photographs of femoral condyles and tibial plateaux are shown with their 
respective schematic diagrams, highlighting the extent of each grade of surface appearance.  Table of the 
estimated percentage of joint surface attributed to each grade is also shown (Walsh et al., 2009).  A = 
anterior, P = posterior, L = lateral and M = medial. 
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n = 288 PM cases
Right and Left knees screened
n = 5 cases                     
Complete data for 
cartilage severity 
not available
n = 27 cases                                                    
Highest total joint chondropathy
score plus the presence of grade 3 
or 4 chondropathy
n = 4 cases                      
Contralateral knee had 
higher chondropathy
and was included
n = 3 cases                           
Medial meniscus 
not available
n = 20 cases   
Selected
n = 32 cases                                                    
Lowest total joint chondropathy
score plus the absence of grade 3 
or 4 chondropathy
n = 12 cases                    
Contralateral knee had 
lower chondropathy and 
was included
n = 20 cases   
Selected
n = 0 cases                           
Medial 
meniscus not 
available
Vascular Cohort     
Formalin Fixed (n = 288)
Nerve Cohort     
Zamboni¶s Fixed (n = 52)
n = 9 cases                                                  
Highest total joint chondropathy
score plus the presence of grade 3 
or 4 chondropathy
n = 9 cases                       
Lowest total joint chondropathy
score plus the absence of grade 3 
or 4 chondropathy
n = 1 case                      
Contralateral knee had 
higher chondropathy
and was included
n = 8 cases   
Selected
n = 1 case                    
Contralateral knee had lower 
chondropathy and was included
n = 8 cases   
Selected
 
 
Figure 2.11 Sample selection criteria for human meniscal study. 
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Figure 2.12 The spread of age and the associated macroscopic chondropathy scores of 200 
consecutive PM cases within the Academic Rheumatology joint tissue repository, 
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2.10 Statistical analysis 
Four fields per section and one section per case were used for synovial macrophage infiltration and 
endothelial cell proliferation data.  For synovial endothelial fractional area (measure of vascular density) 
four consecutive sections per case with four fields of view per section were used.  This optimal number was 
determined in previous experiments to minimise the coefficient of variation and so that the observed mean 
lies within ± 12.5% of the true mean (Walsh et al., 1998). 
 
Data were analysed using Statistical package for the Social Sciences v.16 (SPSS inc., Chicago, Illinois, 
USA) and graphically presented using GraphPad Prism Version 4.03 Software (GraphPad Software, Inc., 
SanDiego CA, USA).  Parametric data (endothelial cell PCNA indices, and endothelial and macrophage 
fractional areas [logarithmically transformed], incapacitance and knee diameter) were analysed using one-
way analysis of variance (ANOVA).  8QLYDULDWH FRPSDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V W-test with 
%RQIHUURQL¶V FRUUHFWLRQ IRU PXOWLSOH FRPSDULVRQV  Non-parametric data (joint damage scores and 
osteochondral vascularity) were analysed using Kruskal-Wallis test followed by Mann-Whitney to compare 
WZR JURXSV ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU PXOWLSOH FRPSDULVRQV  )RU WKH PHQLVFDO GDWD FRPSDULVRQV
between groups were made using the Mann Whitney U test and associations between variables expressed as 
6SHDUPDQ¶VFRUUHODWLRQFRHIILFLHQWV 
 
Numerical data are quoted as mean (95% confidence interval) or median (Interquartile Range [IQR]) in the 
text, and, for clarity, graphically as mean ± standard error of the mean (S.E.M) unless otherwise stated. A 
two- tailed P < 0.05 was taken to indicate statistical significance. 
 
 
2.11 Reagents 
Monoclonal antibody to PCNA (clone PC10) was obtained from DAKO Ltd. (High Wycombe, UK).  
Biotinylated rat-adsorbed horse anti-mouse antibody, biotinylated goat anti-rabbit secondary antibodies, 
lectin GS-1 (L1100), goat anti-lectin (AS 2104), biotinylated rabbit anti-goat (BA 5000) and avidin-biotin 
complexes (ABC Kits) were obtained from Vector Laboratories Ltd.  (Peterborough, UK).  Monoclonal 
antibodies to rat CD31 (Platelet endothelial cell adhesion molecule 1[PECAM-1]) antibody (clone TLD-
3A12) and to macrophages (clone ED1) were from Serotec Ltd. (Oxford, UK).  Polyclonal anti-Į&*53
(human) antibody (Ref: T-4239) was from Peninsula Labs Inc (St. Helens, UK).  FGF-2 was purchased 
from Invitrogen LTD. (Paisley, UK).  DePeX mounting medium and PBS were from VWR Ltd 
(Lutterworth, UK). OCT compound and Mayers haematoxylin and eosin were from Raymond Lamb 
(Eastbourne, UK).  Monoclonal mouse antibody to alpha actin (clone 1A4), VDOLQHȜ-Carrageenan, DAPI, 
%6$7ULV('7$+3ȕ&', neutral buffered formalin, formic acid and other chemicals were obtained from 
Sigma-Aldrich (Poole, UK).  PPI-2458 was a kind donation of GlaxoSmithKline (Middlesex, UK).  
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3 ROLE OF ANGIOGENESIS IN INFLAMMATION AND PAIN IN TWO RAT 
MODELS OF SYNOVITIS  
 
3.1 Introduction 
Inflammation is normally a protective response to pathogenic, traumatic or toxic injury, reducing tissue 
damage and leading to resolution or repair (Benelli et al., 2006).  Despite the traditional classification of 
arthritis as inflammatory (e.g. rheumatoid arthritis [RA]) or non-inflammatory (e.g. osteoarthritis [OA]), 
inflammation is increasingly recognized as an important feature in OA (Ashraf et al., 2008).  Persistent 
inflammation itself causes tissue damage (Charo et al., 2006) but the mechanisms by which inflammation 
persists rather than resolves remain incompletely understood.  Arthritis is a major health problem 
worldwide, leading to pain and disability in the ageing populations (Reginster et al., 2002; Brooks 2006; 
Reyes-Llerena et al., 2009).  Defining factors which lead to persistent inflammation, a prominent feature of 
arthritis should lead to novel therapies, reducing the burden of this debilitating condition by facilitating 
resolution or repair. 
 
Angiogenesis is tightly regulated during normal growth, wound healing and the female reproductive cycle.   
Increased angiogenesis in the synovium is associated with chronic synovitis in OA (Haywood et al., 2003).  
Angiogenesis within the inflamed synovium is also typical of both early and established RA (Griffioen et 
al., 2000; El-Gabalawy 2005; Klareskog et al., 2009).  In chronic synovitis, a shift in the balance from anti-
angiogenic to angiogenic factors promotes endothelial cell proliferation and blood vessel growth 
(O'Connell 2000).  Chronic inflammation maintains blood vessel growth by the secretion of angiogenic 
factors from macrophages and various other cells (Jackson et al., 1997).  Synovial angiogenesis can further 
facilitate inflammation by increasing plasma extravasation and enhancing inflammatory cell recruitment 
(Bonnet et al., 2005; Costa et al., 2007).  
 
The FGF system plays an important role in angiogenesis and the maintenance of vascular integrity (Presta 
et al., 2005; Murakami et al., 2008).  FGF-2 promotes EC proliferation and the physical organisation of 
ECs into tube-like structures.  It also stimulates the proliferation of fibroblasts that give rise to granulation 
tissue in wound healing (Bussolino et al., 1996).  FGF-2-induced angiogenesis occurs in the absence of 
inflammation (Folkman et al., 1991; Zittermann et al., 2006) a characteristic which distinguishes it from 
many other angiogenic factors such as VEGF. 
 
The 2 MetAP isoforms; MetAP-1 and MetAP-2 are co-translational regulators of protein synthesis.  
MetAPs remove the initiator methionine from growing polypeptide chains, a prerequisite for a variety of 
biological processes such as protein stability (Kusaka et al., 1994; Sin et al., 1997).  Inhibition of MetAP-2 
prevents the selective removal of the N-terminal methionine and potently inhibits EC proliferation; a 
prominent mechanism in angiogenesis.  PPI-2458 is an anti-angiogenic fumagillin analogue that is an orally 
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active irreversible inhibitor of MetAP-2 via covalent modification of His-231 in the catalytic site of the 
enzyme.  This triggers growth arrest of ECs in the late G1 phase of the cell cycle, inhibiting EC 
proliferation and angiogenesis without affecting inflammatory cytokine release (Griffith et al., 1997; Sin et 
al., 1997; Bainbridge et al., 2007) or inducing apoptosis in ECs (Bernier et al., 2004).  PPI-2458 has 
reduced toxicity and greater selectivity for angiogenesis inhibition versus inflammation compared to 
another fumagillin analogue AGM-1470/TNP470 (Bernier et al., 2004; Brahn et al., 2009). 
 
PPI-2458 reduces synovitis and bone and cartilage damage in collagen-induced arthritis (CIA) in mice and 
peptidoglycan polysaccharide (PGPS)-induced arthritis in rats (Bainbridge et al., 2007; Lazarus et al., 
2008).  Those studies and studies of other anti-angiogenic strategies (Peacock et al., 1992; Abe et al., 1994; 
Kusaka et al., 1994; Storgard et al., 1999; Clavel et al., 2003) indicate that angiogenesis inhibition may 
have therapeutic potential in arthritis in humans.  However, sustained angiogenesis inhibition for the 
treatment of arthritis may lead to adverse events due to the blockade of physiological blood vessel growth 
such as impaired wound healing.  An anti-angiogenic strategy targeted to key phases in the development of 
chronic inflammation may have a more favourable risk: benefit ratio. 
 
Intra-articular injection ȝO of high dose (2%) of carrageenan induces chronic synovitis with 
angiogenesis, whereas a low dose (0.03%) of carrageenan induces resolving synovitis without angiogenesis 
(Walsh et al., 1998).  Since when synovitis persists it is accompanied by synovial angiogenesis, it led us to 
hypothesise that angiogenesis during the early phase of synovitis may be a key factor in determining its 
persistence, and, where this is the case, that a brief treatment with an angiogenesis inhibitor (PPI-2458) 
during the onset of arthritis could prevent its subsequent persistence.  
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3.2 Aims 
1. To evaluate if a short course of the angiogenesis inhibitor PPI-2458 makes 2% carrageenan 
induced chronic synovitis and pain more transient. 
2. To deduce the dose of FGF-2 that induces synovial angiogenesis without inflammation. 
3. To determine at what time point after injection of FGF-2, synovial angiogenesis returns to levels 
similar to those in naïve controls. 
4. To deduce the dose of carrageenan that induces synovial inflammation without angiogenesis. 
5. To determine at what time point after injection of carrageenan, synovial inflammation returns to 
levels similar to those in naïve controls. 
6. To evaluate the combined effects of FGF-2 and carrageenan on synovial angiogenesis and 
inflammation 
7. To evaluate the dose-response effects of PPI-2458 on angiogenesis 
8. To evaluate the effects of inhibiting angiogenesis (using PPI-2458) on the transition from acute to 
persistent synovitis (using combined injection of carrageenan and FGF-2) to model both inflammation and 
angiogenesis, as seen in early synovitis. 
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3.3 Methods 
General methodology is given in Chapter 2.  Experiments were performed on male Wistar rats (Charles 
River, Margate, Kent, UK) weighing 150-180 gm. 
 
3.3.1 Short-term angiogenesis inhibition using PPI-2458 and 2% carrageenan-induced 
synovitis 
To evaluate if a short course of the angiogenesis inhibitor PPI-2458 makes 2% carrageenan induced chronic 
synovitis and pain more transient, on day 0 animals were given intra-articular injection of 2% carrageenan 
into their left knee joints cavities.  Starting on day -1, and then every other day until day 9, animals were 
JLYHQ DQ RUDO GRVH RI ȝO RI HLWKHU PJNJ RI WKH DQJLRJHQHVLV LQKLELWRU 33,-2458 or vehicle control 
buffer.  This treatment regime was chosen based on previously published data where it was shown that after 
2% carrageenan injection the increases in synovial macrophage fractional area and EC PCNA index started 
to subside by day 14 to 28 (Walsh et al., 1998).   
 
Synovia (n = 6 per treatment group) were harvested on day 3, 10 and 24 after injection.  Naïve animals 
were used as baseline controls.  Weights, knee diameter and incapacitance (n = 8 per treatment group) 
measurements were monitored throughout the experiment (Figure 3.1).     
 
 
 
Figure 3.1 Experimental plan to investigate whether a short course of the angiogenesis inhibitor PPI-
2458 [administered every other day starting a day before the intra-articular injection of 2% carrageenan 
(day 0) to day 9] curtails 2% carrageenan-induced synovitis and pain behaviour.  Animals were habituated 
in the incapacitance meter before collecting weight bearing (pain) measurements.  Joint tissues were 
harvested at day 24.  At various time-points during the experiment, weights, knee diameters and 
incapacitance measurements of the animals were recored. 
 
 
 
-1 0 24 
Habituation 
PPI-2458 
Carrageenan (2%) Harvest Synovia 
1 2 3 4 5 6 7 8 10 9 
Weights, Incapacitance and Knee Diameter 
DAYS 
 91 
3.3.2 Intra-articular injections of FGF-2 and/or carrageenan 
To deduce the dose of FGF-2 that enables synovial angiogenesis without inflammation, on day 0 animals (n 
= 2 per treatment group) were given bilateral intra-articular injections in their knee joint cavities in the dose 
range of 6x10-4 to 6 picomoles (pmoles) of FGF-2 or 10 mM Tris (pH 7.6) containing 0.1% BSA vehicle 
control.  Synovia were collected on day 1.   
 
In order to confirm the previous findings that 0.03% carrageenan induces synovial inflammation without 
angiogenesis (Walsh et al., 1998), on day 0 animals (n = 2 per treatment group) were given bilateral intra-
articular injections in their knee joint cavities in the dose range 3x10-4 to 3x10-2 % of carrageenan or sterile 
0.9% normal saline control (pH 7.4).  Synovia were collected on day 1 (Figure 3.2). 
 
 
 
Figure 3.2 Diagram showing the experimental plan of how the doses of FGF-2 and/or carrageenan 
compounds to be used in this study in inducing angiogenesis/inflammation were selected.  Briefly, intra-
articular injections of various doses of either carrageen or FGF2 were given on day 0, 24 hours after the 
injection (day 1) synovia was harvested and snap frozen.  Immunohistochemistry and computer assisted 
image analysis techniques were used to detect and analyse synovial inflammation and angiogenesis. 
 
 
 
 
0 1    DAYS 
Intra-articular injection: 
 
Right Knee = Vehicle Control  
 
Left Knee = Carrageenan or FGF-2 
 
 Synovia harvested and snap frozen 
 
 Immunohistochemistry 
 
 Computer Assisted Image Analysis 
Synovial Inflammation 
 
Synovial Angiogenesis 
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To determine at what time point after the injection of 6 pmoles of FGF-2 synovial angiogenesis returns to 
levels similar to those in naïve controls, on day 0 bilateral intra-articular injection of 6 pmoles of FGF-2 
were given into the animals knee joint cavities (n = 3 per group).  Synovia were collected from naïve 
controls and on days 1, 2 and 5 after injection (Figure 3.3).   
 
 
 
Figure 3.3 Diagram showing the experimental plan to determine the time point after the injection of 
6 pmoles of FGF-2 that synovial angiogenesis returned to levels similar to those in naïve controls.  Briefly, 
at each time point, synovial were harvested and snap frozen.  Immunohistochemistry and computer assisted 
image analysis techniques were used to detect and analyse synovial angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
0 1 DAYS 
Intra-articular injection: 
 
Right Knee = Vehicle Control 
  
Left Knee = 6 pmoles FGF-2 
 
 Synovia harvested and snap frozen 
 
 Immunohistochemistry 
 
 Computer Assisted Image Analysis 
 
Synovial Angiogenesis 
2 5 
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To investigate the combined effects of FGF-2 and carrageenan, on day 0, animals (n = 6 per treatment 
group) were given intra-articular injections of either 0.03% carrageenan or 0.03% carrageenan and 6 
pmoles of FGF-2 in their left knee joint cavities and appropriate control treatments (sterile 0.9% normal 
saline [pH 7.4] or 10mM Tris [pH 7.6] containing 0.1% BSA) in their right knee joint cavities.  FGF-2 was 
injected first, followed by carrageenan after 30 minutes.  Control injections were given in a similar manner 
(Figure 3.4). 
 
 
 
Figure 3.4 Diagram showing the experimental plan used to elucidate the combined effects of FGF-2 
and carrageenan on angiogenesis and inflammation.  Briefly, after intra-articular injection of either 0.03% 
carrageenan or 0.03% carrageenan and 6 pmoles of FGF-2, at each time point, synovia were harvested and 
snap frozen.  Immunohistochemistry and computer assisted image analysis techniques were used to detect 
and analyse synovial inflammation and angiogenesis.  Knee diameter was also measured at each time point. 
 
 
 
 
 
 
 
 
Day 0 Day 1 Week 2 Week 4 
Intra-articular injection 
 
Right Knee = Vehicle Control 
  
Left Knee = Carrageenan+FGF2 
Knee diameter measured 
Synovial inflammation and angiogenesis 
 Synovia harvested and snap frozen 
 Immunohistochemistry 
 Computer Assisted image Analysis 
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3.3.3 Dose-response effects of PPI-2458 on angiogenesis induced by FGF-2 
In-order to select the appropriate dose of PPI-2458 that best inhibited 6 pmoles FGF2-induced 
angiogenesis, on day -DQLPDOVQ SHUWUHDWPHQWJURXSZHUHJLYHQHLWKHUDȝOVLQJOHRUDOGRVHRI
the angiogenesis inhibitor PPI-2458 at either 5mg/kg, 0.5mg/kg, 0.05mg/kg or vehicle control (11% 
+3ȕ&'>K\GUR[\SURS\OȕF\FORGH[WULQ@EXIIHULQ3%6 %LODWHUDO LQtra-articular injections of 6pmoles 
FGF-2 were given into knee joint cavities on day 0 and the synovia (n=6 per treatment group) were 
harvested on day 1 (Figure 3.5).  Naïve animals (n = 3) were used as the control group.   
 
 
 
Figure 3.5 Diagram showing the experimental plan of how the dose-response effects of PPI-2458 on 
FGF-2 induced angiogenesis were analysed.  Briefly, various doses (5mg/kg, 0.5mg/kg, 0.05mg/kg) of the 
angiogenesis inhibitor were given a day before the intra-articular injection of either 6 pmoles of FGF-2 or 
vehicle control.  A day after the injection, synovia was harvested and snap frozen.   Immunohistochemistry 
and computer assisted image analysis techniques were used to detect and analyse synovial angiogenesis.   
 
 
 
 
 
 
 
-1 0 1 DAYS 
Various doses of PPI-2458 or Vehicle 
control given orally 
Intra-articular injection: 
Right Knee = Vehicle Control  
Left Knee = FGF-2 
 
 Synovia harvested and snap frozen 
 
 Immunohistochemistry 
 
 Computer Assisted Image Analysis:  
 
     SYNOVIAL ANGIOGENESIS 
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3.3.4 PPI-2458 and intra-articular injection of FGF-2 and carrageenan 
On days -DQGDQLPDOVQ SHUWUHDWPHQWJURXSZHUHJLYHQDQRUDOGRVHRIȝORIHLWKHUPJNJ
of PPI-2458 or vehicle control buffer (Lazarus et al., 2008).  Intra-articular injections of 0.03% carrageenan 
& 6 pmoles FGF-2 (left knee joint cavity) or the appropriate vehicle control (sterile 0.9% normal saline [pH 
7.4] or 10mM Tris [pH 7.6] containing 0.1% BSA) (right knee joint cavity) were given at day 0.  Synovia 
was harvested at day 1, week 1 and week 4 (Figure 3.6).   
 
 
 
Figure 3.6 Diagram showing the experimental plan of how the effects of PPI-2458 on the ongoing 
inflammatory response after intra-articular injection of FGF-2 and carrageenan were investigated.  Briefly, 
intra-articular injection of 0.03% carrageenan and 6 pmoles of FGF-2 were given on day 0.  Angiogenesis 
inhibitor PPI-2458 was administered every other day, starting a day before the injection to day 3.  At each 
time point, synovia were harvested and snap frozen.   Immunohistochemistry and computer assisted image 
analysis techniques were used to detect and analyse synovial inflammation and angiogenesis.  Knee 
diameter was also measured at each time point. 
 
 
 
 
 
-1 0 1 3 Week 1 Week 4 DAYS 
PPI-2458 / Vehicle control 
Orally, every other day (5mg/kg) 
Intra-articular injection 
 
Right Knee = Vehicle Control  
 
Left Knee = Carrageenan + FGF2 
Knee diameter measured 
 Synovia harvested and snap frozen 
 Immunohistochemistry 
 Computer Assisted Image Analysis:  
SYNOVIAL INFLAMMATION AND ANGIOGENESIS 
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3.3.5 Tissue collection and preparation 
At each time-point after intra-articular injections (days 3, 10 and 24 for 2% carrageenan; days 1, 2 and 5 for 
FGF-2; days 1, 14 and 29 for 0.03% carrageenan; days 1, 7, 14, 28 and 29 for FGF-2 and carrageenan 
combined; day 1 for PPI-2458 and FGF-2; and days 1, 7 and 28 for PPI-2458 and FGF-2 and carrageenan 
combined) synovia with patellae from right and left knees were immediately harvested. 
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3.4 Results 
 
3.4.1 Synovial inflammation, angiogenesis and pain behaviour after intra-articular injection of 
2% carrageenan and administration of the angiogenesis inhibitor PPI-2458 
ED1-immunoreactive macrophages were localised to the synovial lining, and dispersed throughout the 
synovial sub-lining regions (Figure 3.7 A-C). CD31-immunoreactive blood vessels were distributed 
throughout the depth of rat synovia, sometimes containing PCNA-immunoreactive nuclei (Figure 3.7 E-G).  
Synovia from animals given a single intra-articular injection of 2% carrageenan showed increased staining 
for macrophages, proliferating ECs and EC fractional area.  These increases were reduced by day 24 after 
the administration of 6 doses of PPI-2458 (5mg/kg/every other day) starting a day before the intra-articular 
injection to day 9.  
 
3.4.1.1  Inflammation 
Intra-articular injection of 2% carrageenan treated with vehicle control, was followed by an increase in 
synovial macrophage fractional area, which was reduced at day 10 by the administration of 6 doses of the 
angiogenesis inhibitor PPI-2458 [Vehicle: 23% (95% CI 15 to 30), PPI-2458: 8% (95% CI 2 to 15), P < 
0.01].  The levels however did not reach those of naïve controls [PPI-2458: 8% (95% CI 2 to 15), Naives: 
1.1% (95% CI 0.8 to 1.4), P < 0.001].  This reduction was maintained to day 24 with-out the levels 
reaching to those of naïve controls (Figure 3.8 A).  Knee joint diameter (joint swelling) was transiently 
increased following intra-articular injection of 2% carrageenan and then gradually reduced to naïve control 
levels by day 24.  PPI-2458 did not reduce knee joint swelling following intra-articular injection of 2% 
carrageenan (Figure 3.8 B).    
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Figure 3.7 Histological evidence of synovial macrophage infiltration, angiogenesis and vascular 
density after intra-articular injection of 2% carrageenan and effects of oral administration of a short course 
of either PPI-2458 or vehicle control.  Panels show macrophage infiltration (A-C), endothelial cell 
proliferation (E-G) and vascular density (I-K) 24 days after intra-articular injection of 2% carrageenan.  
Intra-articular injection of 2% carrageenan induced synovial macrophage infiltration (A), angiogenesis (E) 
and vascular density (I).  Synovial macrophage infiltration was reduced following treatment with the 
angiogenesis inhibitor PPI-2458 (B, 5mg/kg/every other day from a day before intra-articular injection of 
carrageenan to day 9) but not to naïve control levels (C).  Synovial angiogenesis and vascular density were 
reduced by the administration of the anti-angiogenic agent PPI-2458 (F and J respectively), to naïve 
control levels (G and K).  A-C; macrophages are delineated by immunoreactivity for CD68 (ED1).  
Negative control section for CD68 (ED1) immunohistochemistry did not show any non-specific staining 
(D). Endothelial cells are delineated in red by immunoreactivity for CD31 [blue arrows (I-K)] and 
proliferating nuclei are delineated black by immunoreactivity for proliferating cell nuclear antigen (PCNA; 
green arrows). Black arrows indicate proliferating endothelial cells which contain PCNA-
immunoreactive nuclei.  Negative control sections for CD31 and/or PCNA immunohistochemistry did not 
show any non-specific staining (H and L).  Colour transmitted light images were taken using ×10 (I-L) and 
×20 (A-H) objective lenses of a single representative section from n = 8 animals per group.  Scale bar = 
100 ȝm. 
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Figure 3.8 Inhibition of measures of inflammation (synovial macrophage infiltration and joint 
swelling) after 2% carrageenan injection in either PPI-2458 or vehicle treated animals.  Intra-articular 
injection was given in rat knee joint cavities on day 0.  Oral administration of either PPI-2458 
(5mg/kg/every other day) or vehicle control was given from a day before the injection to day 9 (dotted line 
marks the end of PPI-2458 treatment).  Synovia were harvested 3, 10 and 24 days after the injection.  Intra-
articular injection of 2% carrageenan (Ŷ) was followed by an increase in synovial macrophage infiltration 
(A) and joint swelling (B).  These increases were higher than the naïve controls (ź) throughout the 
experiment.  Administration of PPI-2458 (Ÿ) reduced synovial macrophage infiltration from day 10 to 24 
but not to naïve control level.  PPI-2458 had no effect on knee joint swelling. Graphs show arithmetic mean 
and ±S.E.M of 8 knees per group.  Macrophage fractional areas (logarithmically transformed) and knee 
diameters were analysed using one way analysis of variance (ANOVA).  Univariate comparisons were 
PDGHXVLQJ6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV  *** P < 0.001 versus 
naïve controls.  ++ P < 0.01 versus vehicle controls. 
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3.4.1.2  Angiogenesis 
Synovial EC PCNA index was reduced by day 3 following 2 doses of the angiogenic compound PPI-2458 
[1.7% (95% CI 0.8 to 2.6)] compared with vehicle treated animals [6.7% (95% CI 5.3 to 8.2), P < 0.001] 
and this reduction was completely abolished to naïve control levels from day 10 to 24.  Increase in synovial 
endothelial cell fractional area following 2% carrageenan injection was however reduced to naïve levels by 
day 24 in PPI-2458 treated animals (Figure 3.9).   
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Figure 3.9 Inhibition of synovial angiogenesis (EC proliferation and vascular density) after 2% 
carrageenan injection in either PPI-2458 or vehicle treated animals.  Intra-articular injection was given in 
rat knee joint cavities on day 0.  Oral administration of either PPI-2458 (5mg/kg/every other day) or vehicle 
control was given from a day before the injection to day 9 (dotted line marks the end of PPI-2458 
treatment).  Synovia were harvested 3, 10 and 24 days after the injection.  Intra-articular injection of 2% 
carrageenan (Ŷ was followed by an increase in EC proliferation index (A; EC PCNA index) and vascular 
density (B; EC fractional area).  These increases were higher than the naïve controls (ź) throughout the 
experiment.  Administration of PPI-2458 (Ÿ) reduced EC proliferation on day 3, with levels reaching those 
of controls by day 10.  This reduction was maintained to day 24 (A).  Synovial vascular density was 
reduced by day 10 after administration of PPI-2458, with levels reaching those of controls by day 24 (B).  
Graphs show arithmetic mean and ±S.E.M of synovia from 8 knees per group.  EC PCNA Index and 
fractional areas (logarithmically transformed) were analysed using one way analysis of variance (ANOVA).  
Univariate compDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V 7-WHVW ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU PXOWLSOH
comparisons. * P < 0.05, *** P < 0.001 versus naïve controls. + P < 0.05, +++ P < 0.001 versus vehicle 
controls. 
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3.4.1.3  Pain Behaviour 
Pain behaviour as measured by difference in weight bearing was reduced by day 7 following treatment with 
PPI-2458 [12g (95% CI 6 to 18)] compared to vehicle treated animals [32g (95% CI 18 to 46), P < 0.05].  
Pain behaviour was reduced to levels observed in naïve controls by day 10.  This reduction was maintained 
to day 24 (Figure 3.10). 
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Figure 3.10 Time course of the inhibition of knee joint pain after 2% carrageenan injection in either 
PPI-2458 or vehicle treated animals.  Intra-articular injection was given in rat knee joint cavities on day 0.  
Oral administration of either PPI-2458 (5mg/kg/every other day) or vehicle control was given from a day 
before the injection to day 9 (dotted line marks the end of PPI-2458 treatment).  Pain behaviour was 
measured as a difference in hind paw weight bearing between 0 to 24 days after intra-articular injection.  
Intra-articular injection of 2% carrageenan (Ŷ) was followed by an increase in pain behaviour which was 
reduced to naïve (ź) levels by day 10. Administration of PPI-2458 (Ÿ) reduced pain behaviour by day 7, 
and completely abolished it to naïve levels by day 10. Bars show arithmetic mean and ±S.E.M of synovia 
from 8 knees per group.  Differences between groups were analysed using one way analysis of variance 
$129$  8QLYDULDWH FRPSDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V 7-WHVW ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU
multiple comparisons.  *** P < 0.001 versus naïve controls.  + P < 0.05 versus vehicle controls. 
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3.4.1.4  Weights 
Animals treated with the angiogenesis inhibitor gained weight at a slower rate from day 7 to day 24 
compared to vehicle treated animals and to naïve controls.  However by day 24, the difference in weight 
gain between the animals from the three treatment groups had narrowed but not completely abolished 
(Figure 3.11 and Table 1).   
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Figure 3.11 Time course of the weight-gain of animals.  Intra-articular injection was given in rat knee 
joint cavities on day 0.  Oral administration of either PPI-2458 (5mg/kg/every other day) or vehicle control 
was given from a day before the injection to day 9 (dotted line marks the end of PPI-2458 treatment).  
Animals treated with the angiogenesis inhibitor PPI-2458 (Ÿ) gained weight at a slower rate compared to 
either the vehicle (Ŷ) treated animals or naïve controls (ź) from day 7 to day 24.  Bars show arithmetic 
mean and ±S.E.M of synovia from 8 knees per group.  Differences between groups were analysed using 
RQHZD\DQDO\VLVRIYDULDQFH$129$ 8QLYDULDWHFRPSDULVRQVZHUHPDGHXVLQJ6WXGHQW¶V7-test with 
%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV  * P < 0.05, *** P < 0.001 versus naïve controls.  + P < 
0.05, +++ P < 0.001 versus vehicle controls. 
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Table 1  Weight gain of animals following treatment with the angiogenesis inhibitor PPI-2458.  
Intra-articular injection was given in rat knee joint cavities on day 0.  Oral administration of either PPI-
2458 (5mg/kg/every other day) or vehicle control was given from a day before the injection to day 9.  
Animals treated with the angiogenesis inhibitor PPI-2458 gained weight at a slower rate from day 7 to day 
24 compared to those animals that were either given the vehicle treatment or the naïve controls.  Data are 
given as mean (95% confidence interval).  Differences between groups (n = 8 animals per group) were 
analysed using one way analysis of variance (ANOVA).  Univariate comparisons were made using 
6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV   * P < 0.05, *** P < 0.001 versus 
naïve controls.  + P < 0.05, +++ P < 0.001 versus vehicle controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
348 (340 to 357) 289 (283 to 294) Naïve Control 
330 (326 to 335) * + 263 (257 to 269) *** +++ 2% Carrageenan + PPI2458 
348 (334 to 362) 282 (276 to 287)  2% Carrageenan + Vehicle Control  
Day 24 Day 7 Treatment Groups 
Weight Gain (g) of animals   
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3.4.2 Synovial angiogenesis and inflammation after intra-articular FGF-2 and/or carrageenan 
injection and administration of the angiogenesis inhibitor PPI-2458 
CD31-immunoreactive blood vessels were distributed throughout the depth of rat synovia, sometimes 
containing PCNA-immunoreactive nuclei (Figure 3.12 A-C). ED1-immunoreactive macrophages were 
localised to the synovial lining, and dispersed throughout the synovial sub-lining regions (Figure 3.12 G-I).  
Negative control sections (Figure 3.7) did not show any non-specific staining.  Synovia from animals given 
intra-articular injections of 6 pmoles FGF-2 showed increased staining for proliferating ECs (Figure 3.12 
A), and those from animals injected with 0.03% carrageenan displayed increased macrophage infiltration 
(Figure 3.12 G). 
 
3.4.3 FGF-2 induced synovial angiogenesis without inflammation 
An increase in EC PCNA index was observed 24 hours after intra-articular injection of FGF-2 (Figure 3.13 
A).  FGF-2 (6 pmoles) injection was followed by increased synovial EC PCNA index at 24 hours [20% 
(95% CI, 15 to 27%)] compared to vehicle controls [3% (95% CI, 1 to 6%), P < 0.01 (Figure 3.13 A)], 
which was reduced to naïve levels by day 5 (Figure 3.14).  No significant effect was seen 24 hours after 
injection of 6 pmoles FGF-2 on joint diameter [9.2 mm (95% CI, 9 to 9.5 mm), control; 9.2 mm (95% CI, 
8.7 to 9.7 mm), P > 0.05], synovial macrophage infiltration (Figure 3.13 B), nor vascular density [EC 
fractional area; 11% (95% CI, 8 to 16%), control; 11% (95% CI, 9 to 14%), P > 0.05].  
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Figure 3.12 Histological evidence of angiogenesis and macrophage infiltration after co-injection of 
FGF-2 and carrageenan into rat knees.  Panels show endothelial cell proliferation at day 1 (A-C), extent of 
endothelial cells at day 7 (D-F) and macrophage infiltration at day 28 (G-I).  Proliferating endothelial cells 
appear more abundant at day 1 (A), after co-injection of FGF-2 and carrageenan compared with vehicle-
injected controls (C).  Administration of PPI-2458 was associated with histological appearances similar to 
non-synovitic controls (B).  Increased vascular density was observed at day 7 (D).  Administration of PPI-
2458 reduced vascular density to levels seen in the controls (E, F).  Macrophage infiltration was increased 
28 days after co-administration of FGF-2 and carrageenan (G), and reduced in groups given PPI-2458 (H) 
to that of control levels (I).  Endothelial cells are delineated by CD31-immunoreactivity (red), and (A-C 
only) proliferating nuclei by immunoreactivity for proliferating cell nuclear antigen (PCNA, black). 
Proliferating endothelial cells (black arrow) contain PCNA-immunoreactive nuclei, whereas non-
proliferating endothelial cells (green arrows) do not. Cells other than endothelial cells also display PCNA-
immunoreactive nuclei (broad arrows). G-I; macrophages are delineated by immunoreactivity for CD68 
(black, arrows).  Negative control sections for CD68 (ED1), CD31 and/or PCNA immunohistochemistry 
did not show any non-specific staining (Figure 3.7).  Colour transmitted light images were taken using ×20 
objective lens of a single representative section from n = 8 animals per group.   Scale bar = 100 ȝm. 
 
 
 106 
 
A      B 
6 0.6 0.0
6
0.0
06
0.0
00
6
Co
nt
ro
l
0
5
10
15
20
25 **
FGF-2 doses (picomoles)
E
C
 P
C
N
A
 I
n
de
x
 
(%
) 2
4
 
h
o
u
rs
6 0.6
 
0.0
6 
0.0
06
 
0.0
00
6 
Co
ntr
ol
0
5
10
15
20
FGF-2 doses (picomoles)
M
a
c
ro
ph
a
ge
 
Fr
a
c
ti
o
n
a
l A
re
a
 
(%
)
a
t 
24
 
ho
u
rs
 
Figure 3.13 Dose response effects of FGF-2 on synovial EC proliferation (A) and macrophage 
infiltration (B).  Twenty four hours after intra-articular injection of either a range of doses of FGF-2 (6x10-4 
to 6 picomoles) or vehicle control, synovial EC proliferation index (EC PCNA index) increased at a dose of 
6 picomoles compared to vehicle injected controls.  Synovial macrophage fractional area remained similar 
to vehicle injected controls at all doses of FGF-2.  Bars show arithmetic mean and +S.E.M of synovia from 
4 knees per group.  EC PCNA Index and macrophage fractional area (logarithmically transformed) were 
analysed using one way analysis of variance (ANOVA).  Univariate comparisons were made using 
6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV    ** P < 0.01 
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Figure 3.14 Synovial endothelial cell proliferation after intra-articular injection of 6 picomoles of 
FGF-2.  Endothelial cell proliferation index (EC PCNA Index) increased 24 h after intra-articular injection 
of FGF-2 and returned to naïve levels by 5 days. Arithmetic means (+ S.E.M) of synovia from n = 6 knees 
per group.   EC PCNA Index (logarithmically transformed) was analysed using one way analysis of 
YDULDQFH $129$  8QLYDULDWH FRPSDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V 7-WHVW ZLWK %RQIHUURQL¶V
correction for multiple comparisons.   ** P < 0.01 compared with naïve controls. 
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3.4.4 Carrageenan induced synovial inflammation without angiogenesis 
There was a dose-dependent increase in synovial macrophage infiltration 24 hours after intra-articular 
carrageenan injection (Figure 3.15).  Synovial macrophage infiltration increased 24 hours after injection of 
0.03% carrageenan compared with saline-injected controls and had returned to levels similar to controls by 
day 14 [carrageenan; 5.2% (95% CI, 2.7 to 10.1%), control; 2.7% (95% CI, 1.4 to 5.2%), P > 0.05] (Figure 
3.16 A).  No significant effects of intra-articular injection were observed on either joint swelling (Figure 
3.16 B), EC proliferation (Figures 3.15 B and 3.16 C), or vascular density [EC fractional area 24 hours after 
0.03% carrageenan; 20% (95% CI, 17 to 23%), control; 16% (95% CI, 12 to 21%), P>0.05]. 
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Figure 3.15 Dose response effects of carrageenan on synovial macrophage infiltration (A) and EC 
proliferation (B).  Twenty four hours after intra-articular injection of either a range of doses of carrageenan 
(3x10-4 to 0.03%) or saline control, synovial macrophage fractional increased at a dose of 0.03% compared 
to saline injected controls.  Synovial EC proliferation index (EC PCNA index) remained similar to saline 
injected controls at all doses of carrageenan.  Bars show arithmetic mean and S.E.M of synovia from 4 
knees per group.  EC PCNA Index and Macrophage Fractional Areas (logarithmically transformed) were 
analysed using one way analysis of variance (ANOVA).  Univariate comparisons were made using 
6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV    ** P < 0.01 
 109 
A      B      C  
1 14 29
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
**
**
***
Days after intra-articular injections
M
a
c
ro
ph
a
ge
 
Fr
a
c
tio
n
a
l A
re
a
 
(%
)
01 14 29
8
9
10
11
***
Days after intra-articular injections
K
ne
e
 
di
a
m
e
te
r 
(m
m
)
1 14 29
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
**
*
***
Days after intra-articular injections
E
C
 P
C
N
A
 In
de
x
 
(%
)
 
Figure 3.16 Persistent synovitis after co-injection of FGF-2 and carrageenan.  Intra-articular injection of 0.03% carrageenan alone (Ÿ) was followed by a 
brief increase in synovial macrophage infiltration (A), and had no significant effect on joint swelling (B) or endothelial proliferation (C) compared with knees 
from control animals (ź). Co-injection of 6 pmoles FGF-2 together with 0.03% carrageenan (Ŷ) was followed by increased endothelial cell proliferation (C) as 
well as increased inflammation [macrophage infiltration (A) and joint swelling (B)] at 24 hours, and by persistent synovitis at days 14 and 29. No significant 
increase in any parameter was observed in vehicle-injected controls compared with naïve knees. EC PCNA Index; Endothelial cell proliferating nuclear antigen 
index. Arithmetic means (± S.E.M) of synovia from 6 knees per group.  Macrophage fractional areas, EC PCNA index (logarithmically transformed) and knee 
GLDPHWHUVZHUHDQDO\VHGXVLQJRQHZD\DQDO\VLVRIYDULDQFH$129$8QLYDULDWHFRPSDULVRQVZHUHPDGHXVLQJ6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶Vcorrection 
for multiple comparisons.  * P < 0.05, ** P < 0.01, *** P < 0.001 compared with vehicle-injected controls. 
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3.4.5 Combined effects of FGF-2 and carrageenan on synovial angiogenesis and inflammation  
Co-injection of 0.03% carrageenan and 6 pmoles FGF-2 into rat knee joints was followed after 24 hours by 
increased synovial macrophage infiltration [9.4% (95% C1, 6.4 to 13.8%), Figures 3.16 A and 3.18 A] and 
joint swelling [9.6 mm (95% CI, 9.2 to 10.0 mm), Figures 3.16 B and 3.18 B] compared with controls 
[1.6% (95% CI, 0.5 to 4.8%), P < 0.05, and 9.1 mm (95% CI, 8.9 to 9.3 mm), P < 0.01, respectively].  Co-
injection of carrageenan and FGF-2 was also followed after 24 hours by increased synovial EC PCNA 
index [3% (95% CI, 2 to 4.5%), Figures 3.12, 3.16 C and 3.18 C] and EC fractional area [8.0% (95% CI, 
6.0 to 10.6%), Figure 3.18 D] compared with controls [0.8% (95% CI, 0.3 to 1.8%), P < 0.01, and [4.9% 
(95% CI, 3.9 to 6.0%), P < 0.05, respectively]. The increases in indices of inflammation and angiogenesis 
were maintained through day 28 after co-injection of carrageenan and FGF-2 (Figures 3.12, 3.16 and 3.18) 
indicating the induction of a chronic synovitis.  Indices of angiogenesis and inflammation resolved within 
28 days in rats injected with FGF-2 or carrageenan alone. 
 
3.4.6 Dose-dependent inhibition of FGF-2-induced angiogenesis by PPI-2458 
Intra-articular injection of FGF-2 alone without PPI-2458 administration was followed 24 hours later by an 
increase in synovial EC PCNA index [6.9% (95% CI, 4.0 to 11.7%)] compared with naïve animals [1.1% 
(95% CI, 0.6 to 1.9%), P < 0.001] (Figure 3.17).  A dose dependent reduction in FGF-2 induced synovial 
angiogenesis was observed in groups treated with increasing doses of PPI-2458 administered orally 1 day 
prior to FGF-2 injection, with complete inhibition of EC PCNA index to naïve levels by 5mg/kg PPI-2458 
[1.1% (95% CI, 0.6 to 2.3%), p>0.05 compared to naïve controls] (Figure 3.17 and 3.18).  PPI-2458 did not 
alter synovial macrophage infiltration and knee diameter (Figure 3.17).  The values remained similar to 
those observed in naïve and vehicle controls.   
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Figure 3.17 Dose-dependent reduction after PPI-2458 in FGF-2-induced synovial endothelial cell proliferation.  Oral doses of PPI-2458 were given a day 
before bilateral intra-articular injection of 6 pmoles FGF-2 into rat knee joints.  Endothelial cell proliferation index (EC PCNA Index; A) was dose dependently 
reduced 24 hours after FGF-2 injection, with the highest dose of PPI-2458 reducing EC PCNA Index to naïve control levels. PPI-2458 did not alter either 
synovial macrophage infiltration (B) or knee diameter (C).  Arithmetic means (+ S.E.M) of synovia from n = 6 knees per group.  EC PCNA index, macrophage 
fractional areas (logarithmically transformed) and knee diameters were analysed using one way analysis of variance (ANOVA).  Univariate comparisons were 
PDGHXVLQJ6WXGHQW¶V7-test with %RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV P < 0.001,  P < 0.01 compared with naïve controls.   
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3.4.7 Synovial angiogenesis and inflammation after brief PPI-2458 administration early during 
FGF-2/carrageenan- induced synovitis 
Animals were given 3 doses of PPI-2458 between the day before and 3 days after the induction of chronic 
synovitis by co-injection of carrageenan and FGF-2.  This dosage regimen was designed to cover the period 
of FGF-2 enhanced angiogenesis as determined above (figure 3.17).  PPI-2458 administration was 
associated with a reduction of angiogenesis indices to control levels 24 hours after carrageenan/FGF-2 
injection (Figures 3.12 and 3.17), whereas inflammation indices were still increased 24 hours after co-
injection of carrageenan and FGF-2 in PPI-2458 treated animals when compared to the control animals 
(Figure 3.18).  Furthermore, synovial macrophage infiltration was only partially reduced 7 days after co-
injection of carrageenan and FGF-2 injection, remaining elevated in animals given PPI-2458 [9.3% (95% 
CI, 7.0 to 12.4%), Figure 3.18 A] compared with non-synovitic controls 2.8% (95% CI, 1.9 to 4.2%), P < 
0.001].  However, inflammation indices were normalised to non-synovitic control levels by day 28 in 
animals briefly treated with PPI-2458 up to 3 days after intra-articular co-injection of carrageenan and 
FGF-2 (Figures 3.12 and 3.18 A). 
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Figure 3.18 Inhibition of FGF-2-induced angiogenesis and promotion of the resolution of synovitis after PPI-2458 administration.  Following co-injection 
of 0.03% carrageenan and 6 pmoles FGF-2 (Ŷ) there were sustained increases in joint inflammation (A: synovial macrophage infiltration, B: joint swelling) and 
synovial angiogenesis (C: endothelial cell  proliferation), compared with vehicle injected controls (ź). Animals given 3 oral doses of PPI-2458 (5mg/kg) on 
alternate days from 1 day before until 3 days after intra-articular injection of 0.03% carrageenan and 6 pmoles FGF-2 (Ÿ) displayed synovial angiogenesis 
indices (C,D) similar to vehicle-injected controls throughout the experiment. PPI-2458 administration did not significantly inhibit joint inflammation at 24 hours 
(A, B) and macrophage infiltration was only partially reduced at day 7. However, the brief treatment with PPI-2458, completely inhibited joint inflammation to 
control levels by day 28, converting the model from one of persistent inflammation to one of transient synovitis (A). EC; endothelial cell, PCNA: proliferating 
cell nuclear antigen, Dashed line: time of last dose of PPI-2458. Arithmetic mean (±S.E.M) of synovia from 6 knees per group.  Macrophage fractional area, EC 
PCNA index (logarithmically transformed) and knee diameters were analysed using one way analysis of variance (ANOVA).  Univariate comparisons were made 
XVLQJ6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV* P < 0.05, ** P < 0.01, *** P < 0.001 compared with vehicle-injected controls. + P 
< 0.05, ++ P < 0.01, +++ P < 0.001 compared with PPI-2458 treated animals. 
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3.5 Summary of Results 
x A short course (6 doses) of the angiogenesis inhibitor PPI-2458, administered during the initial 
phase of inflammation made 2% carrageenan induced chronic synovitis and pain more transient. 
x Administration of FGF-2 (6 picomoles) induced synovial angiogenesis without inflammation.  
Levels of synovial angiogenesis reached those of naïve controls by day 5. 
x At 0.03%, carrageenan induced transient synovitis without angiogenesis.  Synovitis resolved 
within 14 days. 
x Co-injection of FGF-2 (6 picomoles) and carrageenan (0.03%) was followed by synovitis which 
persisted for at least 4 weeks.  
x Administration of the angiogenesis inhibitor PPI-2458 (3 doses) in this combined model (6 
picomoles FGF-2 and 0.03% carrageenan) of chronic synovitis inhibited FGF-2 induced angiogenesis 
leading to the resolution of persistent synovitis. 
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3.6 Discussion 
Using animal models of synovitis, these data show that angiogenesis may be a key factor in the transition 
from acute to persistent inflammation.   
 
In the 2% carrageenan model of persistent synovitis, a short course of PPI-2458 (6 doses) administered 
during the initial phase of inflammation, reduced synovitis by day 24, but did not completely abolish it.  
However synovial angiogenesis (EC proliferation and vascular density) was completely abolished at this 
time point, suggesting that chronic inflammation is in part mediated by angiogenesis.  Pain behaviour in 
this model was also reduced by day 7 following administration of PPI-2458.  At this time point, synovial 
angiogenesis was completely abolished but synovitis persisted, suggesting that angiogenesis, inflammation 
and pain are indeed inter-connected processes.  Inhibiting angiogenesis therefore has the potential to reduce 
pain. 
 
At a dose of 0.03%, carrageenan alone did not induce angiogenesis.  Carrageenan injection alone was 
associated with a transient synovitis that had resolved at 14 days.  When angiogenesis was stimulated with 
6 pmoles FGF-2 at the time that synovitis was induced by intra-articular injection of carrageenan, the 
synovitis persisted for at least 4 weeks.  Inhibition of this effect of FGF-2 by PPI-2458 suggests that this 
chronicity is mediated by angiogenesis rather than other actions of FGF-2.   
 
The mechanisms leading to persistent inflammation in human diseases remain unclear. Autoimmunity 
contributes to inflammation and tissue damage in diseases such as RA, although its contribution to 
persistence in early RA remains incompletely understood. Evidence of autoimmunity, such as circulating 
anti-citrullinated peptide antibodies, has limited sensitivity to predict persistence in early synovitis, and 
immunosuppression does not prevent persistence in the majority of patients.  Many other chronic 
inflammatory diseases (e.g. psoriasis and inflammatory bowel disease) display little evidence of 
autoimmunity.  Angiogenesis inhibition may reduce arthritis severity in animal models of autoimmunity 
(Peacock et al., 1992; Storgard et al., 1999; Bernier et al., 2004; Bainbridge et al., 2007; Hannig et al., 
2007; Brahn et al., 2008; Lazarus et al., 2008).  Inflammation is now increasingly being recognized as one 
of the prominent features of previously thought non-inflammatory arthritic conditions such as OA (Pelletier 
et al., 2001).  In-vitro studies of human OA synovium and in-vivo studies in animal models of OA have 
strongly suggested that the inflamed synovium and synovial macrophages are important in promoting OA 
pathology (Bondeson et al., 2010). 
 
In the current study, FGF-2 and PPI-2458, and specific outcome measures of angiogenesis, inflammation 
and pain, were used in order to determine the effects of angiogenesis inhibition on persistence of 
inflammation.  These data indicate that angiogenesis inhibition may prevent the progression from acute to 
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chronic inflammation in situations where new blood vessel growth is the key switch to persistence as well 
as curtailing pain associated with chronic synovitis. 
 
FGFs are implicated in the initiation and development of synovial hyperplasia and inflammation in RA 
(Malemud 2007).  FGF-8 has been implicated in enhancing cartilage damage and thus exacerbating arthritis 
in the partial meniscectomy model of OA (Uchii et al., 2008).  FGF-2 is upregulated at the cartilage-pannus 
interface in RA (Qu et al., 1995), and increased synovial fluid levels of FGF-2 are associated with greater 
disease severity (Nakashima et al., 1994; Manabe et al., 1999).  FGF-2 has also been shown to augment 
antigen-induced arthritis in rabbits (Storgard et al., 1999), and FGF-2 over expression has worsened 
inflammation and joint damage in adjuvant arthritis in rats (Yamashita et al., 2002). 
 
These data support previous evidence that FGF-2 is pro-angiogenic, but not directly pro-inflammatory 
(Ziche et al., 1992; Cozzolino et al., 1993; Gualandris et al., 1994). FGF-2 is mitogenic for endothelial 
cells and acts via specific FGF-2 receptors displayed on these cells. In some experimental systems, FGF-2 
can additionally enhance vascular integrity (Murakami et al., 2008), and increase adhesion molecule 
expression by cytokine activated endothelial cells, thereby synergistically enhancing the recruitment of 
inflammatory cells (Zittermann et al., 2006). However, in this study it was found that a single intra-
articular injection of FGF-2 either alone, or together with carrageenan, was not sufficient to increase joint 
swelling or macrophage infiltration at 24 hours, despite its ability to increase endothelial cell proliferation.  
Effects of FGF-2 to augment chronic synovitis were inhibited both by the brief administration of PPI-2458 
in this study, and by repeated administration of an anti-DQJLRJHQLFLQKLELWRURIĮYȕLQWHJULQLQa previously 
published study using antigen-induced arthritis (Storgard et al., 1999).  FGF-2 therefore may contribute to 
arthritis by increasing synovial angiogenesis, rather than any direct effect on inflammation. 
 
PPI-2458 inhibits human endothelial cell proliferation by inhibiting MetAP-2, and does not reduce 
angiogenic growth factor production (Griffith et al., 1997; Sin et al., 1997; Bainbridge et al., 2007), and 
neither does it induce apoptosis in endothelial cells (Bernier et al., 2004).  However, high doses of PPI-
2458 may have effects additional to angiogenesis inhibition and mediation of its therapeutic effects by 
angiogenesis inhibition has been uncertain in previous studies (Bernier et al., 2004). It was found that PPI-
2458 administration abolished synovial angiogenesis prior to reduction in synovitis, whereas synovitis 
reduction followed the discontinuation of PPI-2458. This indicates that PPI-2458 may exert its effects not 
through the direct inhibition of inflammation, but rather through the inhibition of angiogenesis.   
 
Similar to previously published data, synovial macrophage infiltration was reduced following 
administration of PPI-2458 in these animal models of synovitis however joint swelling (knee diameter) was 
not affected at these early time-points.  This indicates that synovial macrophage infiltration is not a direct 
index of joint swelling.  Therefore attenuating macrophage infiltration does not necessary mean that joint 
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swelling will also be reduced.  It is also possible that oedema and scar tissues could still be contributing to 
joint swelling measured at these early time points.  It further indicates that PPI-2458 may exert its effects 
through the inhibition of angiogenesis rather than through direct inhibition of inflammation. 
 
Pain behaviour was also reduced following synovial angiogenesis inhibition when synovitis was still 
detected suggesting that angiogenesis inhibition has the potential to reduce pain.  This finding strengthens 
the hypothesis and previously published data that angiogenesis, inflammation and pain are interconnected 
processes (Walsh et al., 2010).  A recently published study indicated that metalloproteinase inhibition 
reduced osteochondral angiogenesis and pain behaviour in a rat model of OA (Mapp et al., 2010).  The 
association between osteochondral angiogenesis and pain behaviour in that study may be explained by 
nerves growing alongside blood vessels or stimulation of subchondral nerves as a result of loss of 
osteochondral integrity.  Similarly in this study a reduction in pain behaviour was observed following 
synovial angiogenesis inhibition and this observation may be explained in part by the theory that chronic 
synovitis is accompanied with increased blood vessel growth and hence perivascular nerves or stimulation 
and sensitization of these nerves by inflammatory and angiogenic factors.  
 
Synovial angiogenesis is an early feature of both OA and RA, and occurs very early in the development of 
persistent synovitis in animal models (Walsh et al., 1998; Brahn et al., 2008). Synovial angiogenesis is also 
a feature of chronic synovitis in both humans and animals (Walsh et al., 1998; Walsh et al., 2001; 
Haywood et al., 2003).  These data also demonstrate increased endothelial cell proliferation during chronic 
synovitis 29 days after co-injection of carrageenan and FGF-2.  It is likely that angiogenesis at day 29 was 
mediated by factors other than the injected FGF-2, since FGF-2 alone induced only a transient increase in 
endothelial cell proliferation that had normalised by 5 days. Angiogenesis during chronic synovitis may be 
mediated by an imbalance between a variety of angiogenic and anti-angiogenic factors (Bonnet et al., 
2005).  Further studies will be required to understand which molecules sustain synovial angiogenesis in 
humans or animal models. 
 
Mechanisms by which acute synovitis may lead on to chronic arthritis remain incompletely understood. 
Clinical trials aiming to induce remission in early synovitis by intensive immunosuppression have raised 
optimism that it may eventually be possible to modify the course of, for example, OA and RA without the 
need for lifelong medication.  Immunosuppression alone, however, has not yet achieved this goal, and other 
factors may be important in the transition from acute to chronic synovitis.  Angiogenesis is a feature of 
early as well as persistent synovitis in humans (Griffioen et al., 2000; El-Gabalawy 2005; Klareskog et al., 
2009), and these data indicate that synovial angiogenesis may be a factor leading to persistent synovitis.  
Animal models of synovitis typically progress more rapidly than does arthritis in humans, and further work 
would be required to determine the duration of any window of opportunity in early synovitis during which 
inhibition of angiogenesis may facilitate its resolution. Furthermore, as there may be multiple factors 
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leading to persistence, angiogenesis inhibition may have greatest therapeutic potential in combination with 
other pharmacological agents. Similar combined approaches with angiogenesis inhibitors have proven 
successful in oncology (Sund et al., 2005; Rini 2009). 
 
Sustained angiogenesis inhibition commenced during the induction of, or at the onset of synovitis can 
reduce inflammation and joint damage (Storgard et al., 1999; Bernier et al., 2004; Bainbridge et al., 2007; 
Hannig et al., 2007; Brahn et al., 2008). However, adverse effects of long term angiogenesis inhibition on 
physiological blood vessel growth may outweigh therapeutic benefit in chronic inflammatory diseases.   
 
In conclusion, these data indicate that short-term angiogenesis inhibition targeted to a key period in the 
development of inflammation has the potential to achieve sustained clinical benefit. Clinical studies will be 
required to determine whether brief anti-angiogenic treatments can facilitate resolution in early synovitis, at 
the onset of synovitis in a previously uninvolved joint, or at reactivation of previously quiescent 
inflammation.  A greater understanding of the mechanisms underlying persistence in different clinical 
scenarios will be necessary in order to realise this potential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
4 ROLE OF ANGIOGENESIS IN INFLAMMATION, JOINT DAMAGE AND PAIN 
IN A RAT MODEL OF KNEE OSTEOARTHRITIS 
 
4.1 Introduction 
Osteoarthritis (OA), a common, chronic disorder of the joints, is one of the major causes of pain and 
disability in ageing populations (Peat et al., 2001).  The exact underlying causes of OA remain 
incompletely understood.  Treatments for OA focus on symptomatic relief with little capacity to modify the 
underlying disease process.  Irreversible joint damage in late stages of the disease benefits most from total 
joint replacement surgery.  OA is associated with loss of articular cartilage (chondropathy), synovitis, 
subchondral bone remodeling, and osteophyte formation (Ashraf et al., 2008).  It is widely thought that OA 
is primarily a disease of the cartilage with associated subchondral and synovial changes (Walsh 1999).  
However, this notion is challenged by the hypothesis that the primary disorder arises in the subchondral 
bone and synovium, with loss of articular cartilage and osteophyte growth being secondary phenomena 
(Imhof et al., 1997). 
 
Normal adult human articular cartilage is avascular (Moses et al., 1990) and aneural (Dye et al., 1998).  In 
OA, loss of integrity of the osteochondral junction is attributed to channels crossing the osteochondral 
junction.  Channels form as extensions of the subchondral bone spaces, breaching the osteochondral 
junction and tidemark, into the non-calcified articular cartilage.  Blood vessels grow into these channels 
from the subchondral bone, thereby invading the articular cartilage (osteochondral angiogenesis) (Walsh et 
al., 2007) and are accompanied by sympathetic and sensory nerves (Suri et al., 2007).  This osteochondral 
angiogenesis may potentiate joint damage by stimulating ossification in the articular cartilage.  
Furthermore, blood vessels and nerves penetrate newly formed cartilage at the joint margins during 
osteophyte formation (Suri et al., 2007). 
 
Although OA is commonly distinguished from inflammatory arthritides such as RA, it is increasingly 
recognized that synovitis may contribute both to symptoms and to joint damage in OA (Bonnet et al., 2005; 
Ashraf et al., 2008; Bondeson et al., 2010).  Osteoarthritic synovium is commonly inflamed and infiltrated 
with macrophages (Walsh et al., 2007).  Subchondral inflammation may also be a feature of OA, where 
fibrovascular tissue replaces fatty bone marrow (Milgram 1983).   
 
Angiogenesis, the growth of new blood vessels from pre-existing ones, is characteristic of OA.  Increased 
angiogenesis in the synovium is associated with chronic synovitis in OA (Walsh et al., 1998; Haywood et 
al., 2003).  Synovial angiogenesis results in a redistribution of blood vessels away from the synovial 
surface, and it is thought that this may impair chondrocyte function and homeostasis of the articular 
cartilage as well as contributing towards articular hypoxia (Walsh et al., 2007; Mapp et al., 2008).  
Although angiogenesis is not in itself painful, it may exacerbate pain by enabling innervation of tissues and 
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by facilitating inflammation (Bonnet et al., 2005).  Inflammation, angiogenesis and innervation are highly 
integrated processes in OA, thus controlling one could have profound effects on the others.  Inhibitors of 
angiogenesis and/or inflammation therefore, have potential for reducing structural damage and pain in OA. 
 
Intra-articular injection of corticosteroids and oral or topical NSAIDs are recommended treatments for knee 
OA (Conaghan et al., 2008).  In addition to their anti-inflammatory actions, corticosteroids and NSAIDs 
may also be anti-angiogenic (Folkman et al., 1987; Madhok et al., 1991).  Dexamethasone, a corticosteroid 
with a multiplicity of actions on a wide range of inflammatory cell functions, is suggested to exert its anti-
inflammatory effects by inhibiting phospholipase A2, reducing the production and release of inflammatory 
mediators such as histamine, bradykinin, IL-1 and IL-6, and reducing the production of arachidonic acid 
metabolism products, including prostaglandins and leukotrienes (Creamer 1999).  Each of these factors 
may stimulate and sensitize nerve fibres, and corticosteroids can therefore reduce pain.  Dexamethasone 
inhibits angiogenic factor production by cultured synoviocytes (Nagashima et al., 2000) as well as 
inhibiting blood vessel growth into sponges implanted subcutaneously in rats (Hori et al., 1996).  Intra-
articular or systemic delivery of dexamethasone reduces joint damage in experimental animal models of 
inflammatory arthritis, such as adjuvant arthritis (AA) and collagen-induced arthritis (CIA) (Bendele 2001; 
Cuzzocrea et al., 2005; Caparroz-Assef et al., 2007). In a rabbit meniscal transection model of OA, 
corticosteroids given before the onset of OA reduced osteophyte formation and cartilage loss (Butler et al., 
1983).  Similar findings have been reported in guinea pig and dog models of experimental OA (Williams et 
al., 1985; Pelletier et al., 1995).  However corticosteroids also inhibit chondrocyte synthetic functions and 
may therefore exacerbate joint damage (Annefeld et al., 1990).   
 
Indomethacin, a NSAID, is a non-selective inhibitor of COX 1 and 2 enzymes, inhibiting PG synthesis 
from arachidonic acid, thereby reducing the pain of inflammation.  Indomethacin can suppress the growth 
of colon cancer by inhibiting tumour angiogenesis (Wang et al., 2005).  In carrageenan-induced 
inflammation in rats, indomethacin inhibits angiogenesis by reducing COX-2 dependent production of 
PGE2 (Ghosh et al., 2000; Ghosh et al., 2002), and indomethacin also reduces inflammation in 
experimental animal models of inflammatory arthritis (Van Arman et al., 1970; Van Arman et al., 1973; 
Hamada et al., 2000; Bernardi et al., 2009).  Oral administration of COX-1/2 inhibitors reduced pain but 
also inhibited anabolic functions of chondrocytes in the MIA model of OA (Bove et al., 2003).  Some 
clinical studies have suggested that indomethacin may increase the rate of radiological deterioration of joint 
space in patients with OA of the knee and hip (Rashad et al., 1989; Huskisson et al., 1995). 
 
Certain anti-inflammatory drugs therefore have the potential to slow the progression of OA structural 
damage by inhibiting synovitis.  However, shared molecular pathways between inflammation and cartilage 
homeostasis may result in adverse structural effects of anti-inflammatory drugs. Corticosteroids and 
NSAIDs are not considered to be disease modifying in human OA, but certainly alleviate symptoms (Ding 
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2002).  Identifying specific mechanisms of inflammation-induced joint damage in OA may therefore 
indicate novel anti-inflammatory therapies that both improve symptoms and protect against progression of 
joint damage.  Keeping this in mind, it was hypothesised that angiogenesis may not only facilitate 
inflammation, but could also be a mechanism by which inflammation leads to pain and joint damage in OA.  
Therefore it was proposed in this study that inhibiting angiogenesis may in turn reduce inflammation, joint 
damage and pain in OA.   
 
PPI-2458, an anti-angiogenic fumagillin analog, reduces synovitis and bone and cartilage damage in rodent 
models of immune-mediated inflammatory arthritis; CIA in mice and PGPS-induced arthritis in rats 
(Bainbridge et al., 2007; Lazarus et al., 2008).  It exerts its effects by inhibiting MetAP-2, triggering 
growth arrest of ECs in the late G1 phase of the cell cycle, inhibiting EC proliferation and angiogenesis 
without affecting inflammatory cytokine release (Griffith et al., 1997; Bainbridge et al., 2007).   
 
Transection of the medial meniscus in the rat results in joint pathology similar to that observed in human 
OA (Bendele 2001; Janusz et al., 2002; Mapp et al., 2008) indicating that this model is useful for the 
development of pharmacological interventions for treatment of and to explore mechanisms underlying pain 
in OA.  This rat MNX model was used to evaluate the potential contributions of inflammation and 
angiogenesis to joint damage and pain in OA.  
 
4.2 Aims 
1. To show that the MNX model of OA is associated with the expected osteoarthritic changes in the 
medial tibial plateaux, similar to that observed in human OA. 
2. To evaluate the effects of anti-inflammatory drugs (indomethacin and dexamethasone) on 
synovitis, joint damage and pain in the rat MNX model of OA. 
3. To find out if the anti-angiogenic compound, PPI-2458 specifically inhibits angiogenesis without 
directly affecting inflammation in the rat MNX model of OA. 
4. The effects of enhancing synovitis using 2% carrageenan on joint damage and pain in the rat MNX 
model of OA. 
5. To use PPI-2458 to specifically inhibit angiogenesis without directly affecting inflammation in the 
rat MNX and 2% carrageenan model to explore the contribution of angiogenesis to inflammation, joint 
damage and pain in OA.  
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4.3 Methods 
General methodology is given in Chapter 2.  Experiments were performed on male Lewis rats (Charles 
River, Margate, Kent, UK) weighing 250-280 gm (n = 8 per treatment group, unless otherwise stated). 
 
4.3.1 Intra-articular injection of 2% carrageenan and MNX model of OA 
Animals (n = 8 per treatment group) having either meniscal transection or SHAM surgery on day 0 (left 
knee joint) were given an intra-articular injection of 2% carrageenan in the operated knee (day 12).  
Meniscal transection only operated animals, SHAM only operated animals and naïve animals were used as 
controls.  Synovia and knee joints were collected 35 days post surgery.  Knee diameter and incapacitance 
measurements were taken throughout the experiment (Figure 4.1).   
 
Statistical analysis to evaluate joint damage (osteophytosis, chondropathy and integrity of the 
osteochondral junction) was performed by combining two separate experiments (MNX+2% carrageenan: n 
= 16, MNX: n = 16, SHAM+2% carrageenan: n = 8, SHAM: n = 8, Naives: n = 16), to increase the number 
of animals, hence the power of the study.   
 
4.3.2 Dexamethasone and Indomethacin 
Animals (n = 8 per treatment group) that had meniscal transection surgery were dosed daily, starting on day 
XQWLOVDFULILFHDWGD\E\RUDOJDYDJHZLWKHLWKHUȝOVWHULOHQRUPDOVDOLQHYHKLFOHFRQWURO
(pH 7.4) or vehicle control containing either dexamethasone (0.1 mg/kg) or indomethacin (2 mg/kg).  Day 
11 was chosen to start intervention studies in the MNX model of OA to allow sufficient amount of time for 
the animals to recover from the surgical procedure.  By this time the sutures had also fallen out and the 
visible wound on rat knee joints had sufficiently healed.  These doses were shown in previous studies to 
inhibit inflammation in the joint (Ku et al., 1996; Takagi et al., 1998; Cuzzocrea et al., 2005; Sharma 
2010).  Naïve animals were used as additional controls. Weights, knee diameter and pain behaviour of 
animals were monitored throughout the experiment and blood glucose levels were measured at day 35 
(Figure 4.1).   
 
4.3.3 PPI-2458 
Animals (n = 8 per treatment group) that either had meniscal transection surgery or meniscal transection 
surgery (day 0) and 2% carrageenan intra-articular injection (day 12) were dosed every other day (from day 
11 to 35), by oral gavage with either  ȝO YHKLFOH FRQWURO  +3ȕ&' EXIIHU LQ 3%6 RU YHKLFOH
containing the angiogenesis inhibitor PPI-2458 (5 mg/kg). This dose of PPI-2458 was shown in previous 
studies to suppress angiogenesis, inflammation and improve bone structure (Bainbridge et al., 2007; 
Lazarus et al., 2008).  At the dose of 5 mg/kg, PPI-2458 was also shown in chapter 3 of this thesis to 
resolve chronic synovitis.  Naïve animals were used as additional controls. Weights of animals, knee 
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diameter and pain behaviour were monitored throughout the experiment.  Synovia and knee joints were 
harvested 35 days post surgery (Figure 4.1). 
 
 
 
 
Figure 4.1 Diagram highlighting the experimental plans.  (i) The effects of either anti-inflammatory 
(indomethacin and dexamethasone) or anti-angiogenic (PPI-2458) drugs on synovitis, joint damage and 
pain in the rat MNX model of OA.  (ii) Whether enhancing inflammation using 2% carrageenan has any 
effects on synovitis, joint damage and pain in this model and (iii) if these structural and behaviour changes 
can be inhibited using PPI-2458.  Surgery was performed on day 0.  A single dose of intra-articular 
carrageenan injection was given on day 12 and treatment was started from day 11 to 35 after surgery, after 
which joint tissues were harvested.  At various time-points during the experiments, weights, knee diameters 
and incapacitance measurements of the animals were recorded.  Blood glucose levels were measured at day 
35. 
 
 
 
 
 
 
 
DAYS 0 11 12 35 
Meniscal 
Transection Surgery 
Habituation 
Dexamethasone / Indomethacin / PPI-2458 
Carrageenan 
(2%) 
13 14 19 26 29 32 
Measure blood 
glucose levels, 
harvest knee 
joints and 
synovia 
Weights, Incapacitance and Knee Diameter 
 124 
4.4 Results 
 
4.4.1 MNX model of OA 
The MNX model was associated with the expected osteoarthritic changes in the medial tibial plateaux at 
day 35.  These osteoarthritic changes included loss of articular cartilage, reduced chondrocyte density and 
proteoglycan staining, with subchondral bone remodeling including increased numbers of channels 
breaching the osteochondral junction, and formation of osteophytes at joint margins (Figure 4.2 A).   
 
Sensory nerves were located in the osteophytes, synovium, and the subchondral bone, adjacent to blood 
vessels (Figure 4.2 B-D).  Increased pain behaviour was also observed following meniscal transection 
surgery (Figure 4.6).   
 
Measures of inflammation (synovial macrophage infiltration and joint swelling), synovial angiogenesis (EC 
proliferation index and vascular density) and vascular channels crossing the osteochondral junction were 
increased 35 days post meniscal transection surgery (Figures 4.3, 4.4. and 4.7).   
 
ED1-immunoreactive macrophages were localized to the synovial lining and dispersed throughout the 
synovial sublining regions.  CD31-immunoreactive blood vessels were distributed throughout the depth of 
rat synovia, occasionally containing PCNA-immunoreactive nuclei (Figure 4.3).  Negative control section 
did not show any non-specific staining (Figure 3.7).  
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Figure 4.2 Histological changes (chondropathy, osteophytosis, and vascular channels at the 
osteochondral junction) of the medial tibial plateaux and sensory nerve growth 35 days after meniscal 
transection surgery in a rat MNX model of OA.  A, arthritic animal showing full thickness cartilage loss 
(arrows), large osteophyte at the joint margin (circled) and several channels crossing into (black asterisk) 
or approaching (blue asterisk) the cartilage (dotted line marks the osteochondral junction).  CGRP 
positive sensory nerves located in the osteophytes (B), in the synovium (C) and in the subchondral bone 
spaces (D) of arthritic animals.  Coronal sections of the medial tibial plateaux stained with either 
Haematoxylin and Eosin (A) or by immunoreactivity for CGRP positive sensory nerves (B-D).  Colour 
transmitted light images were taken using ×4 (A, B and D) and ×40 (C) objective lenses of a single 
representative section from n = 8 animals per group.   ScalHEDU ȝP 
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Figure 4.3 Histologic evidence of synovial angiogenesis, vascular density and macrophage 
infiltration in rat knee joints 35 days after meniscal transection and effects of oral administration of either 
anti-inflammatory or anti-angiogenic drugs. Macrophage infiltration (A-E), EC proliferation (F-J) and 
vascular density (K-O) were reduced by the administration of anti-inflammatory drugs (dexamethasone (B, 
G and L) and indomethacin (C, H and M), and the anti-angiogenic agent PPI-2458 (D, I and N), compared 
with vehicle-treated arthritic rats (A, F and K), to naïve control levels (E, J and O).  A-E; macrophages 
(black) delineated by immunoreactivity for ED1.  F-J; ECs are delineated in red by immunoreactivity for 
CD31 (blue arrows) and proliferating nuclei are delineated black by immunoreactivity for proliferating 
cell nuclear antigen (PCNA; green arrows).  Black arrows indicate proliferating ECs, which contain 
PCNA-immunoreactive nuclei.  K-O; Extent of ECs delineated in red by immunoreactivity for CD31.   
Negative control sections for CD68 (ED1), CD31 and/or PCNA immunohistochemistry did not show any 
non-specific staining (Figure 3.7).  Colour transmitted light images were taken using ×10 (A-E, K-O) and 
×20 (F-J) objective lenses of a single representative section from n = 8 animals per group.  Scale bar = 100 
ȝP 
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4.4.2 Effects of inhibiting inflammation on angiogenesis, joint damage and pain in the MNX 
model of OA 
Following treatment with anti-inflammatory compounds (indomethacin or dexamethasone) measures of 
synovial inflammation were reduced to levels observed in naïve controls (Figures 4.3 and 4.4 A).  Vehicle-
treated animals had a greater difference in knee diameter between the operated and non-operated knees at 
day 12 compared with naïve controls [0.5mm (95% CI 0.2 to 0.8), 0.03 mm (95% CI -0.03 to 0.09), P < 
0.05], and this persisted to day 35.  Treatment with anti-inflammatory drugs reduced knee joint diameter to 
naïve controls by day 35 (Figure 4.3 B). Indomethacin or dexamethasone significantly reduced indices of 
synovial angiogenesis (Figures 4.7).  
 
Indomethacin did not significantly reduce joint damage scores (chondropathy and/or osteophytosis) (Figure 
4.5 and Table 2), whereas dexamethasone reduced total joint damage [median score 7 (IQR 6 to 8)] 
compared with vehicle treated controls [median score 12 (IQR 11 to 13), P = 0.015] (Figure 4.5 and Table 
2).  This effect was primarily due to a reduction in chondropathy score [vehicle: median score 10 (IQR 10 
to 10), dexamethasone: median score 5 (IQR 5 and 7), P = 0.03] (Figures 2C and Table 2).  Neither 
dexamethasone nor indomethacin affected the numbers of channels crossing the osteochondral junction 
(Table 2). 
 
Vehicle-treated animals having meniscal transection surgery showed a greater weight-bearing asymmetry at 
day 12 [32g (95% CI 25 to 40)] compared with naïve controls [7g (95% CI -2 to 16), P < 0.001].  This 
asymmetry persisted to day 35 [MNX; 33g (95% CI 25 to 42), naïve; 8 g (95%CI 2 to 13), P < 0.001].  
Treatment with indomethacin reduced weight-bearing asymmetry at day 14 [13g (95% CI -09 to 27)], 
compared with vehicle treated controls (40g [95% CI 23 to 56], P < 0.05), and weight-bearing asymmetry 
was completely abolished to naïve control levels by day 35 (Figure 4.6 B).  Treatment with dexamethasone 
was also followed by a reduction at day 26 in weight-bearing asymmetry [4g (95% CI -9 to 17)] compared 
to vehicle-treated animals [35g (95% CI 25 to 44), P < 0.01], and weight-bearing asymmtry was completely 
abolished to naïve control levels by day 35 (Figure 4.6 A).   
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Figure 4.4 Inhibition of measures of inflammation (synovial macrophage infiltration and joint swelling) after meniscal transection surgery in 
indomethacin, dexamethasone and PPI-2458 treated animals when compared to naïve controls.  From day 11 (vertical dotted line in graphs B and D) to 35, 
animals having meniscal transection surgery were given oral doses of either indomethacin (2mg/kg/daily) or dexamethasone (0.1mg/kg/daily) or PPI-2458 
(5mg/kg/every other day) or vehicle control. Following administration of either indomethacin or dexamethasone (A and B) macrophage infiltration (A) and joint 
swelling (B) were reduced 35 days after meniscal transection surgery compared with vehicle treated animals.  The levels were not different from to naïve 
controls.  Similarly, following PPI-2458 administration (C and D), macrophage infiltration (C) and joint swelling (D) were also reduced 35 days after meniscal 
transection surgery, compared with vehicle treated animals.  The levels were not different from naïve controls.  Joint swelling measured by a difference in knee 
diameter remained higher in animals that had meniscal transection surgery and were treated with vehicle control compared to naïves throughout the experiment.  
All 3 drugs inhibited joint swelling to levels that were not different to naïve controls by day 35 (B and D).     Arithmetic means (± S.E.M) of n = 8 animals per 
group.  Macrophage fractional area (logarithmically transformed) and knee diameters were analysed using one way analysis of variance (ANOVA).  Univariate 
comparisons weUHPDGHXVLQJ6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV* P < 0.05, ** P < 0.01, *** P < 0.001 versus arthritic, 
vehicle control.  + P < 0.05, ++ P < 0.01, +++ P < 0.001 versus naïve controls. 
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Figure 4.5 Histological changes (chondropathy, osteophytosis and vascular channels at the 
osteochondral junction) of the medial tibial plateaux 35 days post MNX surgery.  A, medial tibial plateau 
of an animal having meniscal transection surgery and vehicle treated arthritic control showing severe, full 
thickness cartilage loss (arrows) with a large osteophyte formed at the joint margin (circled) and several 
channels crossing into (black asterisk) or approaching (blue asterisk) the cartilage (dotted line; separates 
underlying bone from cartilage).  B and C, medial tibial plateaux from animals that have undergone 
meniscal transection surgery and treated with anti-inflammatory drugs indomethacin and dexamethasone 
respectively, showing moderate cartilage loss with fibrillation and reduced proteoglycan staining and 
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chondrocyte density (arrows).  A large osteophyte is evident at the joint margins (circled) with channels 
(black asterisk) crossing into the cartilage.  D, medial tibial plateau from PPI-2458 treated animal showing 
mild cartilage fibrillation and loss of proteoglycan staining and chondrocyte density (arrows).  A 
developing osteophyte can be seen at the joint margin (circled) with some channels crossing into the 
cartilage from underlying subchondral bone (black asterisk).  E, naïve control showing normal smooth 
cartilage and joint margins.  The chondrocytes are homogenously distributed throughout the cartilage and 
there is neither evidence of proteoglycan loss nor channels entering the avascular cartilage.  Coronal 
sections of the medial tibial plateaux stained with Safranin-O.  Colour transmitted light images were taken 
using ×4 objective lens of a single representative section from n = 8 animals per group.  Scale bar = 100 
ȝP 
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Table 2  Reduction in OA structural changes in medial tibial plateaux following anti-inflammatory/anti-angiogenic treatment in the MNX model of OA.  
From day 11 to 35, animals having meniscal transection surgery were given oral doses of either indomethacin (2mg/kg/daily) or dexamethasone 
(0.1mg/kg/daily), PPI-2458 (5mg/kg/every other day) or vehicle control.  Following administration of dexamethasone, total joint damage (combined 
chondropathy and osteophyte score) was reduced compared to vehicle treated controls.  This reduction in total damage score was mainly due to a reduction of 
cartilage damage.  Indomethacin did not significantly reduce joint damage.  Channels crossing the osteochondral junction were not significantly reduced 
following treatment with either indomethacin or dexamethasone, and remained more abundant than in naïve controls.  Following PPI-2458 administration total 
joint damage in the MNX model of OA was reduced compared with vehicle treated controls.  This reduction was mainly due to the attenuation of osteophyte 
growth.  Channels growing into the cartilage from underlying subchondral bone were not significantly different after PPI-2458 compared with either naïve or 
with vehicle treated arthritic controls.  Data are given as median (Interquartile Range [IQR]).  Differences between groups (n = 8 animals per group) are analysed 
using Kruskal-Wallis test followed by Man-:KLWQH\8WHVWWRFRPSDUHWZRJURXSVZLWK%RQIHUURQL¶VFRUUHFWLRQIRU multiple comparisons . + P < 0.05, ++ P < 0.01, 
+++ P < 0.001 versus vehicle-treated arthritic animals. 
1 (0 to 1) ++ 3 (2 to 3)  3 (2 to 4)  3 (3 to 5)  Channels crossing 
medial OCJ 
1 (0 to 2) ++ 5 (5 to 7) + 9 (5 to 10)  10 (10 to 10) Cartilage damage 
0 (0 to 0) +++ 2 (1 to 2)  2 (2 to 3)  2 (2 to 3) Osteophytes 
1 (0 to 2) ++ 7 (7 to 9) ++ 10 (8 to 12)  12 (11 to 13)  Total damage score  
Naives Dexamethasone Indomethacin Vehicle Structural Change 
Anti-inflammatory Treatment 
1 (0 to 1) ++ 2 (1 to 5) 5 (4 to 6)  
1 (0 to 1) ++ 6 (4 to 8)  10 (8 to 10)  
0 (0 to 0) +++ 1 (0 to 3) + 3 (2 to 3)  
1 (0 to 1) ++ 8 (4 to 10) + 13 (10 to 13)  
Naives PPI-2458 Vehicle 
Anti-angiogenic Treatment 
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Figure 4.6 Time course of the inhibition of meniscal transection-induced knee joint pain behaviour 
following the administration of anti-inflammatory or anti-angiogenic treatment.  A, pain behaviour in 
arthritic animals treated with either indomethacin (ź) or dexamethasone (Ÿ) or vehicle control (Ŷ).  B, 
pain behaviour in arthritic animals treated with either PPI-2458 (Ɣ) or vehicle control (Ŷ).  On day 0, 
animals underwent meniscal transection surgery.  From day 11 (vertical dotted line) to 35, the arthritic 
animals were given oral doses of either indomethacin (ź 2mg/kg/daily), of dexamethasone (Ÿ 
0.1mg/kg/daily), PPI-2458 (Ɣ 5mg/kg/every other day) or vehicle control (Ŷ).  Pain behaviour was 
measured by a difference in hind paw weight bearing between 0 to 35 days after meniscal transection 
surgery.  Vehicle-treated arthritic animals showed increased pain behaviour compared to naïve controls (Ƈ) 
12 days post meniscal transection surgery and this increase was maintained to day 35.  Indomethacin 
significantly inhibited pain behaviour in the arthritic animals on day 14 and completely abolished it to 
naïve levels by day 35. In dexamethasone treated animals, pain behaviour was inhibited to naïve levels on 
day 26 and this inhibition was maintained to day 35.  PPI-2458 treated animals showed a reduction in pain 
behaviour on day 19 which was completely inhibited to naive control levels by day 35.  Data is shown as 
arithmetic means (± S.E.M) of n = 8 animals per group.  Differences between groups were analysed using 
RQHZD\DQDO\VLVRIYDULDQFH$129$ 8QLYDULDWHFRPSDULVRQVZHUHPDGHXVLQJ6WXGHQW¶V7-test with 
%RQIHUURQL¶V FRUUHFWLRQ IRU PXOWLSOH FRPSDULVRQV  * P < 0.05, ** P < 0.01, *** P < 0.001 versus naïve 
controls.  
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4.4.3 Effects of inhibiting angiogenesis on inflammation, joint damage and pain in the MNX 
model of OA 
Following treatment with the angiogenesis inhibitor PPI-2458, measures of inflammation (synovial 
macrophage infiltration and joint swelling) were reduced 35 days after meniscal transection surgery to 
levels observed in the naïve controls (Figures 4.3 and 4.4). PPI-2458 reduced indices of synovial 
angiogenesis (Figures 4.3 and 4.7).  PPI-2458 also reduced the number of vascularised channels at the 
osteochondral junction [1 vascularised channel per medial tibial plateau section (IQR 0 to 2)] compared 
with vehicle treated controls [4 vascularised channels per medial tibial plateau section (IQR 2 to 5), P = 
0.026] (Figure 4.7).   
 
Total joint damage score was also reduced following treatment with PPI-2458 [Score 8 (IQR 4 to 9.5)] 
compared with vehicle treated controls [Score 13 (IQR 10 to 13), P = 0.016] but not completely abolished 
to naïve levels (Figure 4.5 and Table 2).  Reduction in total joint damage score was primarily due to the 
attenuation of osteophyte growth [vehicle: median score 3 (IQR 3 to 3), PPI-2458: median score 1 (IQR 0 
to 3), P = 0.044].  PPI-2458 had no significant effect on the integrity of the osteochondral junction as 
indicated by the total number of channels crossing the osteochondral junction (Table 2).   
 
PPI-2458 reduced weight-bearing asymmetry [17g (95% CI 6 to 27)] compared with vehicle treatment [39g 
(95% CI 29 to 49), P < 0.01] in the MNX model of OA at day 19.  Weight-bearing asymmetry was 
completely inhibited to naïve control levels by day 35 (Figure 4.6B). 
 
Animals treated with either dexamethasone or PPI-2458 gained weight at a slower rate compared to 
animals in other treatment groups and to naïve controls.  Blood glucose levels (not-fasting) of 
dexamethasone did not differ significantly between the groups at time on day 35 (Figure 4.8). 
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Figure 4.7 Synovial angiogenesis (synovial EC proliferation and vascular density) and 
vascularisation of channels crossing osteochondral junction in the medial tibial plateaux.  From day 11 to 
35, animals having meniscal transection surgery were given oral doses of either indomethacin 
(2mg/kg/daily) or dexamethasone (0.1mg/kg/daily) or PPI-2458 (5mg/kg/evey other day) or vehicle 
control.  Following administration of either indomethacin or dexamethasone (A and B), EC proliferation 
index (EC PCNA index; A) and vascular density (B) were significantly reduced compared with vehicle 
Cartilage 
Bone 
* 
* 
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treated animals.  The levels were similar to naïve controls.  Similarly, following PPI-2458 administration 
(C and D), EC PCNA index (C) and vascular density (D) were also significantly reduced compared with 
vehicle treated animals.  The levels were similar to naïve controls.  Coronal section of medial tibial plateau 
from an animal having meniscal transection surgery and treated with vehicle control, showing positive-
staining with Griffonia simplicifolia lectin-1 (alkaline phosphatase reaction product) (E) of vascular 
channels crossing (blue asterisk) or approaching (black asterisk) the osteochondral junction (dotted line; 
separates underlying bone from cartilage).  Following PPI-2458 administration, vascular channels crossing 
the medial osteochondral junction were reduced (F).  Graphs show the arithmetic means (± S.E.M) of n = 8 
animals per group.  EC PCNA index and fractional area (logarithmically transformed) were analysed using 
RQHZD\DQDO\VLVRIYDULDQFH$129$ 8QLYDULDWHFRPSDULVRQVZHUHPDGHXVLQJ6WXGHQW¶V7-test with 
%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV2VWHRFKRQGUDOYDVFXODULW\ZDVDQDO\VHGXVLQJ.UXVNDO-
Wallis test followed by Mann-Whitney WRFRPSDUH WZRJURXSVZLWK%RQIHUURQL¶VFRUUHFWLRQ IRUPXOWLSOH
comparisons.  * P < 0.05, ** P < 0.01, *** P < 0.001 versus vehicle control.  Colour transmitted light 
image was taken using ×20 objective lens of a single representative section from n = 8 animals per group.  
6FDOHEDU ȝP 
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Figure 4.8 Weight gain and blood glucose levels following the administration of either anti-inflammatory or anti-angiogenic treatment. A, weight gain of 
arthritic animals treated with either indomethacin (ź) or dexamethasone (Ÿ) or vehicle control (Ŷ). Naïve controls were used as baseline (Ƈ).  B, weight gain of 
arthritic animals treated with either PPI-2458 (Ɣ) or vehicle control (Ŷ).  Naïve controls were used as baseline (Ƈ).  On day 0, animals underwent meniscal 
transection surgery. From day 11 (vertical dotted line) to 35, the arthritic animals were given oral doses of either indomethacin (ź 2mg/kg/daily), or 
dexamethasone (Ÿ 0.1mg/kg/daily), PPI-2458 (Ɣ 5mg/kg/every other day) or vehicle control (Ŷ).  Animals treated with either dexamethasone (A) or PPI-2458 
(B) gained weight at a slower rate compared to naïve controls.  Animals in all other treatment groups gained weight at a similar rate.  At day 35 following 
meniscal transection surgery, non-fasting blood glucose levels did not differ significantly between groups (C).  Graphs show the arithmetic means (± S.E.M) of n 
= 8 animals per group.  Comparisons between groups were made using one way analysis of variance (ANOVA).  Univariate comparisons were made using 
6WXGHQW¶V7-WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV* P < 0.05, *** P < 0.001 versus naïve controls. + P < 0.05, +++ P < 0.001 versus vehicle 
controls. 
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4.4.4 Effects of enhancing synovitis using 2% carrageenan on angiogenesis, joint damage and 
pain in the MNX model of OA 
Following intra-articular injection of 2% carrageenan into the operated knee, 12 days after meniscal 
transection surgery, synovial inflammation and angiogenesis were increased compared with saline injected 
controls (Figures 4.9 to 4.13).  Knee joint swelling was transiently increased above the levels of sham 
operated and carrageenan injected controls, before returning to naïve levels at day 19 (Figure 4.12).   
 
Carrageenan injection did not significantly exacerbate structural changes observed in the MNX model of 
OA (Figure 4.14 and Table 3).  However, combining data from two separate experiments (Table 4) showed 
that 2% carrageenan injection did exacerbate total joint damage in the MNX model of OA and this was 
mainly due to increase in cartilage damage (chondropathy).  A greater weight-bearing asymmetry was 
observed following carrageenan injection at day 13 compared to meniscal transected and saline injected 
controls [Carrageenan: 94g (95% CI 81 to 106), MNX: 45g (95% CI 33 to 58), P < 0.001].  This 
asymmetry persisted to day 14 before reaching similar levels as those observed in meniscal transected and 
saline injected controls at day 19 to day 35 (Figure 4.15 A).   
 
4.4.5 Effects of inhibiting angiogenesis on synovitis, joint damage and pain in the combined 
MNX and 2% carrageenan model  
Following treatment with the angiogenesis inhibitor PPI-2458, synovitis and synovial angiogenesis were 
reduced but not completely abolished to naïve control levels, 35 days after meniscal transection surgery and 
23 days after intra-articular injection of 2% carrageenan (Figures 4.9 to 4.13).  Total joint damage score 
was also reduced following treatment with PPI-2458 [Score 9 (IQR 1 to 11)] compared with vehicle treated 
controls [Score 13 (IQR 12 to 15), P = 0.02] but not completely abolished to naïve levels (Figures 4.14 and 
Table 3).  PPI-2458 had no significant effect on the integrity of the osteochondral junction as indicated by 
the total number of channels crossing the osteochondral junction (Table 3).  PPI-2458 reduced weight-
bearing asymmetry [42g (95% CI 28 to 57)] compared with vehicle treatment [82g (95% CI 68 to 97), P < 
0.001] in the meniscal transected and carrageenan injected animals at day 14.  Weight-bearing asymmetry 
was gradually reduced but not completely inhibited to naïve control levels by day 35 (Figure 4.15 B).  
SHAM operated animals displayed a reduction in weight-bearing asymmetry [12g (95% CI -2 to 27)] 
compared with meniscal transected animals [40g (95% CI 24 to 55), P < 0.01] at day 19.  This reduction 
was maintained to day 35 [SHAM: 2g (95% CI -15 to 21), MNX: 48g (95% CI 22 to 75), P < 0.001] 
(Figure 4.15 C).  
 
PPI-2458 treated animals failed to gain weight at the same rate as naïve controls from day 29 [PPI2458: 
351g (95% CI 338 to 364), naïve controls: 376g (95% CI 366 to 386), P < 0.01] to day 35 [PPI2458: 361g 
(95% CI 350 to 372), naïve controls: 392g (95% CI 382 to 401), P < 0.01] (Figure 4.16). 
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Figure 4.9 Histological evidence of synovial macrophage infiltration in rat knee joints 35 days after 
either meniscal transection or SHAM surgery with intra-articular injection of 2% carrageenan and either 
oral administration of PPI-2458 or vehicle control treatment.  Macrophage infiltration was increased after 
meniscal transection surgery (A) compared to naïve controls (B) and further exacerbated after the intra-
articular injection of 2% carrageenan into rat knee joints 12 days after meniscal transection surgery (C).  
A B 
C D 
Naïve MNX 
MNX+2%+Vehicle MNX+2%+PPI2458 
SHAM 
F E 
SHAM+2% 
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This exacerbation was reduced following administration of anti-angiogenic agent PPI-2458 (D).  Intra-
articular injection of 2% carrageenan following SHAM surgery (E) also increased synovial macrophage 
infiltration compared to the arthritic rats (A) and naïve controls (B).  Levels were however lower than the 
combined MNX and 2% carrageenan model (C).  SHAM operated controls (E) displayed similar extent of 
synovial macrophage infiltration to naïve control animals (B).  Macrophages (black) are delineated by 
immunoreactivity for ED1. Negative control sections did not show any non-specific staining (Figure 3.7).  
Colour transmitted light images were taken using ×10 objective lens of a single representative section from 
n = 8 animals per group.  6FDOHEDU ȝP 
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Figure 4.10 Histological evidence of synovial angiogenesis in rat knee joints 35 days after either 
meniscal transection or SHAM surgery with intra-articular injection of 2% carrageenan and either oral 
administration of PPI-2458 or vehicle control treatment.  Synovial angiogenesis was increased after 
meniscal transection surgery (A) compared to naïve controls (B) and further exacerbated after the intra-
articular injection of 2% carrageenan into rat knee joints 12 days after meniscal transection surgery (C).  
D 
B 
Naïve 
A 
MNX 
C 
MNX+2%+Vehicle 
SHAM+2% SHAM 
E 
MNX+2%+PPI2458 
F 
 141 
This exacerbation was reduced following administration of anti-angiogenic compound PPI-2458 (D).  Intra-
articular injection of 2% carrageenan following SHAM surgery (E) also increased synovial angiogenesis 
compared to the arthritic rats (A) and naïve controls (B).  Levels were however lower than the combined 
MNX and 2% carrageenan model (C).  SHAM operated controls (E) displayed similar extent of synovial 
angiogenesis to naïve control animals (B).  ECs are delineated in red by immunoreactivity for CD31 (blue 
arrows).  Proliferating nuclei are delineated black by immunoreactivity for proliferating cell nuclei antigen 
(PCNA; green arrows).  Black arrows indicate proliferating ECs, which contain PCNA-immunoreactivie 
nuclei. Negative control sections for CD31 and/or PCNA immunohistochemistry did not show any non-
specific staining (Figure 3.7).  Colour transmitted light images were taken using ×20 objective lens of a 
single representative section from n = 8 animals per group.   6FDOHEDU ȝP 
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Figure 4.11 Histological evidence of synovial vascular density in rat knee joints 35 days after either 
meniscal transection or SHAM surgery with intra-articular injection of 2% carrageenan and either oral 
administration of PPI-2458 or vehicle control treatment.  Synovial vascular density was increased after 
meniscal transection surgery (A) compared to naïve controls (B) and further exacerbated after the intra-
articular injection of 2% carrageenan into rat knee joints 12 days after meniscal transection surgery (C).  
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This exacerbation was reduced following administration of anti-angiogenic agent PPI-2458 (D).  Intra-
articular injection of 2% carrageenan following SHAM surgery (E) did not significantly increase synovial 
vascular density compared to the arthritic rats (A) but did to naïve controls (B).  Levels were similar to the 
combined MNX and 2% carrageenan model (C).  SHAM operated controls (E) displayed similar extent of 
synovial angiogenesis to naïve control animals (B).  The extent of endothelial cells are delineated in red by 
immunoreactivity for CD31. Negative control sections for CD31 immunohistochemistry did not show any 
non-specific staining (Figure 3.7).  Colour transmitted light images were taken using ×20 objective lens of 
a single representative section from n = 8 animals per group.  6FDOHEDU ȝP 
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Figure 4.12 Inhibition of measures of inflammation (synovial macrophage infiltration and joint 
swelling) 35 days after meniscal transection surgery and 23 days after 2% carrageenan injection in either 
PPI-2458 or vehicle treated animals.  Animals had either meniscal transection or SHAM surgery on day 0.  
Intra-articular injection of either 2% carrageenan or saline control (Ÿ) was given in the operated knee on 
day 12.  From day 11 (vertical dotted line in graphs B and D) to 35, animals having either meniscal 
transection or sham surgery were given oral doses of either PPI-2458 (5mg/kg/every other day) or vehicle 
control.  Intra-articular injection of 2% carrageenan was followed by an increase in macrophage infiltration 
(A) and joint swelling (B) in the mensical transected (Ŷ) and sham operated (ź) animals.  Macrophage 
infiltration was reduced following the administration of PPI-2458 (C), in meniscal transected animals given 
2% carrageenan injection (Ɣ), 35 days after surgery compared with vehicle treated animals (×). The levels 
were not reduced to naïve controls (Ƈ).  However PPI-2458 did not affect joint swelling in these animals 
(D).  Joint swelling measured by a difference in knee diameter remained higher in animals that had 
meniscal transection surgery and were treated with vehicle control compared to naïves throughout the 
experiment. Graphs show arithmetic mean and ±S.E.M of 8 knees per group.  Macrophage fractional areas 
(logarithmically transformed) and knee diameters were analysed using one way analysis of variance 
$129$  8QLYDULDWH FRPSDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V 7-WHVW ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU
multiple comparisons.  * P < 0.05, ** P < 0.01, *** P < 0.001 versus arthritic, saline control (Ÿ).  + P < 
0.05, ++ P < 0.01, +++ P < 0.001 versus arthritic animals, treated with vehicle control and given 2% 
carrageenan injection (×). 
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Figure 4.13 Synovial angiogenesis (EC proliferation and vascular density) after meniscal transection 
surgery and 2% carrageenan injection in PPI-2458 treated animals. Twelve days after either meniscal 
transection or SHAM surgery, animals were given intra-articular injection of 2% carrageenan into their 
operated knee joint. From day 11 to 35, the arthritic animals were given oral doses of either PPI-2458 
(5mg/kg/evey other day) or vehicle control. Following carrageenan injection, EC proliferation index (EC 
PCNA index; A) and vascular density (EC fractional area) (B) were increased in the arthritic animals. 
Indices of angiogenesis were reduced following PPI-2458 treatment, (C and D), compared with vehicle 
treated animals. The levels were not similar to naïve controls.  Graphs show arithmetic mean and ±S.E.M 
of 8 knees per group.  EC PCNA index and fractional areas (logarithmically transformed) were analysed 
usLQJRQHZD\DQDO\VLVRIYDULDQFH$129$8QLYDULDWHFRPSDULVRQVZHUHPDGHXVLQJ6WXGHQW¶V7-test 
ZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV * P < 0.05, *** P < 0.001 versus arthritic and saline 
injected control. ++ P < 0.01, +++ P < 0.001 versus arthritic-carrageenan injected and vehicle treated animals. 
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Figure 4.14 Histological changes (chondropathy, osteophytosis and channels at the osteochondral 
junction) of the medial tibial plateaux 35 days after either meniscal transection or SHAM surgery with 
intra-articular injection of 2% carrageenan and either oral administration of PPI-2458 or vehicle control 
treatment.  A, medial tibial plateau from an animal having meniscal transection surgery showing severe, 
full thickness cartilage loss (arrows) with a large osteophyte formed at the joint margin (circled) and 
several channels crossing into (blue asterisk) or approaching (pink asterisk) the cartilage (dotted line; 
separates underlying bone from cartilage).  No inflammatory tissue infiltration is evident.  B, medial 
tibial plateau from an animal having intra-articular injection of 2% carrageenan (12 days after surgery) into 
the operated knee joint, showing infiltration of inflammatory tissue (black asterisk), an osteophyte 
(circled) and grossly enhanced, full thickness cartilage loss (arrows).  C, naïve control showing normal 
smooth cartilage, joint margins and no inflammatory tissue infiltration.  The chondrocytes are 
homogenously distributed throughout the cartilage and there is neither evidence of proteoglycan loss nor 
channels entering the avascular cartilage.  D, medial tibial plateau from an animal that has undergone 
meniscal transection surgery with 2% carrageenan injection and treated with PPI-2458 showing cartilage 
loss, reduced proteoglycan staining and chondrocyte density (arrows). An osteophyte can be seen at the 
joint margin (circled) with some channels crossing into the cartilage from underlying subchondral bone 
(blue asterisk).   E, medial tibial plateau from a sham-operated animal having 2% carrageenan intra-
articualr injection (12 days after surgery) into the operated knee joint, showing inflammatory tissue 
infiltration (black asterisk), moderate cartilage changes with very few channels crossing into the cartilage 
(blue asterisk).  F, medial tibial plateau from a SHAM-operated animal, showing normal smooth cartilage 
and joint margins with no inflammatory tissue infiltration.  The chondrocytes are homogenously distributed 
throughout the cartilage and there is neither evidence of proteoglycan loss nor channels entering the 
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avascular cartilage.  Coronal sections of the medial tibial plateaux stained with Safranin-O. Colour 
transmitted light images were taken using ×4 objective lens of a single representative section from n = 8 
animals per group.  6FDOHEDU ȝP 
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Table 3  Exacerbation and/or reduction in OA structural changes in medial tibial plateaux following intra-articular injection of 2% carrageenan into 
operated knee joints and/or anti-angiogenic treatment in the MNX model of OA.  Arthritic or SHAM operated animals were given intra-articular injection into 
their operated knee joint of 2% carrageen 12 days after meniscal transection surgery.  From day 11 to 35, animals having meniscal transection or SHAM surgery 
were given oral doses of PPI-2458 (5mg/kg/every other day) or vehicle control.  Intra-articular injection of 2% carrageenan did not significantly exacerbate the 
structural changes in the MNX model of OA.  Administration of PPI-2458 was followed by a reduction in total joint damage in the combined MNX and 2% 
carrageenan model compared with vehicle treated controls.  Data are given as median (Interquartile Range [IQR]).  Differences between groups (n = 8 animals 
per group) are analysed using Kruskal-Wallis test followed by Man-:KLWQH\ 8 WHVW WR FRPSDUH WZR JURXSV ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU PXOWLSOH
comparisons.  * P < 0.05, ** P < 0.01, *** P < 0.001 versus naives. + P < 0.05 versus meniscal transected and carrageenan injected animals. 
 
 
0 (0 to 1)  2 (2 to 3) ** 7 (4 to 9) ** 4 (4 to 5) ** Channels crossing 
medial OCJ 
0 (0 to 0) 1 (1 to 4) ** + 9 (4 to 15) ** 3 (2 to 8) ** Cartilage damage 
0 (0 to 0)  1 (0 to 1)  3 (1 to 3) ** 2 (1 to 3) ** Osteophytes 
0 (0 to 0)  2 (1 to 5) * + 12 (6 to 18) ** 5 (3 to 11) ** Total damage score  
Naive SHAM + 2% MNX + 2% MNX Structural Change 
Exacerbation of inflammation using 2% carrageenan 
2 (1 to 2)  5 (5 to 6) ** 6 (5 to 7) ** 
0 (0 to 1)  8 (1 to 10) ** 10 (10 to 15) ** 
0 (0 to 0)  1 (0 to 1)  2 (1 to 2) *** 
0 (0 to 1)  9 (1 to 11) * + 13 (12 to 16) ** 
Naive PPI-2458 Vehicle 
Anti-angiogenic Treatment 
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Table 4  Exacerbation in OA structural changes in medial tibial plateaux following intra-articular injection of 2% carrageenan in the rat MNX model of 
OA.  These are combined data from two separate experiments (MNX: n = 16, MNX+2%: n = 16, SHAM: n = 8, SHAM+2%: n = 8, Naives: n = 16).  Arthritic or 
SHAM operated animals were given intra-articular injection into their operated knee joint of 2% carrageen 12 days after meniscal transection surgery.  Intra-
articular injection of 2% carrageenan in the rat MNX model of OA was followed by an increase in total joint damage score which was mainly due to an increase 
in cartilage damage.   Structural changes in the joints were more severe in the combined MNX and carrageenan model compared to SHAM operated and 
carrageenan treated controls.  No difference in structural damage was seen between the SHAM operated and naïve animals.  Data are given as median 
(Interquartile Range [IQR]).  Differences between groups are analysed using Kruskal-Wallis test followed by Man-Whitney U test to compare two groups with 
%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV ** P < 0.01, *** P < 0.001 versus naives. + P < 0.05, ++ P < 0.01, +++ P < 0.001 versus meniscal transected and 
carrageenan injected animals.   
 
0 (0 to 4) +++ 5 (2 to 6) + 18 (12 to 29) *** 15 (10 to 22) *** Channels crossing medial OCJ 
0 (0 to 0) +++ 0 (0 to 0) +++ 10 (10 to 12) *** 6 (5 to 10) *** +++ Cartilage damage 
0 (0 to 0) ++ 
 
0 (0 to 0) + 2 (0 to 3) ** 2 (1 to 3) *** Osteophytes 
0 (0 to 0) +++ 
 
0 (0 to 0) +++ 13 (13 to 13) *** 9 (9 to 9) *** + Total damage score  
Naive SHAM + 2% MNX + 2% MNX Structural Change 
Exacerbation of inflammation using 2% carrageenan in the rat MNX model of OA 
SHAM 
0 (0 to 2) +++ 
0 (0 to 1) +++ 
0 (0 to 1) 
1 (1 to 1) +++ 
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Figure 4.15 Time course of the inhibition of meniscal transection-induced and carrageenan exacerbated knee joint pain behaviour following the 
administration of anti-angiogenic compound PPI-2458.  A, pain behaviour in arthritic (Ŷ) or SHAM-operated (ź) animals given intra-articular injection of 2% 
carrageenan into their operated knee joint.  B, pain behaviour in arthritic animals given carrageenan injection and treated with either PPI-2458 (Ɣ) or vehicle 
control (×).  C, pain behaviour in arthritic animals (Ƒ) and SHAM controls (ż).  On day 0, animals underwent meniscal transection (Ƒ) or SHAM (ż) surgery.  
From day 11 (vertical dotted line) to 35, the arthritic animals given a single intra-articular injection of 2% carrageenan (day 12) were orally dosed with either 
PPI-2458 (Ɣ 5mg/kg/every other day) or vehicle control (×).  Pain behaviour was measured by a difference in hind paw weight bearing between 0 to 35 days after 
meniscal transection surgery.  Arthritic animals given intra-articular injection of saline controls (Ÿ) showed increased pain behaviour compared to naïve controls 
(Ƈ) 12 days after meniscal transection surgery and this increase was maintained to day 35.  Arthritic animals (Ƒ) showed increase pain behaviour compared to 
SHAM (ż) controls 19 days after meniscal transection surgery and this increase was maintained to day 35.  Intra-articular injection of 2% carrageenan in either 
the meniscal transected or SHAM operated animals was followed by a transient increase in pain behaviour.  PPI-2458 treated animals showed a reduction in pain 
behaviour on day 14 which was reduced but not completely inhibited to naive control levels by day 35. Data are shown as arithmetic mean ± S.E.M.  Differences 
between groups (n = 8 animals per group) were analysed using one way analysis of variance (ANOVA).  Univariate comparisons weUHPDGHXVLQJ6WXGHQW¶V7-
WHVWZLWK%RQIHUURQL¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV.  ** P < 0.01, *** P < 0.001 versus either arthritic animals given saline control (Ÿ) or arthritic animals 
not having intra-articular injection (Ƒ).  + P < 0.05, +++ P < 0.001 versus combined MNX and 2% carrageenan injected model treated with vehicle control (×). 
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Figure 4.16 Weights of animals following the administration of anti-angiogenic compound PPI-2458.  
On day 0, animals underwent meniscal transection or SHAM surgery.  From day 11 (vertical dotted line) 
to 35, the arthritic animals given a single intra-articular injection of 2% carrageenan (day 12) were orally 
dosed with either PPI-2458 (Ɣ 5mg/kg/every other day) or vehicle control (×).  PPI-2458 treated animals 
gained weight at a slower rate compared to naïve controls (Ƈ).  Data are shown as arithmetic mean ± S.E.M.  
Differences between groups (n = 8 animals per group) were analysed using one way analysis of variance 
$129$  8QLYDULDWH FRPSDULVRQV ZHUH PDGH XVLQJ 6WXGHQW¶V 7-WHVW ZLWK %RQIHUURQL¶V FRUUHFWLRQ IRU
multiple comparisons.  ** P < 0.01 versus naïve controls. 
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4.5 Summary of Results 
x The MNX model of OA was associated with osteoarthritic changes in the medial tibial plateaux 
similar to those seen in human knee OA as well as increased pain behaviour. 
x Anti-inflammatory drugs dexamethasone and indomethacin each reduced synovitis, synovial 
angiogenesis and pain behaviour in the rat MNX model of OA. 
x Treatment with dexamethasone reduced total joint damage score by decreasing cartilage damage. 
x Anti-angiogenic compound, PPI-2458 reduced synovial and osteochondral angiogenesis, 
synovitis, joint damage (by reducing osteophyte growth) and pain behaviour in the rat MNX model of OA. 
x Exacerbating synovitis in the MNX model of OA enhanced synovial angiogenesis, joint damage 
and pain behaviour. 
x Following treatment with the anti-angiogenic compound PPI-2458, synovitis, joint damage and 
pain behaviour were all reduced in the rat MNX and 2% carrageenan model.  
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4.6 Discussion 
This study using the rat MNX model of knee OA examines whether synovitis contributes to joint damage 
and pain through the stimulation of angiogenesis.  These data show that exacerbating synovitis leads to 
more profound structural damage and pain behaviour in the rat MNX model of knee OA.  Inhibiting 
synovitis using either anti-inflammatory or anti-angiogenic compounds can reduce the joint damage and 
pain behaviour in this model of OA.  Angiogenesis may therefore contribute both to inflammation and joint 
damage, and inhibition of blood vessel growth may be a useful strategy in reducing OA pain. 
 
4.6.1 MNX model of OA 
These data reproduce previous evidence that transection of the medial meniscus in the rat results in 
osteoarthritic changes in the medial tibial plateaux, consisting of fibrillation and eventual loss of cartilage, 
accompanied by reduced density of chondrocytes and loss of proteoglycan staining, and growth of 
osteophytes at the joint margins (Janusz et al., 2002; Bove et al., 2006; Mapp et al., 2008; Mapp et al., 
2010).  The MNX model of OA also demonstrates loss of integrity of the osteochondral junction as 
channels penetrate the articular cartilage from the subchondral bone spaces, as well as synovitis, indicated 
by increased synovial macrophage infiltration, and pain behavior, indicated by a reluctance to 
symmetrically weight bear on the hind limbs.   
 
In each of these respects, this rat model of OA effectively mimics the human condition, and may provide 
important insights into mechanisms underlying structural changes, pain behavior and responses to 
pharmacological therapies.   
 
Naïve animals were used as controls rather than SHAM-operated animals because synovitis is an integral 
component of OA, and it was not the purpose of these studies to separate inflammation due to different 
sources within this model.  SHAM surgery to the knee joint will however induce an inflammatory response 
but data (pain behaviour) shown in this study and previous published literature has indicated that hindlimb 
weight-distribution (pain behaviour) and tibiofemoral pathology do not differ between SHAM-operated and 
naïve animals beyond the first 7 days after surgery (Mapp et al., 2008; Mapp et al., 2010).  Hence naïve 
control group was chosen over SHAM-operated control group and for the purpose of most of these studies 
it was not felt to be ethically justifiable to have two groups of control animals.  In these studies using the 
MNX model of OA by day 35 a reduction in synovial pathology and hindlimb weight distribution (pain 
behaviour) compared to naïve control levels was observed, hence it is reasonable to speculate that a 
reduction to SHAM-operated control group would have been obtained.  Similarly, comparing two separate 
experiments highlighted that following treatment with the angiogenesis inhibitor PPI-2458, meniscal 
injury-induced hindlimb weight bearing was reduced to SHAM-operated controls by day 19, but not 
completely abolished to naïve control levels. 
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4.6.2 Inflammation and pain in OA 
OA manifests as joint pain with progressive loss of joint function.  A great deal is known about symptoms 
of the disease, but the pathophysiology underlying those symptoms is less well understood.  While the pain 
of OA is felt to originate from the joint, it is now widely recognized to be of multifactorial origin 
moderated by both the peripheral and central nervous system (Bove et al., 2006).  In the absence of disease 
modifying drugs to treat OA, pharmacological interventions often target central pain mechanisms in order 
to relieve symptoms (McColl 2001). Current treatments are often limited by potential adverse events, and a 
better understanding of how joint pathology leads to pain is required to develop new therapies. 
 
Synovitis is now increasingly recognised as contributing to pain in OA. Intra-articular corticosteroids and 
topical and oral NSAIDs are established for symptomatic relief of knee OA.  The 71)ĮEORFNLQJDQWLERdy 
adalimumab recently has been found to improve pain, whilst reducing synovitis and  bone marrow oedema 
on magnetic resonance images (Grunke et al., 2006).  The data presented in this thesis confirms that 
increasing synovitis enhances structural damage and pain in the rat MNX model of knee OA which can be 
inhibited by anti-inflammatory treatments. 
 
4.6.3 Angiogenesis and inflammation in OA 
Angiogenesis is a feature of OA in rats as well as in humans, both in the synovium and at the osteochondral 
junction (Walsh et al., 2007; Mapp et al., 2008).  Synovial angiogenesis is associated with synovitis.  New 
blood vessel growth may be a consequence of synovitis through the expression of angiogenic factors by 
macrophages, and also may exacerbate inflammation by facilitating plasma extravasation and cellular 
influx (Walsh 1999; Bonnet et al., 2005).  Synovial and osteochondral angiogenesis are also associated 
with OA structural changes, and may contribute to those changes either directly or by facilitating 
inflammation (Haywood et al., 2003).  Angiogenesis is followed by innervation of newly formed blood 
vessels by fine unmyelinated sensory nerves, and may therefore directly contribute to pain in OA 
(Haywood et al., 2003).  These data show that inhibition of angiogenesis by administration of PPI-2454 is 
associated with reduced synovitis, structural damage and pain behavior in the rat MNX model of knee OA.  
Angiogenesis inhibition therefore offers a novel therapeutic strategy in OA. 
 
The reduction in synovitis that was observed after targeting angiogenesis using PPI-2458 was similar in 
extent to that observed after systemic treatment with indomethacin or dexamethasone. PPI-2458 prevents 
persistence of synovitis after combined intra-articular injection of carrageenan and fibroblast growth factor-
2 as well as 2% carrageenan injection in rats (Chapter 3).  Synovitis persists throughout the development of 
knee OA after meniscal injury in rats (Mapp et al., 2008), and these data demonstrate that the anti-
inflammatory effects of PPI-2458 commence 12 days after mensical injury indicating that angiogenesis 
inhibition can reduce inflammation even after synovitis has become established.  PPI-2458 has also 
inhibited synovitis in collagen and in PGPS-induced arthritis in mice and rats (Bainbridge et al., 2007; 
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Lazarus et al., 2008), indicating that the anti-inflammatory effects of angiogenesis inhibition may be 
observed in synovitis induced by a wide variety of agents. 
 
It is difficult to completely exclude the possibility that PPI-2458 might be having other effects distinct from 
its anti-angiogenic properties.  Studies have shown PPI-2458 to be a potent inhibitor of the in-vitro 
proliferation of activated human umbilical vein endothelial cells (HUVECs) and human fibroblast like 
synoviocytes (FLS) from RA patients (Bernier et al., 2004; Bernier et al., 2005).  Moreover, in a rat model 
of PG-PS-induced arthritis, the in-vivo protective effect of PPI-2458 against bone destruction leading to 
structural preservation of affected arthritic joints was attributed to the ability of PPI-2458 to inhibit 
osteoclast mediated bone resorption in-vitro (Hannig et al., 2007; Lazarus et al., 2008).  PPI-2458 was 
selected as an anti-angiogenic agent because it is believed not to have any direct inhibitory effects on 
inflammation (Brahn et al., 2009).  Data shown in Chapter 3 supports this theory because PPI-2458 
inhibited angiogeneis prior to the inhibiton of inflammation in two different models of chronic 
inflammation.   These findings further add to the body of evidence which supports PPI-2458 as a selective 
angiogenesis inhibitor.  However it should be noted that since angiogenesis is closely associated with 
inflammation it would be difficult, if not impossible, to tease out this relationship. 
 
4.6.4 Structural effects of anti-inflammatory and anti-angiogenic treatments 
Synovitis is associated with greater chondropathy in human OA (Walsh et al., 2009), and predicts 
progression of joint damage in longitudinal studies (Ledingham et al., 1995).  Inhibition of synovitis is 
therefore an attractive target for disease modification in OA, although coincidental and detrimental effects 
of current anti-inflammatory agents on chondrocyte function (Annefeld et al., 1990; Bove et al., 2003) may 
limit their efficacy as disease modifying agents.  In this study, treatment with either dexamethasone or PPI-
2458 inhibited total joint damage score.  Although dexamethasone predominantly affected chondropathy in 
this model of OA, angiogenesis inhibition reduced osteophyte size, suggesting that the structural effects of 
angiogenesis inhibition are not entirely mediated by its anti-inflammatory effects.  VEGF blockade has also 
been found to reduce new bone formation around arthritic joints, an effect that may be partly mediated by 
inhibition of endochondral ossification (Miotla et al., 2000). 
 
Loss of integrity of the osteochondral junction results, in part, from the extension of channels from 
subchondral bone spaces into the articular cartilage, both in human and rodent OA (Walsh et al., 2007; 
Mapp et al., 2008).  These channHOV DUH W\SLFDOO\ YDVFXODULVHG OHDGLQJ WR WKH WHUP CYDVFXODU FKDQQHOV¶ 
Vascular channel formation and pain behavior in the MNX model of knee OA is reduced by matrix 
metalloproteinase inhibition (Mapp et al., 2010).  These data showing that PPI-2458 inhibited 
vascularisation of channels at the OCJ is consistent with its anti-angiogenic activity.  However, the 
significant increase in total channel numbers in animals having meniscal transection surgery and treated 
with PPI-2458 compared with non-arthritic control animals indicates that angiogenesis is not a prerequisite 
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for channel formation.  Reductions in pain and structural damage observed in the osteoarthritic animals 
following treatment with PPI-2458 may be partly due to inhibition of osteophyte growth and angiogenesis 
at the osteochondral junction, as well as inhibition of synovitis. 
 
This study suffers from limitations that are common to investigations of complex biological processes in 
intact animals.  Although PPI-2458 is well characterized as a specific inhibitor of angiogenesis, the exact 
consequences of angiogenesis inhibition responsible for its analgesic activity can not be pin-pointed.  
Similarly indomethacin and dexamethasone may have effects additional to inhibiting inflammation, 
including direct anti-angiogenic actions.   
 
Animals treated with the angiogenesis inhibtor PPI-2458, failed to gain weight at the same rate as animals 
in other groups (vehical-treated and naïve animals), this reduction may well be due to the inhibition of 
angiogenesis at the growth plate, hence smaller animals.  In keeping with previous studies using 
dexamethasone (Roussel et al., 2003; Caparroz-Assef et al., 2007), corticosteroid-treated animals failed to 
gain weight at the same rate as animals in other groups. This reduction in growth may be due to negative 
effects on glucose metabolism, although growth curves paralleled those of the other treatment groups by 
day 35, and non-fasting blood glucose levels did not differ significantly between the groups at the time of 
sacrifice.  Another adverse effect associated with steroid use is myopathy, it is possible that this could be 
the reason for the slow weight gain of dexamethasone treated animals.  Despite these limitations, however, 
the data presented in this thesis supports the view that anti-inflammatory and anti-angiogenic strategies 
may have potential not only to relieve symptoms, but also to modify structural progression in OA. 
 
In conclusion, these findings indicate that synovitis and total joint damage are closely associated with pain 
behaviour in OA and this may, in part, be explained by angiogenesis in the synovium and at the 
osteochondral junction. Targeting angiogenesis could therefore prove useful in reducing pain and structural 
damage in OA, either alone or in combination with other drugs. 
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5 VASCULARISATION AND INNERVATION OF HUMAN MENISCUS 
 
5.1 Introduction 
Osteoarthritis (OA), one of the commonest joint diseases (Arden et al., 2006), is a major source of pain and 
disability in the ageing population (van Saase et al., 1989; Peat et al., 2001; Dixon et al., 2004).  OA is 
associated with loss of articular cartilage (chondropathy), sclerosis and osteophyte formation in the 
subchondral bone.  Chondropathy alone does not equate to OA, but emerging research shows chondropathy 
scores are representative of the presence and severity of OA (Walsh et al., 2009). 
 
Pain is the predominant symptom of OA, but little is certain about the mechanisms by which this pain 
arises.  Pain has been suggested to originate from articular cartilage (Suri et al., 2007), periosteum 
(Gronblad et al., 1984), subchondral bone (Reimann et al., 1977), synovium (Mapp 1995), ligaments, 
muscle and joint capsule (Hukkanen et al., 1992; Hirasawa et al., 2000; Lanzetta et al., 2004; Suri et al., 
2007). 
 
Angiogenesis may contribute to pain in OA by enabling growth of new unmyelinated sensory nerves 
(Bonnet et al., 2005; Ashraf et al., 2008).  Angiogenesis and sensory nerves are seen in the synovium and 
at the osteochondral junction in OA (Walsh et al., 2007) penetrating into non-calcified articular cartilage 
and osteophytes (Suri et al., 2007).  These perivascular, unmyelinated, nerve fibres containing substance-P 
and CGRP are implicated in mediating sustained burning pain described by patients with OA (Kidd et al., 
1992; Dieppe et al., 2005). 
 
The menisci are cresenteric wedges of fibrocartilage, located between the femoral condyles and the tibial 
plateaux (Arnoczky et al., 1982).  They increase joint congruity, dispersal of weight, proprioception, and 
shock absorption, and reduce friction (Seedhom et al., 1974; Messner et al., 1998).   
 
Meniscal tissue consists of cells suspended in an ECM of collagen (mainly type 1), glycoproteins, 
proteoglycans and elastin (McDevitt et al., 1990).  Disruption of collagen bundles, proteoglycan loss, peri-
meniscal synovitis and calcification not limited to the outer, peripheral portion of the meniscus (Burman et 
al., 1933; Herwig et al., 1984; Kapadia et al., 2000; Grainger et al., 2007; Sun et al., 2010) are described as 
meniscal degeneration (Bennett et al., 2002; Englund 2009).  A strong association between meniscal 
degeneration, articular cartilage damage and joint space narrowing has been reported (Gale et al., 1999; 
Hunter et al., 2006).  As well as being a consequence of OA, meniscal changes may contribute to OA 
structural damage (Bhattacharyya et al., 2003; Hunter et al., 2006; Englund 2009). 
 
Meniscectomy in OA can lead to a reduction in pain (Jackson et al., 1982; Bin et al., 2008), although 
mechanisms by which this occurs are yet to be elucidated.  Myelinated and unmyelinated nerve fibres, and 
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free nerve endings have been localised in the meniscus (Wilson et al., 1969; Day et al., 1985; Zimny et al., 
1988; Assimakopoulos et al., 1992), with perivascular nerves containing  substance P (Mine et al., 2000).  
Blood vessels and nerves penetrate the outer portion of the normal human meniscus, reaching as far as its 
middle third portion, with the innermost portion remaining avascular and aneural (Wilson et al., 1969; Day 
et al., 1985).  Large variations have been reported in the degree of vascular penetration and innervation 
between individuals, but it is unclear whether disease contributes to this heterogeneity (Arnoczky et al., 
1982).  Two studies comparing human menisci with extensive degeneration to normal menisci found no 
change in vascularity and innervation (Kennedy et al., 1982; Danzig et al., 1983) whilst another indicated 
increased penetration of blood vessels into the inner portion of the osteoarthritic meniscus (Burman et al., 
1933).  Most previous studies of human menisci have used small numbers of surgical samples, and the 
heterogeneity of human meniscal tissue and high prevalence of OA may have compromised their ability to 
associate changes with disease. 
 
Elucidation of the mechanisms involved in the generation of pain is needed to enable the development of 
more effective therapeutic and surgical strategies.  Therefore examining the role that meniscus might have 
in the genesis of pain in OA through angiogenesis and nerve growth is vital in increasing our understanding 
of the pathophysiology of OA.  Furthermore, the vasculature plays important roles in tissue repair, and a 
better understanding of the vascular and neural anatomy of both healthy and diseased meniscus may help 
develop new treatments for meniscal injuries and OA.  It was therefore hypothesised that vascularisation 
into the meniscus may be increased in OA and could be associated with increased sensory nerve growth. 
 
5.2 Aims 
1. To compare the meniscal structure of osteoarthritic and control menisci. 
2. To compare the vascular penetration between osteoarthritic and control menisci. 
3. To compare the sensory nerve growth between osteoarthritic and control menisci. 
4. To determine whether vascular penetration is associated with nerve growth in human menisci. 
 
5.3 Methods 
General methodology is given in Chapter 2.  Patient and sample selection criteria is stated in section 2.9, 
whilst demographic details of patients are listed in Table 5.  Detailed steps of the image analysis and 
quantification procedures are given in section 2.8.   
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Table 5  Patient details and chondropathy scores (possible range 0 to 400) for samples used in study of meniscal vascularity and nerve growth.  Data for 
age and chondropathy scores are medians (IQR).  Comparison between groups are made using Man Whitney-U Test.  P < 0.05 indicates significant difference 
between high and low chondropathy groups. 
 
5 patients taking 
paracetamol 
1 patient taking 
long term 
steroids (not for 
rheumatological 
reasons)  
2 patients taking 
paracetamol 
2 patients taking 
long term steroids 
(not for 
rheumatological 
reasons)  
2 patients taking 
paracetamol 
none taking long 
term steroids  
1 patient taking 
opioids  
3 patients taking 
paracetamol 
1 patient taking 
long term steroids 
(not for 
rheumatological 
reasons)  
Medications  
(at time of death) 
 
 
 
 
 
 
0.0002 
 
33 (19 to 46) 
 
199 (181 to 240) 
 
<0.0001 
 
24 (15 to 27) 
 
203 (198 to 245) 
Chondropathy 
Score (Possible 
range 0 to 400) 
0.005 46 (33 to 55) 66 (65 to 72) <0.0001 41 (34 to 46) 69 (65 to 81) Age (years) 
0.32 3 (38%) 5 (63%) 0.32 11 (55%) 14 (70%) Number Male (%) 
P Value Low 
Chondropathy 
(n = 8) 
High 
Chondropathy 
(n = 8) 
P Value Low 
Chondropathy 
(n = 20) 
High 
Chondropathy 
(n = 20) 
 
Patient/Sample 
Characteristics 
VASCULARITY NERVE GROWTH 
1 patient taking 
opioids 
1 patient taking 
opioids 
9 patients taking 
opioids 
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5.4 Results 
 
5.4.1 Meniscal Structure 
Inner and outer regions of the meniscus were distinguished by differences in matrix structure and 
proteoglycan staining.  The inner region of the meniscus displayed large collagen bundles with a regular 
arrangement whilst in the outer region fibres were arranged in smaller bundles with a more irregular 
orientation (Figure 5.1).  The junction separating these two regions we refer to as the fibrocartilage junction 
(Figure 5.1).  Synovium, localised to the surface of the outer region of the meniscus, extended to 
approximately the fibrocartilage junction in menisci from the low chondropathy group (Figure 5.1 A).  In 
menisci from the high chondropathy group, synovium appeared thicker and extended over part of the inner 
region (Figure 5.1 D).  Menisci from high chondropathy group had a more fragmented appearance than 
menisci from low chondropathy group, displaying more clefts in the matrix of the outer region (Figure 5.1 
F), whereas menisci from low chondropathy group displayed homogeneous eosinophilic matrix (Figure 5.1 
C).  Proteoglycan staining was present in the inner, but not in the outer region of the menisci from both the 
low and high chondropathy groups.  No difference was seen in the intensity of proteoglycan staining 
between groups.  Blood vessels of varying sizes were observed in the outer region of the meniscus, ranging 
from arteries with a continuous layer of smooth muscle to capillaries with walls of single cell thickness 
(Figure 5.1 and 5.2). 
 
The extent of synovial ingrowth towards the tip of the meniscus was greater in the high chondropathy 
group [0.12 mm (IQR 0.04 to 0.20)] compared to the synovia from the low chondropathy group [0.00 mm 
(IQR 0.00 to 0.00), P = 0.003] (Figure 5.1).  
 
Grading of collagen bundle appearance indicated greater degeneration in the outer region of menisci from 
high chondropathy cases [Grade 1 (IQR 0 to 1)] than from low chondropathy cases [Grade 0 (IQR 0 to 0), P 
= 0.048]. Greater collagen bundle irregularity was associated with higher chondropathy (r = 0.43, P = 
0.005).  No significant difference was demonstrated in collagen bundle appearance in the inner region 
between high [Grade 1 (IQR 0 to 1)] and low chondropathy groups [Grade 0 (IQR 0 to 1), P = 0.35] (Figure 
5.1 B and E).   
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Figure 5.1 Structure of human menisci.  Haematoxylin and eosin staining of menisci from the low 
(A-C) and high (D-F) chondropathy groups.  In menisci from the low chondropathy group, a distinct 
fibrocartilage junction [FCJ (large dotted line)] (A) separated the inner (IR), characterized by regular 
matrix fibre bundles (B), from the outer (OR) region which displayed irregular fibre bundles (C). A thin 
synovium (S) was adherent to the OR but did not extend over the IR (A).  In menisci from the high 
chondropathy group, a thick layer of synovium (S) extended over the intact IR (D, E), with the OR having 
progressive disorientation of fibre bundles bordering hypocellular regions, having clefts (astrix) (F).  
Transmitted light images were taken using ×4 (A) and ×20 (B-F) objective lenses of a single representative 
section from n = 20 menisci per group.  6FDOHEDU ȝP 
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5.4.2 Meniscal Vascularity 
Repeatability for synovial vascularity density was 1.9 for 95% of pairs of observations (i.e. the difference 
between two measurements for the same case is expected to be <1.9% for 95% of pairs) (Bland et al., 
1996). Vascular densities were greater in the high than in the low chondropathy group both in the synovium 
[3.8% (IQR 2.6 to 5.2), 2.0% (IQR 1.4 to 2.9), P = 0.002] and at the fibrocartilage junction [2.3% (IQR 1.7 
to 3.1), 1.1% (IQR 0.8 to 1.9), P=0.003].  A degree of vessel penetration into the inner region along the 
midline of the menisci was observed in both groups (Figure 5.2).   
 
The outer meniscal region was more vascular than the inner region, with an abrupt drop in vascularity in 
the field 4 along the midline from the meniscal tip, which corresponded to the region of the fibrocartilage 
junction, separating the inner from the outer region of the menisci (Figure 5.2 and 5.3).  Vascular densities 
in field 4 (the fourth consecutive microscopic field from the meniscal tip) were greater in the high than in 
the low chondropathy group [1.0% (IQR 0.3 to 1.5), 0.3% (IQR 0.0 to 0.8), P = 0.015] indicating a greater 
degree of vascular penetration in the high chondropathy group.  Meniscal vascularity at the fibrocartilage 
junction, in field 4, or in the synovium were not associated with collagen bundle appearance in the outer 
region (r = 0.16, P = 0.33, r = 0.08, P = 0.61, and r = 0.21, P = 0.20 respectively). Synovial vascular density 
was associated with meniscal vascularity at the fibrocartilage junction (r = 0.46, P = 0.003), and in field 4 (r 
= 0.46, P = 0.003). 
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Figure 5.2 Vascularity of human menisci.  Alpha-actin positive vasculature in menisci from the low 
(A and C) and high (B and D) chondropathy groups. In the low chondropathy group, low densities of 
vessels were found in the outer region (OR), both in the synovium (s) and along the fibrocartilage junction 
(large dotted line) (A), with vascular penetration into the inner region (IR) along the midline (C).  In 
menisci from high chondropathy group, high densities of vessels were observed in the OR, both in the 
synovium and along the fibrocartilage junction (B) with increased penetration into the IR along the midline 
(D). Transmitted light images were taken using ×4 objective lens of a single representative section from n = 
20 menisci per group.  6FDOHEDU ȝP 
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Figure 5.3 Depth of vascular penetration along the midline of menisci.  The highest densities of 
alpha-actin positive vessels were observed in the outer region (OR) of the menisci, where there was no 
significant difference in vascular density between the low and high chondropathy groups.  Fewer vessels 
were observed in the inner region (IR) of both groups.  Menisci from the high chondropathy group were 
characterised by increased vascular density in the 4th field of view, which corresponded to the region of the 
fibrocartilage junction (FCJ), indicating increased penetration of vessels from the outer into the inner 
meniscal region.  Each field was 1.4mm in length.  Graph shows arithmetic mean ± S.E.M of n = 20 
menisci per group.  Comparison between groups are made using Man Whitney-U Test.  * P <0.05 
 
5.4.3 Sensory Innervation 
CGRP-immunoreactive nerve profiles were identified alongside blood vessels (small arterioles) and 
sometimes at a distance from them (Figure 5.4).  These vessels and nerves were commonly observed in the 
outer region near the fibrocartilage junction of the meniscus.  The inner region of the meniscus was mostly 
aneural.  Menisci from high chondropathy group had greater number of perivascular sensory nerve profiles 
in the outer region [144 nerve profiles/mm² (IQR 134 to 189)] compared to menisci from the low 
chondropathy group [119 nerve profiles/mm² (IQR 104 to 144), P = 0.049].  Nerve profiles in the outer 
region of the menisci were associated with chondropathy (r = 0.59, P = 0.015), but not with collagen bundle 
appearance (r = 0.10, P = 0.97). 
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Figure 5.4 Calcitonin gene-related peptide (CGRP)-immunoreactive (sensory) nerve profiles in the 
outer region of human menisci.  A:  Nerve profiles (arrows) associated with small arterioles (BV).  B:  
Apparently free nerve profiles not associated with small arterioles.  C:  Meniscus from low chondropathy 
group having few nerve profiles associated with small arterioles.  D:  Meniscus from high chondropathy 
group having several nerve profiles associated with small arterioles.  Sample of menisci from high (A, B 
and D) or low (C) chondropathy cases. Dotted line indicates the boundary of the synovium (S).  
Transmitted light images were taken using ×10 (D), ×20 (B and C) and ×40 (A) objective lenses of a single 
representative section from n = 20 menisci per group.   $OOVFDOHEDUV ȝP  
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5.5 Summary of Results 
x Menisci from knees with high chondropathy had a greater degree of collagen bundle degeneration 
in the outer region compared with menisci from knees with low chondropathy. 
x In menisci from the high chondropathy group, synovium appeared thicker and synovial ingrowth 
towards the tip of the menisci was greater compared with menisci from the low chondropathy group.  
x Outer regions of the menisci from knees with high chondropathy were more vascular than the 
inner regions with an abrupt drop in vascularity at the fibrocartilage junction separating the outer from the 
inner region of the menisci. 
x Increased vascular densities were observed in menisci from the high compared with low 
chondropathy group both in the synovium and at the fibrocartilage junction. 
x A greater density of perivascular sensory nerve profiles in the outer region of menisci from knees 
with high chondropathy was seen compared to those with low chondropathy. 
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5.6 Discussion 
This study examines whether vascularisation into the meniscus increases in OA and if it is associated with 
increased sensory nerve growth.  These data show that menisci from knees with high tibiofemoral 
chondropathy have increased blood vessel densities near the fibrocartilage junction, which are associated 
with a greater number of perivascular sensory nerves.  Angiogenesis and increased meniscal innervation are 
therefore possible mechanisms contributing to knee pain in tibiofemoral OA.  
 
This study confirms an association between disorganisation of collagenous matrix structure and 
chondropathy in human knees, and demonstrates increased penetration of blood vessels and nerves towards 
the meniscal tip with high chondropathy scores.  Vascularisation of normally avascular tissues has also 
been demonstrated in articular cartilage in OA and inner regions of the annulus fibrosus of the 
intervertebral disc in back pain (Kauppila 1995).  Meniscal angiogenesis may be a homeostatic response to 
minimise meniscal damage in OA.  Vascularisation changes tissue biomechanics and may predispose to 
further damage.  Interventional studies would be required to determine whether meniscal angiogenesis 
protects against or contributes to joint damage in OA. 
 
These findings show that increased angiogenesis previously observed in OA synovium (Bonnet et al., 
2005; Ashraf et al., 2008) extends to include synovium attached to menisci. Increased synovial vascularity 
was associated with vascularisation at the fibrocartilage junction of the meniscus, suggesting that 
angiogenesis in these different joint compartments may be regulated by common factors.  Synovial 
angiogenesis is associated with synovitis in OA, and may be driven by increased expression of angiogenic 
factors such as VEGF by cells within the inflamed synovium (Bonnet et al., 2005; Ashraf et al., 2008).  
Furthermore, the meniscus is closely apposed to articular cartilage in vivo, and VEGF is also upregulated 
by superficial chondrocytes in OA (Walsh DA 2010).  The stimuli to meniscal blood vessel growth deserve 
further study, but may originate, as well as from cells within the meniscus itself, from adjacent structures 
such as the synovium and articular cartilage. 
 
These data demonstrate that CGRP positive sensory nerve profiles are present in the outer region of 
menisci, and most of these nerves are associated with blood vessels.  CGRP is co-localised with substance 
P in unmyelinated sensory nerve fibres, and this work therefore extends previous findings that perivascular 
nerves containing substance P are located in the peripheral portion of torn menisci (Mine et al., 2000).  This 
study shows an increase in sensory innervation in the outer region of menisci from knees with high 
chondropathy scores.  Nerve growth in menisci may contribute to pain in OA both through an increased 
density of nociceptive fibres, and through increased sensitivity that occurs during nerve growth (Ma et al., 
1997).  Recent controlled trials of nerve growth factor blockade have demonstrated its ability to inhibit OA 
knee pain (Cattaneo 2010), although the rapid onset of its analgesic effect may suggest an action on 
sensitisation rather than on nerve growth.  CGRP-immunoreactive nerves were localised adjacent to blood 
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vessels within the meniscus, and sensory nerve growth follows blood vessel growth in a variety of tissues 
(Aoki et al., 1994; Walsh et al., 1996).  Angiogenesis inhibition may therefore also have analgesic potential 
by reducing aberrant innervation in the osteoarthritic knee (Walsh et al., 2001).  Substance P and CGRP 
released from sensory nerve terminals can amplify the inflammatory response (Kidd et al., 1990; Garrett et 
al., 1992) as well as initiating angiogenesis, with the potential to contribute to both pain and structural 
damage (Seegers et al., 2003).  It remains possible that the increased sensory innervation in menisci from 
knees with chondropathy contributes to, as well as being a consequence of meniscal angiogenesis. 
 
Macroscopic appearance of chondropathy is used as an indicator of tibiofemoral OA. Chondropathy scores 
for high chondropathy group are similar to those previously observed at total joint replacement surgery for 
knee OA [257 (IQR 228-283)] (Walsh et al., 2009), all of whom fulfilled the American College of 
Rheumatology revised criteria for OA [60].  Synovial and meniscal angiogenesis do not appear to be 
restricted to knees undergoing arthroplasty.  These findings of meniscal pathology are consistent with MRI 
studies showing meniscal abnormalities associated with symptomatic radiographic OA compared to 
asymptomatic and non-radiographic groups (Fukuta et al., 2002; Fukuta et al., 2009). Chondropathy alone, 
however, is insufficient to diagnose knee OA (Altman et al., 1986) and further studies would be required to 
determine whether the observed meniscal changes are associated with other features of OA.  During 
selection of cases for this study, 3 were excluded from the high chondropathy group due to non-availability 
of meniscal tissue.  Menisci can be completely disrupted in severe OA and the current findings may only be 
relevant to cases where menisci remain intact.  The prevalence and severity of OA increases with age, and 
it was not possible in this study to exclude the possibility that differences in vascularity and innervation 
between high and low chondropathy groups may have been age- rather than disease-related.  It is not 
known whether patients from whom the menisci were obtained suffered from knee pain, and the proposal 
that meniscal pathology may be associated with knee pain remains speculative.  Despite these limitations, 
however, the use of post mortem tissues in this study permitted the analysis of two discrete patient groups, 
with menisci harvested and processed and chondropathy assessed by identical methodologies, avoiding 
differences between surgical and control specimens that can often limit interpretation of pathological 
studies. 
 
In conclusion, these data show an increased vascularity and innervation of menisci from knees displaying 
high chondropathy scores.  Neovascularisation and innervation may contribute to both structural change 
and pain in OA.  Inhibition of angiogenesis and/or nerve growth may each offer the potential to prevent 
meniscal innervation, and interventional studies are needed to further elucidate the contribution of and the 
links between angiogenesis, nerve growth and pain. 
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6 OVERALL SUMMARY OF RESULTS 
 
Using animal models of synovitis, these data show that angiogenesis may be a key factor in the transition 
from acute to persistent inflammation.   
 
In the 2% carrageenan model of persistent synovitis, a short course of PPI-2458 (6 doses) administered 
during the initial phase of inflammation, reduced synovitis by day 24, but did not completely abolish it.  
However synovial angiogenesis (EC proliferation and vascular density) was completely abolished at this 
time point, suggesting that chronic inflammation is in part mediated by angiogenesis.  Pain behaviour in 
this model was also reduced by day 7 following administration of PPI-2458.  At this time point, synovial 
angiogenesis was completely abolished but synovitis persisted, suggesting that angiogenesis, inflammation 
and pain are indeed inter-connected processes.  Inhibiting angiogenesis therefore has the potential to reduce 
pain. 
 
In order to confirm that angiogenesis may indeed be an integral component of persistent synovitis it was 
shown that at a dose of 0.03%, carrageenan alone did not induce angiogenesis.  Carrageenan injection alone 
was associated with a transient synovitis that had resolved at 14 days.  When angiogenesis was stimulated 
with 6 pmoles FGF-2 at the time that synovitis was induced by intra-articular injection of carrageenan, the 
synovitis persisted for at least 4 weeks.  Inhibition of this effect of FGF-2 by PPI-2458 suggests that this 
chronicity is mediated by angiogenesis rather than other actions of FGF-2.   
 
This relationship of angiogenesis and inflammation was further studied in the rat MNX model of knee OA.  
Data gathered using the rat MNX model of knee OA highlighted that exacerbating synovitis leads to more 
profound structural damage and pain behaviour and this may partly be due to the stimulation of 
angiogenesis in the synovium and at the osteochondral junction.  Inhibiting synovitis using either anti-
inflammatory or anti-angiogenic compounds reduced the joint damage and pain behaviour in this model of 
OA.  Angiogenesis may therefore contribute both to inflammation and joint damage, and inhibition of 
blood vessel growth may be a useful strategy in reducing OA pain.  
 
Extending these in-vivo findings to human meniscal tissue showed that tibiofemoral chondropathy is 
associated with altered matrix structure, increased vascular penetration and increased sensory nerve 
densities in the medial meniscus.  Moreover data from this study showed that increased angiogenesis 
previously observed in OA synovium extends to include synovium attached to the menisci.  Hence, 
angiogenesis and associated sensory nerves in the meniscus may therefore contribute to pain in knee OA 
and inhibition of angiogenesis and/or nerve growth may each offer the potential to prevent meniscal 
innervation and hence pain experienced during OA.  Interventional studies are however needed to further 
elucidate the contribution of and the links between angiogenesis, nerve growth and pain.   
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Collectively these findings support the hypothesis that inflammation and angiogenesis are indeed co-
dependent processes, exacerbating and mediating structural damage and pain in OA.  Angiogenesis 
inhibition has the potential to reduce synovitis, joint damage and pain in OA. 
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7 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Arthritic conditions on the whole are a significant health problem worldwide placing an enormous burden 
on global economy (Zhang et al., 2010).  OA, undoubtedly by far the most common form of arthritis 
affecting synovial joints is a heterogeneous condition of unknown aetiology (Driban et al., 2010).  OA is 
one of the leading causes of chronic pain and disability not only in the elderly but also in individuals of 
working age (Dieppe et al., 2005; Issa et al., 2006).  Current treatment recommendations for OA focus on 
symptomatic relief as pharmacological interventions that slow, arrest or reverse disease progression are not 
available (Fitzcharles et al., 2010; Zhang et al., 2010), and therefore in many affected individuals OA often 
leads to total joint replacement surgery (Altman 2010; Feeley et al., 2010).  Thus a more in depth 
knowledge is required to further understand the pathogenesis of disease initiation and progression in OA 
inorder to fulfil the goal of disease modification. 
 
OA is characterised pathologically by a progressive loss of articular cartilage accompanied by new bone 
formation at the joint margins (osteophytosis), changes in subchondral bone and synovitis (Goldring et al., 
2007).  Angiogenesis, the growth of new blood vessels from pre-existing ones, is thought to contribute to 
each of these pathological features of OA.  Although the hallmark of OA is the progressive loss of articular 
cartilage and joint space narrowing (Goldring et al., 2010), abnormalities are also detected in the 
subchondral bone and the synovium even in very early disease (Martel-Pelletier et al., 2010).  Hence an 
important emerging theme in OA is a broadening of focus from the popular belief that OA is primarily a 
disease of the cartilage WRWKHRQHRILQYROYLQJWKH³ZKROHMRLQW´.   
 
Pain, the predominant symptom of OA can originate from several sources (Dieppe et al., 2005).  The 
mechanisms underlying OA pain are not particularly well understood.  Inflammation is implicated in 
sensitising the sensory nerves growing alongside blood vessels in various compartments of the joints and 
these sensitised nerves are thought to contribute to neurogenic inflammation, initiating new vessel growth.  
Angiogenesis may therefore contribute both to the symptoms and pathology of OA and further analysis of 
its role seems vital in leading to discovering more effective therapies. 
 
In this thesis evidence is presented that angiogenesis contributes to inflammation, structural damage and 
pain in OA, and targeting angiogenesis reduces these changes.  These findings support the hypothesis that 
inflammation and angiogenesis are co-dependent processes, exacerbating and mediating structural damage 
and pain in OA. 
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7.1 Angiogenesis and chronic inflammation 
The mechanisms leading to persistent inflammation in human diseases are not fully elucidated.  Chronic 
inflammation is always accompanied by angiogenesis, and although angiogenesis can occur without 
inflammation, it facilitates plasma extravasation and inflammatory cell recruitment (Costa et al., 2007).  
Angiogenesis can exacerbate pain by facilitating inflammation (Bonnet et al., 2005).  Inflammation is now 
increasingly being recognized as one of the prominent features of previously thought non-inflammatory 
arthritic conditions such as OA (Ashraf et al., 2008; Bondeson et al., 2010).   
 
Intra-articular inMHFWLRQRIȜFDUUDJHHQDQKDVEHHQVKRZQLQSUHYLRXVVWXGLHV WR LQGXFHV\QRYLWLV (Lam et 
al., 1989; Lam et al., 1991; Walsh et al., 1998), similarly in this study, intra-articular injection of either 
0.03% or 2% carrageenan was used to induce either acute or chronic synovitis respectively in rats.  With 
carrageenan, joint swelling begins within minutes of injection, permitting an accurate definition of the time 
of synovitis onset.  In this study, chronic synovitis was associated with increased pain behaviour and a short 
course of the angiogenesis inhibitor, PPI-2458 was shown to reduce this pain behaviour in the 2% 
carrageenan model of chronic synovitis by directly inhibiting synovial angiogenesis prior to the reduction 
in synovitis.  This highlights that angiogenesis could indeed be one of the components of chronic 
inflammation, indicating that even though angiogenesis is not in itself painful, it may synergise with 
inflammation to exacerbate pain by sensitizing nerves growing alongside blood vessels.  Hence inhibiting 
angiogenesis may curtail the sensation of pain.  
 
In order to further verify the role of angiogenesis in chronic inflammation, and to show that indeed 
synovitis persists due to the involvement of angiogenesis and it is this angiogenesis which is being targeted 
by the angiogenesis inhibitor PPI-2458 in curtailing chronic synovitis, it was shown for the first time that 
conversion of acute synovitis to chronic synovitis could indeed in part be due to the stimulation of 
angiogenesis.  Previous studies have implicated angiogenic factors including FGFs in the initiation and 
progression of synovial hyperplasia and inflammation in RA (Malemud 2007).  FGFs are one of the 
candidates that cause progression of OA (Daouti et al., 2005).  Angiogenesis induction using FGF-2 at the 
onset of carrageenan induced acute synovitis in this study resulted in the transition from acute to chronic 
synovitis.  This chronic synovitis was in turn inhibited by a short course of the angiogenesis inhibitor PPI-
2458. 
 
The data presented in this thesis supports previous evidence that FGF-2 is pro-angiogenic, but not directly 
pro-inflammatory (Ziche et al., 1992; Cozzolino et al., 1993; Gualandris et al., 1994) because a single 
intra-articular injection of FGF-2 either alone, or together with carrageenan, was insufficient to increase 
joint swelling or macrophage infiltration at 24 hours, despite its ability to increase endothelial cell 
proliferation.  The ability of FGF-2 to augment chronic synovitis were shown to be inhibited in this study 
by the brief administration of PPI-2458, and in another study by repeated administration of an anti-
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DQJLRJHQLF LQKLELWRU RI ĮYȕ LQWHJULQ LQ DQWLJHQ-induced arthritis (Storgard et al., 1999).  These data 
support the idea that FGF-2 therefore may contribute to arthritis by increasing synovial angiogenesis, which 
may indirectly enhance synovitis, rather than any direct effect on inflammation.  Also PPI-2458 abolished 
synovial angiogenesis prior to reduction in synovitis, whereas synovitis reduction followed the 
discontinuation of PPI-2458.  This indicates that PPI-2458 may exert its effects not through the direct 
inhibition of inflammation, but rather through the inhibition of angiogenesis.   
 
Synovial angiogenesis is an early feature of both OA and RA, and occurs very early in the development of 
persistent synovitis in animal models (Walsh et al., 1998; Brahn et al., 2008). Synovial angiogenesis is also 
a feature of chronic synovitis in both humans and animals (Walsh et al., 1998; Walsh et al., 2001; 
Haywood et al., 2003).  These data also demonstrate increased endothelial cell proliferation during chronic 
synovitis after co-injection of either carrageenan and FGF-2 or single injection of 2% carrageenan.  It is 
likely that angiogenesis 4 weeks after the induction of chronic synovitis was mediated by factors other than 
the injected FGF-2, since FGF-2 alone induced only a transient increase in endothelial cell proliferation 
that had normalised by 5 days.  Angiogenesis during chronic synovitis may be mediated by an imbalance 
between a variety of angiogenic and anti-angiogenic factors (Bonnet et al., 2005).  Further studies will be 
required to understand which molecules sustain synovial angiogenesis in humans or animal models. 
 
Mechanisms by which acute synovitis may lead on to chronic arthritis remain incompletely understood.  
However, this study supports previous findings that angiogenesis is a feature of early as well as persistent 
synovitis in humans (Griffioen et al., 2000; El-Gabalawy 2005; Klareskog et al., 2009).  It also goes on to 
provide further evidence that synovial angiogenesis may indeed be a factor leading to persistent synovitis 
and inhibiting synovial angiogenesis at the onset of chronic synovitis has the capability of reducing pain 
associated with chronic synovitis. 
 
7.2 Angiogenesis, inflammation, structural damage and pain in OA 
Transection of the medial meniscus in the rat was shown to result in osteoarthritic changes in the medial 
tibial plateaux, consisting of fibrillation and eventual loss of cartilage, accompanied by reduced density of 
chondrocytes and loss of proteoglycan staining, and growth of osteophytes at the joint margins (Janusz et 
al., 2002; Bove et al., 2006; Mapp et al., 2008; Mapp et al., 2010).  The MNX model of OA also 
demonstrated loss of integrity of the osteochondral junction as channels were shown in this study to 
penetrate the articular cartilage from the subchondral bone space.  Additionally there is synovitis, indicated 
by increased synovial macrophage infiltration, and pain behavior, exhibited by a reluctance of the animals 
to symmetrically weight bear on their hind limbs (Bove et al., 2006; Mapp et al., 2008; Mapp et al., 2010).  
In each of these respects, MNX model of OA used in this study was shown to effectively mimic the human 
condition, and provided important insights into mechanisms underlying structural changes, pain behavior 
and responses to pharmacological therapies.   
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Typically OA presents as joint pain with progressive loss of joint function.  A great deal is known about 
symptoms of the disease, but the pathophysiology underlying those symptoms is widely acknowledged to 
be complex and less well understood.  In the absence of disease modifying drugs to treat OA, 
pharmacological interventions often act by subduing pain in order to relieve symptoms (McColl 2001).  
Current treatments are often limited by potential adverse events, and a better understanding of how joint 
pathology leads to pain is required to develop new therapies. 
 
It is well documented that angiogenesis is a feature of OA in rats as well as in humans, both in the 
synovium and at the osteochondral junction (Walsh et al., 2007; Mapp et al., 2008).  Synovial angiogenesis 
is associated with synovitis by either being a consequence of synovitis through the expression of 
angiogenic factors by macrophages, or angiogenesis could exacerbate inflammation by facilitating plasma 
extravasation and cellular influx (Walsh 1999; Bonnet et al., 2005).  Synovial and osteochondral 
angiogenesis are also associated with OA structural changes, and could contribute to those changes either 
directly or by facilitating inflammation (Haywood et al., 2003).  Angiogenesis is followed by innervation 
of newly formed blood vessels by fine unmyelinated sensory nerves, and could therefore directly contribute 
to pain in OA (Haywood et al., 2003). 
 
Synovitis is associated with increased chondropathy in human OA (Walsh et al., 2009), and predicts 
progression of joint damage in longitudinal studies (Ledingham et al., 1995; Palosaari et al., 2006).  
Clinically, osteoarthritic patients have a variable degree of synovitis.  In-vitro studies of human OA 
synovium and studies of OA pathology in animal models have implicated the inflamed synovium and 
synovial macrophages as important contributors in promoting OA pathology (Bondeson et al., 2010).  
Synovitis is implicated in many signs and symptoms of OA including swelling and effusion (Pelletier et al., 
2001; Benito et al., 2005).  Synovitis also contributes to disease progression as indicated by the correlation 
between biologic markers of inflammation, such as C-reactive protein and cartilage oligomeric matrix 
protein, with the progression of OA structural changes (Clark et al., 1999; Sowers et al., 2002).  
 
After showing that angiogenesis is an integral component in chronic synovitis, whether synovitis could 
exacerbate osteoarthritic changes was investigated and if by targeting the angiogenic component of this 
chronic synovitis instead of directly inhibiting inflammation using anti-inflammatory drugs it would be 
possible to curtail the structural damage seen and the pain experienced in OA was also looked at.  Using the 
rat MNX model of knee OA, the results presented in this thesis confirm previous findings and show that 
synovitis exacerbates structural damage and pain.  The results go on to illustrate that the administration of 
either anti-inflammatory (dexamethasone or indomethacin) or anti-angiogenic (PPI-2458) treatments are 
associated with reduced synovitis, structural damage and pain behavior.  This indicates that angiogenesis 
may contribute both to inflammation and joint damage, and that angiogenesis inhibition works just as well 
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as anti-inflammatory drugs in reducing inflammation even after synovitis has become established.  Hence 
these data support the notion that inhibition of blood vessel growth may be a useful strategy in reducing 
OA pain.  These findings are an extension of previously published data, where researchers have shown PPI-
2458 inhibits synovitis in collagen and in PGPS-induced arthritis in mice and rats (Bainbridge et al., 2007; 
Lazarus et al., 2008).  This indicates that the anti-inflammatory effects of angiogenesis inhibition are 
observed in synovitis induced by a wide variety of agents. 
 
7.3 Anti-inflammatory and anti-angiogenic treatments in OA 
Inhibition of synovitis is an attractive target for disease modification in OA, although coincidental and 
detrimental effects of current anti-inflammatory agents on chondrocyte function (Annefeld et al., 1990; 
Bove et al., 2003) could limit their efficacy as disease modifying agents.  In this study, treatment with 
either dexamethasone; a synthetic adrenal corticosteroid or an angiogenesis inhibitor PPI-2458 reduced 
total joint damage score.  Dexamethasone predominantly affected chondropathy in the MNX model, 
whereas angiogenesis inhibition reduced osteophyte size, suggesting that the structural effects of 
angiogenesis inhibition could not be entirely mediated by its anti-inflammatory effects.  This data 
complements previous findings where angiogenesis inhibition with VEGF blockade was found to reduce 
new bone formation around arthritic joints, an effect that could partly be mediated by inhibition of 
endochondral ossification (Miotla et al., 2000).   
 
Similarly, intra-articular or systemic delivery of dexamethasone have previously been shown to reduce 
joint damage in experimental animal models of inflammatory arthritis, such as adjuvant arthritis (AA) and 
collagen-induced arthritis (CIA) (Bendele 2001; Cuzzocrea et al., 2005; Caparroz-Assef et al., 2007).  In a 
rabbit meniscal transection model of OA, corticosteroids given before the onset of OA reduced osteophyte 
formation and cartilage loss (Butler et al., 1983).  Similar findings have been reported in guinea pig and 
dog models of experimental OA (Williams et al., 1985; Pelletier et al., 1995).   
 
In-vitro findings have shown that functional properties of cartilage explants could be maintained in culture 
through the addition of dexamethasone to cell media (Bian et al., 2010).  However conflicting studies exist 
indicating that corticosteroids also inhibit chondrocyte synthetic functions and may therefore exacerbate 
joint damage, limiting their frequent use in clinical setting (Boland 1964; Annefeld et al., 1990). 
 
Similar to previous studies where vascular channel formation and pain behavior in the MNX model of OA 
was shown to be reduced by matrix metalloproteinase inhibition (Mapp et al., 2010), the data in this thesis 
show that PPI-2458 inhibited vascularisation of channels at the osteochondral junction which is consistent 
with its anti-angiogenic activity.  However, the significant increase in total channel numbers in animals 
having meniscal transection surgery and treated with PPI-2458 compared with non-arthritic control animals 
indicated that angiogenesis is not a prerequisite for channel formation.  Reductions in pain and structural 
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damage observed in the osteoarthritic animals following treatment with PPI-2458 could partly be due to 
inhibition of osteophyte growth and angiogenesis at the osteochondral junction, as well as inhibition of 
synovitis. 
 
These findings indicate that synovitis and total joint damage are closely associated with pain behaviour in 
the rat MNX model of OA and this could, in part, be explained by angiogenesis in the synovium and at the 
osteochondral junction.  Targeting angiogenesis could therefore prove useful in reducing pain and 
structural damage in OA, either alone or in combination with other drugs (Figure 6.1). 
 
7.4 Meniscus as a source of pain in human tibiofemoral OA 
After showing that angiogenesis is an integral component in chronic synovitis, and that synovitis could 
exacerbate osteoarthritic changes in the rat MNX model of knee OA, I went on to highlight that by 
targeting the angiogenic component of this chronic synovitis and also by directly inhibiting synovitis using 
anti-inflammatory drugs it was possible to curtail the structural damage seen and the pain experienced in 
this MNX model of OA.  Angiogenesis is not in itself painful, but since it is possible that angiogenesis may 
contribute to pain in OA by enabling growth of new unmyelinated sensory nerves (Bonnet et al., 2005; 
Ashraf et al., 2008), I went on to establish whether menisci could be a source of pain in OA through these 
mechanisms.  I had already shown that in the MNX model of OA, CGRP positive sensory nerves were seen 
in the synovium, subchondral bone and in osteophytes.  Previous literature complements these findings as 
angiogenesis and sensory nerves have been observed in the synovium and at the osteochondral junction in 
OA (Walsh et al., 2007) penetrating into non-calcified articular cartilage and osteophytes (Suri et al., 
2007).  These perivascular, unmyelinated, nerve fibres containing substance-P and CGRP have been 
implicated in mediating sustained burning pain described by patients with OA (Kidd et al., 1992; Dieppe et 
al., 2005). 
 
Examining the vascularisation and innervation of human menisci between high and low tibiofemoral 
chondropathy groups highlighted an association between disorganisation of collagenous matrix structure 
and chondropathy in human knees.  Menisci with high chondropathy scores had increased synovial 
penetration towards the tip, extending over part of the inner region.  The synovium also appeared thicker, in 
menisci from high chondropathy group compared with those from the low chondropathy group.  An 
increase in penetration of blood vessels and nerves towards the meniscal tip with high chondropathy scores 
was also demonstrated.  Vascularisation of normally avascular tissues has also been demonstrated in 
articular cartilage in OA and inner regions of the annulus fibrosus of the intervertebral disc in back pain 
(Kauppila 1995).  Meniscal angiogenesis on the other hand could also be a homeostatic response to 
minimise meniscal damage in OA.  Vascularisation changes tissue biomechanics and could predispose to 
further damage.  Interventional studies would therefore be required to determine whether meniscal 
angiogenesis protects against or contributes to joint damage in OA. 
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These findings showed that increased angiogenesis and thickness of the synovium observed in OA extends 
to include synovium attached to menisci.  Increased synovial vascularity was associated with 
vascularisation at the fibrocartilage junction of the meniscus, suggesting that angiogenesis in these different 
joint compartments may be regulated by common factors.  The stimuli to meniscal blood vessel growth 
deserve further study, because they could originate from cells within the meniscus itself and also from 
adjacent structures such as the synovium and articular cartilage. 
 
These data demonstrated that CGRP positive sensory nerve profiles were present in the outer region of 
menisci, and most of these nerves were associated with blood vessels.  CGRP is co-localised with 
substance P in unmyelinated sensory nerve fibres, and this work therefore extends previous findings that 
perivascular nerves containing substance P are located in the peripheral portion of torn menisci (Mine et 
al., 2000).  In this study, increase in sensory innervation in the outer region of the menisci from knees with 
high chondropathy scores was observed, therefore, nerve growth in menisci could contribute to pain in OA 
both through an increased density of nociceptive fibres, and also through increased sensitivity that occurs 
during nerve growth (Ma et al., 1997).  Recent controlled trials of nerve growth factor blockade have 
demonstrated its ability to inhibit OA knee pain (Cattaneo 2010), although the rapid onset of its analgesic 
effect could suggest an action on sensitisation rather than on nerve growth.  CGRP-immunoreactive nerves 
were localised adjacent to blood vessels within the meniscus, and sensory nerve growth follows blood 
vessel growth in a variety of tissues (Aoki et al., 1994; Walsh et al., 1996).  It is therefore not far-fetched to 
predict that angiogenesis inhibition could also have analgesic potential by reducing aberrant innervation in 
the osteoarthritic knee (Walsh et al., 2001).   
 
So collectively the data collected as part of this thesis highlights that synovium, cartilage, subchondral bone 
and menisci could all be possible sources of pain in knee OA.  In light of the findings shown in this thesis, 
neovascularisation and innervation of otherwise avascular and aneural regions of the joints could contribute 
to both structural change and pain in OA.  Inhibition of either angiogenesis and/or inflammation and/or 
nerve growth may each offer the potential to reduce structural damage and pain in OA (Figure 6.1).  
However interventional studies are needed to further elucidate the contribution of and the links between 
angiogenesis, inflammation, nerve growth and pain.  Never-the-less the data presented in this thesis support 
the hypothesis that inflammation and angiogenesis are co-dependent processes that can exacerbate and 
mediate structural damage and pain in OA. 
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7.5 Limitations of the current studies 
Although the results reported in this thesis provide novel evidence of a role for angiogenesis in chronic 
synovitis, structural damage, innervation and pain in OA, conclusions are limited by a number of factors 
that are common to investigations of complex biological processes in intact animals.  These limitations are 
discussed below: 
x Even though PPI-2458 is well characterized as a specific inhibitor of angiogenesis, it was not fully 
possible to separate in these in-vivo studies whether the inhibition of angiogenesis following PPI-2458 
treatment leads to reduced inflammation and hence pain or whether PPI-2458 is acting in an anti-
inflammatory manner distinct from its anti-angiogenic properties. 
x The effects of either angiogenesis or inflammation inhibition on innervation of the joint was also 
not investigated due to time and cost constraints, hence innervation of the joint was not correlated to pain 
behaviour in these in-vivo models.   
x Indomethacin and dexamethasone could have had effects additional to inhibiting inflammation, 
including direct anti-angiogenic actions.   
x Macroscopic appearance of chondropathy is used in the human menisci study as an indicator of 
tibiofemoral OA.  Even though chondropathy scores for high chondropathy group are similar to those 
previously observed at total joint replacement surgery for knee OA (Walsh et al., 2009), all of whom 
fulfilled the American College of Rheumatology revised criteria for OA (Altman et al., 1986), 
chondropathy alone, however, is insufficient to diagnose knee OA and further studies would be required to 
determine whether the observed meniscal changes are associated with other features of OA.   
x During selection of cases for the meniscal study, 3 cases were excluded from the high 
chondropathy group due to non-availability of meniscal tissue.  Menisci can be completely disrupted in 
severe OA and the current findings will only be relevant to cases where menisci remain intact.   
x The prevalence and severity of OA increases with age, and it was not possible in this study to 
exclude the possibility that differences in vascularity and innervation between high and low chondropathy 
groups may have been age- rather than disease-related.   
x It is not known whether patients from whom the menisci were obtained suffered from knee pain, 
and the proposal that meniscal pathology may be associated with knee pain remains speculative.   
x The meniscal study is not age-matched, it is however extremely difficult to carry out age and 
disease matched study as it would require a very large repository of human joint tissues.  The Academic 
Rheumatology joint tissue repository is an ongoing repository where joint tissues from PM cases are 
continuously being added over time.  In the current repository containing 288 PM cases, 20 cases within the 
age range of 23 to 59 and 56 to 91 years fulfilled the criteria of having low and high macroscopic 
chondropathy scores respectively.  Only 1 case in the total repository within the age range 23 to 59 had a 
high macroscopic chondropathy score.  In order to be able to select 20 cases with high chondropathy scores 
within the age range 23 to 59, repository having 5760 PM cases would be required.  Correspondingly, only 
2 cases in our repository within the age range 56 to 91 had low macroscopic chondropathy scores.  In order 
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to be able to select 20 cases with low chondropathy scores within the age range 56 to 91, a repository 
containing 2880 PM cases would have been needed.  Therefore an extremely large repository containing 
approximately over 2500 PM cases is needed to carry out an age matched study.  At the moment the 
Academic Rheumatology joint tissue repository does not house such large number of PM cases.  An 
alternative approach was considered of including cases with milder chondropathy in the high chondropathy 
group, or more severe chondropathy within the low chondropathy group, but this would have reduced the 
validiaty of case selection, increasing the likelyhood of cross-contamination between the groups.  Including 
smaller numbers of cases within the groups would have reducecd the power of the study to detect clinically 
important differences in vascularity.   
 
Despite these limitations, however, the data presented in this thesis support the view that anti-inflammatory 
and anti-angiogenic strategies may have the potential not only to relieve symptoms, but also to modify 
structural progression in OA.  The use of post mortem tissues in the human meniscal study permitted the 
analysis of two discrete patient groups, with menisci harvested and processed and chondropathy assessed 
by identical methodologies, avoiding differences between surgical and control specimens that can often 
limit interpretation of pathological studies.  Hence these data presented should help direct the design of 
future experiments to further elucidate the mechanisms connecting angiogenesis to inflammation, 
innervation, structural damage and pain in OA. 
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7.6 Future directions 
This thesis has highlighted the contributions of angiogenesis to inflammation, innervation, structural 
damage and pain in OA both in-vivo using animal models and ex-vivo using human meniscal tissue.  The 
data from two animal models of chronic synovitis presented in this thesis shows that angiogenesis is an 
important component in the transition of acute to chronic synovitis and a brief anti-angiogenic treatment 
during the acute phase of synovitis could prevent its subsequent progression.  Increased synovitis also 
exacerbated structural damage and pain in the MNX model of OA and treatment with the anti-angiogenic 
compound was followed by a reduction in these enhanced pathological changes.  Similarly, in the MNX 
model of OA, both anti-inflammatory (either dexamethasone or indomethacin) and anti-angiogenic (PPI-
2458) compounds were able to reduce synovitis, total joint damage and pain behaviour.  This indicates that 
synovitis and joint damage are closely associated with pain behaviour in the MNX model of OA and 
angiogenesis inhibition may reduce pain behaviour both by reducing synovitis and preventing structural 
damage.  However, future studies mentioned below are needed to address the limitations of the findings 
presented in this thesis as well as exploring new avenues to further elucidate the connection between 
inflammation, angiogenesis, structural damage and pain in OA: 
x To further characterise the mechanism of action of the angiogenesis inhibitor PPI-2458 in 
reducing synovitis and understanding whether it is the inhibition of angiogenesis following PPI-2458 
treatment which leads to reduced inflammation and hence pain or whether PPI-2458 is acting in an anti-
inflammatory manner distinct from its anti-angiogenic properties, it is proposed that the effects of PPI-2458 
need to be first verified in an in-vivo model of inflammation without angiogenesis, such as the 0.03% 
carrageenan model of resolving synovitis.   
x Since it was also not possible to investigate whether anti-inflammatory and anti-angiogenic 
treatments had any effects on the innervation of the osteoarthritic knee joints in the MNX model of OA and 
hence to correlate those data to the pain measurements as joint tissues needed to be preserved and 
decalcified separately for innervation and vascular studies and this required the same experiments to be run 
twice.  Looking at the effects that anti-angiogenic (PPI-2458) and anti-inflammatory (Dexamethasone and 
Indomethacin) drugs have on the innervation of the various compartments of the osteoarthritic knee joint in 
the MNX model of OA and correlating those data to pain measurements is a logical step forward forming 
the basis of future investigations. 
x To rule out the possibility that indomethacin and dexamethasone could have had effects additional 
to inhibiting inflammation, including direct anti-angiogenic actions, the behaviour of these drugs need to be 
tested in an angiogenic model without inflammation such as the 6 picomoles of FGF-2 synovial 
angiogenesis rat model. 
x To further explore the role of angiogenesis in inflammation, joint damage and pain in OA, 
enhancing angiogenesis in the MNX model of OA using various angiogenic factors such as FGF and VEGF 
to see whether they have any effect if at all in exacerbating inflammation, joint damage and pain in the 
osteorthritic animals could prove interesting.   
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x The results presented in this thesis have shown that long-term angiogenesis inhibition has the 
potential to reduce inflammation, structural damage and pain in the MNX model of OA, but this is not 
without its attached side-effects, but whether short-term angiogenesis inhibition has any effects is not 
known and needs to be investigated, to reduce the chances of possible side-effects attached to other long 
term drug-treatment use. 
x Looking at the effects of different combinations and durations of anti-inflammatory and anti-
angiogenic treatment regimes on synovitis, structural damage and pain in the MNX model of OA are also 
worth investigating as well as seeing whether the findings reported in this thesis hold true in another model 
of OA, such as the monosodium-iodoacetate (MIA) model.   
x Since it is highly likely that multiple factors could lead to chronic inflammation, angiogenesis 
inhibition may have greatest therapeutic potential in combination with other pharmacological agents.   
x Eventually, clinical studies are also necessary to determine whether the interventional studies done 
in animal models hold true in clinical settings. 
  
Together, the results from the above mentioned experiments should further elucidate the role of 
angiogenesis in inflammation, structural damage and pain in the MNX model of OA. 
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7.7 Concluding remarks 
OA is the commonest form of arthritis and is of unknown aetiology.  It is associated with articular cartilage 
loss, synovitis, subchondral bone remodelling and osteophyte formation.  Angiogenesis, the growth of new 
blood vessels from pre-existing ones, contributes to each of these pathological features of OA.  Pain, the 
main symptom of OA originates from several sources within the knee joint some of which are synovium, 
cartilage, bone and menisci.  Inflammation sensitises the sensory nerves growing alongside blood vessels in 
various compartments of the joints and these sensitised nerves contribute to neurogenic inflammation, 
initiating new vessel growth.  Hence, angiogenesis contributes both to the symptoms and pathology of OA 
and further analysis of its role seems vital in leading to discovering more effective therapies. 
 
The findings outlined in this thesis have provided evidence in-vivo using animal models of synovitis and of 
OA that synovitis, synovial angiogenesis and structural damage are closely associated with pain behaviour.  
Angiogenesis inhibition may therefore have the potential to reduce pain behaviour both by reducing 
synovitis and also by preventing structural damage.  Ex-vivo, using human meniscal tissue it is shown that 
tibiofemoral chondropathy is associated with altered matrix structure, increased vascular penetration and 
increased sensory nerve densities in the medial meniscus.  Indicating that angiogenesis and associated 
sensory nerve growth in menisci could contribute to the pain observed in OA (Figure 6.1).   
 
Further studies will concentrate on assessing the effects that anti-inflammatory and anti-angiogenic 
treatments have on the innervation of the osteoarthritic knee joints in the MNX model of OA and how this 
data correlates with pain behaviour measurement.  Moreover looking at the effects of different 
combinations and durations of anti-inflammatory and anti-angiogenic treatment regimes on synovitis, 
structural damage and pain in the MNX model of OA as well as seeing whether these findings hold true in 
other models of OA, such as the MIA model and other models of synovitis.  Looking at whether PPI-2458 
has any effects on other angiogenic factors such as VEGF could also be useful.  This information could 
prove vital to increasing our understanding of the contributions of angiogenesis to inflammation, structural 
damage and pain in OA. 
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Figure 6.1 Relationship between inflammation, angiogenesis, innervation, structural damage and 
pain in OA.  OA is a dynamic disease process, where the symptoms and structural changes are all 
interconnected.  Angiogenesis inhibition in the synovium and at the osteochondral junction (OCJ) has the 
potential to curtail synovitis, structural damage and pain in a rat MNX model of OA.  Similar effects were 
seen using anti-inflammatory drugs.  Angiogenesis (fibroblast growth factor [FGF] -2) and associated 
sensory nerve growth (calcitonin gene related peptide; CGRP) in the cartilage, synovium, bone and menisci 
could contribute to pain in OA.  
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9 APPENDICES 
 
9.1 Materials and Reagents  
Acetic acid       VWR Ltd. Lutterworth, UK 
Acetone        VWR Ltd. Lutterworth, UK 
Albumin, Bovine (A-4503)     Sigma Aldrich, Poole, UK 
Ammonium Chloride      VWR Ltd. Lutterworth, UK 
Basic FGF, Human, Recombinant (13256-029)   Invitrogen Ltd. Paisley, UK 
Beta-D-glucose (G5250)      Sigma Aldrich, Poole, UK  
Calcium Chloride (C3306)      Sigma Aldrich, Poole, UK 
Ceporex TM   Schering-Plough Animal - Health, 
Middlesex, UK 
Cork Blocks 20mm x 3mm (E7.15/CD) Raymond Lamb, Eastbourne, UK 
Coverslips 22mm x 64mm      VWR Ltd. Lutterworth, UK 
DAPI        Sigma Aldrich, Poole, UK 
DePeX TM VWR Ltd. Lutterworth, UK 
Dexamethasone (D1756)      Sigma Aldrich, Poole, UK 
Diaminobenzidine (D5637)     Sigma Aldrich, Poole, UK  
Diammonium Nickle II Sulphate (A1827)    Sigma Aldrich, Poole, UK 
Disodium phosphate heptahydrate (S9390) Sigma Aldrich, Poole, UK 
EDTA Disodium Salt (E5134)     Sigma Aldrich, Poole, UK 
Electronic Caliper Miyutoyo UK Ltd. Andover, UK 
Eosin (1%) Raymond Lamb, Eastbourne, UK 
Ethanol absolute (32221)      Sigma Aldrich, Poole, UK 
Fast Green (F-7258)      Sigma Aldrich, Poole, UK 
Formalin Neutral buffered pH 7.0 (4% formaldehyde)  VWR Ltd. Lutterworth, UK 
Formic Acid (399388)      Sigma Aldrich, Poole, UK 
Glucose Oxidase Aspergillus Niger (G2133)    Sigma Aldrich, Poole, UK 
Glycerol (G2025)      Sigma Aldrich, Poole, UK 
Goat serm (G9023)      Sigma Aldrich, Poole, UK 
Hematoxylin (H3136)      Sigma Aldrich, Poole, UK 
Horse Serum       Sigma Aldrich, Poole, UK 
Hydrochloric Acid      VWR Ltd. Lutterworth, UK 
Hydrogen peroxide (H1009)     Sigma Aldrich, Poole, UK 
Hydroxy-propyl-beta-cyclodextrin (C0926)     Sigma Aldrich, Poole, UK  
Incapacitance Meter Linton Instruments, Norfolk, UK 
Indomethacin (I7378)      Sigma Aldrich, Poole, UK 
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Iron (III) Chloride (157740)     Sigma Aldrich, Poole, UK 
Isopentane       VWR Ltd. Lutterworth, UK 
KS300 image analysis software Imaging Associates Ltd. Thame, 
UK 
Lambda Carrageenan (C-3889)     Sigma Aldrich, Poole, UK 
Lewis or Wistar rats      Charles River, Kent, UK 
Mayers Haematoxylin Raymond Lamb, Eastbourne, UK 
Methanol       Sigma Aldrich, Poole, UK 
Monosodium Phosphate Monohydrate (S9638)   Sigma Aldrich, Poole, UK 
Neuraminidase Clostridium perfringens (N2876)   Sigma Aldrich, Poole, UK 
Novasapa Cold Steriliser Pfizer Animal Health, Surrey, UK 
OneTouch® Ultra® Blood Glucose Meter and Test Strips LifeScan Inc. High Wycombe, UK 
Paraformaldehyde (P6148) Sigma Aldrich, Poole, UK 
Phosphate Buffered Saline pH 7.4 (43711) VWR Ltd. Lutterworth, UK 
Picric Acid (1.2%) VWR Ltd. Lutterworth, UK 
Polyvinylpyroolidene (PVP40T) Sigma Aldrich, Poole, UK 
Rabbit Serum Sigma Aldrich, Poole, UK 
RimadylTM        Pfizer Ltd. Kent, UK 
Safranin-O (S-2255)      Sigma Aldrich, Poole, UK  
Shandon Pathcentre Tissue Processor Shandon ThermoScientific, 
Leicestershire, UK  
Sigma FastTM  Red Alkaline Phosphatase Tablets (F4523)  Sigma Aldrich, Poole, UK 
Sodium acetate trihydrate (236500)     Sigma Aldrich, Poole, UK 
Sodium Azide (8032)      Sigma Aldrich, Poole, UK 
Sodium Chloride (S-3014)      Sigma Aldrich, Poole, UK  
Sodium Chloride Solution, 0.9% (S8776)    Sigma Aldrich, Poole, UK 
Sodium HEPES (H-3375)      Sigma Aldrich, Poole, UK 
Sodium Pentobarbital (Euthatal)     Pfizer Ltd. Kent, UK 
Sony DSC-s85 CyberShot digital camera Carl Zeiss Ltd. Welwyn Garden 
City, UK 
Sterile Op-Cover Kruuse Ltd. Sherburn in Elmet, 
North Yorkshire 
Sucrose (5016) Sigma Aldrich, Poole, UK 
Surgical Instruments Interfocus Ltd. Cambridge, UK 
Tergitol NP40 (NP-40) Sigma Aldrich, Poole, UK 
Tissue Tek® Embedding Centre Sakura Finetek Europe, The 
Netherlands 
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Tissue Tek OCT® mounting medium Raymond Lamb, Eastbourne, UK 
Tris base (T1509)      Sigma Aldrich, Poole, UK 
Vectastain® Elite ABC Kit (PK6100) Vector Laboratories Ltd. 
Peterborough, UK 
Vectastain® ABC-AP Kit (AK-5000) Vector Laboratories Ltd. 
Peterborough, UK  
Vetasept Povidone-Iodine Scrub Animalcare Ltd. Dunnington, York  
Xylene VWR Ltd. Lutterworth, UK 
Zeiss Axioscop-50 microscope  Carl Zeiss Ltd. Welwyn Garden 
City, UK 
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9.2 Antibody List 
 
Primary antibodies:  
 
 
 
Dilution Reference Company Code Product 
Type 
Clone Other names Specificity Description 
1:1000 Suri et al., 
2007 
Peninsula Labs 
Inc. St. Helens, 
UK  
T-4239 Polyclonal - - CGRP Rabbit anti-Į-
CGRP (human) 
1:2000 Kennedy et 
al., 2010 
Sigma Aldrich, 
Poole, UK 
A2547 Monoclonal 1A4 - Alpha-
smooth 
muscle 
actin 
Mouse Anti-Actin 
1:1000 Dijkstra et 
al., 1985 
 
Serotec Ltd. 
Oxford, UK 
MCA341GA Monoclonal ED1 ED1, 
MACROSIALIN 
CD68 Mouse Anti-rat 
CD68 
1:400 
 
Male et al., 
1995 
 
Serotec Ltd. 
Oxford, UK 
MCA1334G Monoclonal TLD-3A12 GPIIA, 
PECAM-1 
CD31  Mouse Anti-rat 
CD31 
1:1000 Walsh et. 
al., 1998 
DAKO Ltd. 
High 
Wycombe, UK 
M0879 Monoclonal PC-10 - PCNA Mouse Anti-rat 
Proliferating Cell 
Nuclear Antigen 
(PCNA)  
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Secondary antibodies: 
1:100 Vector Laboratories 
Ltd. Peterborough, UK 
 
BA-5000 Biotinylated Rabbit Goat IgG Anti-Goat IgG, 
Affinity Purified 
1:6000 Vector Laboratories 
Ltd. Peterborough, UK 
 
AS-2104 - Goat Lectin-1 Griffonia (Bandeiraea) 
Simplicifolia Lectin 1, 
Affinity Purified 
1:6000 Vector Laboratories 
Ltd. Peterborough, UK 
 
L-1100 - - Lectin-1 Griffonia (Bandeiraea) 
Simplicifolia Lectin 1 
1:100 Vector Laboratories 
Ltd. Peterborough, UK 
BA-1000 Biotinylated Goat Rabbit IgG Anti-Rabbit IgG, 
Affinity Purified 
1:100 Vector Laboratories 
Ltd. Peterborough, UK 
BA-2001 Biotinylated Horse Mouse IgG Anti-Mouse IgG 
Affinity Purified, Rat 
Absorbed 
Dilution Company Code Label Donor Antigen Description 
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9.3 Buffers and solutions used for immunohistochemistry 
 
x Acid Alcohol:    Hydrochloric Acid (1.0 M)  5.0 ml 
Ethanol     350 ml 
Distilled H2O    145 ml 
 
x Acetic Acid Solution:    Acetic Acid (Glacial)   4 ml 
Distilled H2O    396 ml 
 
x DAPI:     Tergitol NP40    0.6 g 
      DAPI     0.1 mg 
      PBS (0.01 M)    100 ml  
 
x Decalcification Fluid:    Tris base    3.35 g 
EDTA (10%)    250 g 
PVP (7.5%)    187.5 g 
Distilled H2O    2.5 L 
pH     6.95 
 
x Fast Green Solution:    Fast Green     0.1 g 
Distilled H2O    500 ml 
 
x Goat Blocking Buffer:   BSA (5%)    0.01 g 
Goat Serum (3.3%)   0.7 ml 
PBS (0.1 M)    2.0 ml 
Distilled H2O    17.3 ml 
 
x HEPES buffer:    NaHEPES (10 mM)   2.603 g  
      NaCl (150 mM)    8.766 g  
      CaCl2 2H2O (0.1mM)   0.015 g 
      Distilled H2O    1 L 
      pH adjusted to     7.5 
 
x Horse Blocking Buffer:   BSA (5%)    0.01 g 
Horse Serum (3.3%)   0.7 ml 
PBS (0.1 M)    2.0 ml 
Distilled H2O    17.3 ml 
 216 
 
x Hydrochloric Acid (1.0 M):   Hydrochloric Acid (37%)   0.5 ml 
Distilled H2O    4.5 ml 
 
x Hydrogen Peroxide in Methanol:  Hydrogen Peroxide (0.33%)  3.0 ml 
Methanol    300 ml 
 
x PBS (10 x concentrated at 0.1 M):  Sodium Chloride    70.1 g 
Sodium dihydrogen Orthophosphate 4.4 g 
Di-sodium hydrogen Orthophosphate 12.8 g 
Potassium Chloride   2.0 g 
pH     7.4 
Working dilution of PBS: From 10 x concentrated 0.1M stock solution to working solution of 
0.01M using distilled water. 
 
x Phosphate Buffer (0.2 M):   Monosodium Phosphate Monohydrate 7.41 g 
Disodium Phosphate heptahydrate 39.2 g 
Distilled H2O    1 L 
 
x PBS and Sucrose:    Sucrose (15%)    375 g 
Sodium Azide (0.01%)   0.25 g 
PBS (0.01 M)    2.5 L 
pH     7.4 
 
x Rabbit Blocking Buffer:   BSA (5%)    0.01 g 
Rabbit Serum (3.3%)   0.7 ml 
PBS (0.1 M)    2.0 ml 
Distilled H2O    17.3 ml 
 
x Safranin-O Solution:    Safranin-O    0.4 g 
Distilled H2O    400 ml 
 
x Sodium Acetate (0.1 M):   Sodium Acetate Trihydrate  5.64 g 
Glacial Acetic Acid   3.51 ml 
Distilled H2O    1 L 
 
x Sodium Acetate (0.2 M):   Sodium Acetate Trihydrate  25.77 g 
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Glacial Acetic Acid   0.6 ml 
Distilled H2O    1 L 
 
x :HLJHUW¶V+DHPDWR[\OLQ    
Reagent A 
Haematoxylin        2.0 g 
Ethanol        200 ml 
Distilled H2O       10 ml 
Reagent B 
Iron (III) Chloride (2.9 g in 10 ml distilled H2O)   8 ml 
HCL (37% concentrated)      2 ml 
Distilled H2O       190 ml 
 
$GGHTXDOYROXPHRI5HDJHQW$WR5HDJHQW%WRPDNH:HLJHUW¶V+DHPDWR[\OLQ   
 
x =DPERQL¶V)L[DWLYH    Paraformaldehyde Solution (16%)  250 ml 
Saturated Picric Acid Solution  150 ml 
Phosphate Buffer (0.2 M)   500 ml 
Distilled H2O    100 ml 
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9.4 Calculations 
x Number of fields per section required to give a statistically significant result. 
Approximately 8 consecutive sections were stained for the appropriate antigen of interest.  Quantification 
was performed using image analysis and data was recorded on excel for statistical analysis.  Indices of each 
cumulative field per section were Log transformed.  The mean and standard deviation for each first field, 
second field etc. for all sections was calculated using the Log transformed values.  Co-efficient of variation 
for each field was then determined.  Two graphs representing, mean versus the number of cumulative fields 
and co-efficient of variation versus the number of cumulative fields were plotted.  Co-efficient of variation 
expresses the standard deviation as a percentage of the sample mean.  It is used to determine the size of the 
variation relative to the size of the observation.  The size of variation decreases with each cumulative field 
upto a saturation point.  The cumulative field that has the lowest variation in the observations determines 
the number of fields required per section. 
 
x Number of sections per case required to give a statistically significant result. 
Once the fields required per section were determined, weighted mean of that field for all sections was 
determined.  For normally distributed data, true mean was calculated from the weighted mean.  Standard 
deviation and standard error of the mean were also calculated.  Standard error measures how precisely the 
population mean is estimated by the sample mean.  The size of the standard error depends both on how 
much variation there is in the population and on the size of the sample i.e. the standard deviation of the 
mean.  In these cases it was determined to be within ±25% of the true mean i.e. there is 95% confidence 
that the observed mean is between ±25% of the true mean.  Number of sections = Standard deviation 2 / 
Standard error 2. 
 
x Sample Size 
A power calculation was performed to determine the minimal number of animals required to test for a 
significant difference in the data.  A power of 80% was decided to show a difference of 10% at P value of 
0.05.  Pilot data was used to determine mean and standard deviation.  The formula used was; (u + v)2 ı12 + 
ı12   ȝ12 ȝ12), where u is the one sided percentage point of the normal distribution corresponding to 
100% minus the power.  In this case 100-80 = 20%, so u = 0.84.  v is the percentage of the normal 
distribution corresponding to the two sided significant level.  In this case the significant level used was 5% 
LHS VRY ıLVVWDQGDUGGHYLDWLRQDQGȝLVWKHPHDQ  
 
x Intra-observer reliability for image analysis 
Repeated measurements on the same case varies around the true value as a result of measurement error, the 
standard deviation of repeated measurements on the same case determines the size of the measurement 
error.  Measurement error between repeat measurements is expressed as repeatability co-efficient (Bland et 
al., 1996).   
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9.5 Consent Forms 
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